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Abstract 
 
Hypertrophic cardiomyopathy (HCM) is a common inherited heart muscle disease. 
Symptoms (exertional breathlessness, chest pains, palpitations, syncope) occur frequently. In at 
least half of these patients exertional breathlessness is usually a consequence of impaired left 
ventricular diastolic filling.  For these patients therapies are frequently ineffective. Pulmonary 
hypertension frequently develops acutely on exercise in such patients (due to the acute rise in left 
ventricular end diastolic pressure). The associated increase in right ventricular volume might be 
expected to stretch the surrounding pericardium. In these circumstances left ventricular filling may 
be impeded by external constraint from the pericardium (pericardial constraint) and from the right 
ventricle via the interventricular septum (diastolic ventricular interaction).  
 We hypothesised that deleterious diastolic ventricular interaction may be present at rest in 
some patients with HCM and develop on exercise in others, and that biventricular pacing may be 
able to relieve diastolic ventricular interaction with consequential improvement in myocardial 
performance. We also hypothesized that given the nature of the myocardial substrate in HCM, that 
biventricular pacing may affect improved contractile function through amelioration of 
dyssynchrony both acutely and chronically.  
To test these hypotheses, we conducted initially a set of acute studies. Using gated heart 
pool scanning, we measured myocardial performance indices at rest, on exercise, and following 
application of lower body negative pressure, with and without biventricular pacing. Using 
echocardiography, we measured parameters of dyssynchrony at rest, with and without biventricular 
pacing. 
 
 
In addition, we hypothesised that chronic biventricular pacing (4 months) in patients with 
symptomatic, exercise-limited non-obstructive HCM, would improve exercise capacity (study 
primary end point) and improve quality of life (study secondary end point). To test these two 
hypotheses, we undertook a double blind, randomised, sham-controlled, cross over study of 
biventricular pacing in a group of 31 patients who met the inclusion and exclusion criteria.  
We demonstrate that biventricular pacing significantly increases exercise capacity 
(measured as peak Oxygen consumption - by 1.17ml/kg/min p=0.032) and significantly improves 
quality of life (p=0.001).  
We found that these HCM patients had only minor left ventricular systolic dyssynchrony at 
rest. We report that following acute biventricular pacing, some parameters of dyssynchrony 
improved, but that these improvements were not sustained with chronic biventricular pacing.  
Using gated heart pool scanning, we found that none of the patients had a left ventricular 
ejection fraction less than 50% at rest and none developed significant left ventricular systolic 
dysfunction on exercise. Further, we report that biventricular pacing had no effect on resting or 
exercise left ventricular ejection fraction or on left ventricular end systolic elastance. 
We found that following right ventricle volume unloading, (when supine, at rest) using 
lower body negative pressure, that left ventricular end diastolic volume decreased in the majority 
of patients, however in a small number of patients (4) it increased, and that biventricular pacing 
was able to reverse this increase in left ventricular end diastolic volume in 3 of these 4 patients. In 
approximately half of the patients left ventricular diastolic volume increased on exercise with 
‘sham’ pacing, but in the remainder, it fell. The latter patients had a greater degree of exercise 
limitation and the increase in peak Oxygen consumption associated with chronic biventricular 
pacing was almost exclusively confined to this group. In the group of patients in whom left 
 
 
ventricular end diastolic volume decreased with exercise, biventricular pacing augmented late 
diastolic filling during exercise and this resulted in an increase in left ventricular end diastolic 
volume on exercise - resulting in stroke volume augmentation via the Starling mechanism. These 
effects are consistent with relief of diastolic ventricular interaction as the mechanism.  
Thus, for the first time, we show that severely symptomatic patients with non-obstructive 
hypertrophic cardiomyopathy may benefit, subjectively and objectively, from biventricular pacing. 
Furthermore, we present data that argues for the first time for the amelioration of diastolic 
ventricular interaction, rather than mechanical resynchronisation, as the predominant mechanism 
of benefit following biventricular pacing in this group of patients.  
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Publications resulting from projects 
Abstract: Oral presentation American Heart Association, New Orleans. 
Circulation. 2008;118:S_869 
Biventricular Pacemaker Therapy Corrects Dyssynchrony in Non-Obstructive Hypertrophic 
Cardiomyopathy.  
 
Background.  
Previous studies have reported dyssynchrony using Tissue Doppler in patients with hypertrophic 
cardiomyopathy (HCM). In this study, we assessed dyssynchrony using Speckle tracking 
echocardiography (STE) in patients with non-obstructive hypertrophic cardiomyopathy vs. a 
healthy control group and in a subgroup of highly symptomatic patients evaluated the acute effects 
of biventricular pacing on STE and Tissue Doppler (TDI) derived measures of dyssynchrony. 
Methods. 
We studied 48 healthy controls (age 48 ± 18yrs, 22 males, LVEF 63 ± 5%, QRS 86 ± 7ms) and 57 
patients with HCM (age 54 ± 11yrs, 38 males, LVEF 61 ± 7%, QRS 110 ± 36ms). A subgroup of 
15 symptomatic patients with HCM (Peak VO2< 60% predicted) underwent biventricular pacing 
(age 53 ± 12yrs, 12 males, LVEF 61 ± 7%, QRS 110 ± 32ms). Echocardiography was performed 
with the pacemaker off (VVI30) and on (DDDR, AV delay 90ms, LV-RV delay 0-4ms). Using 
STE, the standard deviation (SD) in time to peak longitudinal strain (Tε-SD), the time to peak 
longitudinal systolic velocity (Ts) for each of 18 left ventricular segments and the SD of this timing 
(Ts-SD) was derived. Using TDI dyssynchrony was assessed from the SD of Ts for the basal six 
segments and the maximum difference in Ts between any two basal segments (Ts-peak[basal]). 
 
Results. 
Using STE, Tε-SD (54.99 ± 33.61ms vs. 24.55 ± 21.18ms p< 0.001), Ts-SD (71.06 ± 32.32ms vs. 
46.17 ± 21.50ms p< 0.001) and Ts (155.74 ± 23.14ms vs. 123.71 ± 11.25ms p< 0.001) were greater 
in HCM than in controls. Using STE, we demonstrated that biventricular pacing significantly 
reduced Tε-SD and Ts-SD to values similar to those observed in controls (Ts-SD p=0.13). Using 
TDI we demonstrated that biventricular pacing significantly reduced Ts, Ts-SD, and Ts-
peak[basal]. See Table. (All values expressed as mean ± SD) 
Conclusion. Cardiac resynchronisation therapy significantly reduced dyssynchrony in symptomatic 
patients with non-obstructive HCM as demonstrated using STE and TDI. 
             
       
Off-Pace 
(mean ± SD) 
On-Pace 
(mean ± SD) P 
     Tε-SD (ms)   51.94 ± 26.93 37.44 ± 17.88 0.02 
   STE Ts-SD (ms)   67.93 ± 21.15 55.05 ± 19.84  0.02 
     Ts (ms)   159.68 ± 23.49  133.83 ± 24.27  0.001 
                   Ts (ms)   195 ± 22 169 ± 32   0.003 
   TDI Ts-SD (ms)   68 ± 42 36 ± 20  0.008 
     Ts-peak[basal] (ms) 151 ± 94  85 ± 50  0.006 
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Chapter 1 	
 
 
Introduction 
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Hypertrophic cardiomyopathy (HCM), (Figure 1.1), is the myocardial phenotypic 
expression of single gene mutations affecting sarcomeric components5 (Figure 1.3), in association 
with environmental factors. Macroscopically observed as an abnormal thickening of the 
myocardium, in variable distributions, (Figure 1.2), histologically myocyte disarray with increased 
interstitial fibrosis is described (Figure 1.4). The functional consequences are widely varied with 
some patients being asymptomatic, others having severe symptoms, and others dying suddenly 
with or without prior symptoms (Figure 1.5). In patients who have obstruction to the outflow of 
blood from the left ventricle (LV) and those that develop LV systolic dysfunction, successful 
treatment modalities exist. However approximately a third of patients have marked limitations of 
exercise tolerance and experience breathlessness, in the absence of obstruction to the outflow of 
blood6, and a ‘normal’ LV ejection fraction. This subgroup of patients has at present few medical 
management options, mainly beta blockers and Verapamil (Figure 1.6), with  heart transplantation 
remaining the final recourse should symptoms of refractory heart failure develop7. In this subgroup 
of patients diastolic dysfunction8 is thought to account for the symptoms experienced. The 
mechanisms involved in producing the abnormalities of diastolic function have not been clearly 
elucidated. This has been compounded by limitations in current non-invasive techniques of 
assessing diastolic function9.  
 In previous work, Frenneaux et al. and others have described mechanisms involved in the 
genesis of diastolic dysfunction in patients with chronic heart failure, in particular diastolic 
ventricular interaction4 (DVI). Because pulmonary hypertension is associated with DVI and is 
present in a minority of HCM patients at rest, but a substantial proportion of patients on exercise 
there is reason to believe that diastolic ventricular interaction may be present in patient with HCM 
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at rest, and develop on exercise. Further, Frenneaux et al. have shown that using pacing techniques 
that this mechanism may be modified10. 
Against this background, the aims of the present study were to use gated ventriculography 
to assess myocardial performance at rest, on exercise, and following lower body negative pressure. 
These measurements were made with and without BiV pacing, focussing on the presence of DVI 
at rest and its development on exercise, and on the effects of BiV pacing.  Given that HCM exhibits 
increased myocyte disarray and fibrosis, this may be suitable substrate to give rise to a 
dyssynchronously contracting and relaxing myocardium11. Dyssynchronous contraction has been 
well established in patients with systolic heart failure, with few studies in HCM patients12 13. A 
number of studies have demonstrated improvement in parameters of mechanical dyssynchrony 
following BiV pacing in patients with systolic heart failure14. However, as far as we know, the 
impact of BiV pacing on dyssynchrony in HCM has not been reported.  Therefore, in the present 
study we assessed the effect of acute and chronic BiV pacing on echocardiographic measures of 
dyssynchrony in patients with HCM. 
 Chronic BiV pacing has been well established to improve exercise tolerance, (as measured 
using peak Oxygen consumption) in patients with systolic heart failure15, 16. In order to assess the 
impact of chronic BiV pacing on exercise tolerance in this group of patients, we carried out a double 
blind, randomised, cross over trial (Figure 1.15). The primary end point was peak Oxygen 
consumption (VO2max), and the secondary endpoint being quality of life (Minnesota living with 
heart failure questionnaire).  As far as we know The trial described in this thesis is the first one to 
assess the effect of chronic BiV pacing on peak Oxygen consumption in patients with symptomatic 
limited non-obstructive hypertrophic cardiomyopathy. 
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Given these general aims, the remainder of this Chapter provides a detailed overview of the 
clinical presentation of Hypertrophic Cardiomyopathy, its underlying pathophysiology and its 
current clinical management. This is followed by a discussion of how its pathophysiology may 
overlap with the more established entity of systolic heart failure focussing in particular on the 
origins and measures of dyssynchrony and diastolic ventricular interaction. Finally, the treatment 
modality of BiV pacing is discussed and the mechanisms by which it might have beneficial effects, 
so providing a foundation for the hypotheses tested in the present study.  
Hypertrophic Cardiomyopathy Definition 
Hypertrophic Cardiomyopathy (HCM) is defined as the presence of left ventricular wall 
hypertrophy (LVH), in any distribution, occurring in the absence of a disease process sufficient to 
explain the extent of hypertrophy seen17. It is inherited in an autosomal dominant fashion18.  
Clinically a wall thickness of greater than or equal to 15mm is required for the diagnosis except in 
known gene carriers or in those with affected first degree relative in whom a maximum wall 
thickness of greater than 12mm is sufficient 17. Electrocardiographic changes and deterioration in 
diastolic function may precede the development of visible hypertrophy19. There are histologically 
characteristic features, though none are pathognomonic. Classically, there is extensive myocyte 
disarray20, with disorientation of myocytes, which vary in size and shape. In the interstitial space 
the amount of collagen is increased seen as fibrotic scar tissue21. Even in what appears 
macroscopically normal myocardium the content of interstitial matrix is increased. Small vessels 
show wall thickening with reduction of lumen22. 
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Sub classification 
Patients with Hypertrophic Cardiomyopathy can be further sub classified dependent on the 
distribution of hypertrophy23, and presence or absence of significant obstruction, usually affecting 
the outflow tract6 (LVOT) (gradient  > 30mmHg)24 and less commonly the midcavity (Figure 1.1). 
Virtually any distribution of hypertrophy can be consistent with a diagnosis of HCM. The 
commonest distribution is hypertrophy affecting predominantly the septum (asymmetric septal 
hypertrophy) (ASH)25. Patients may however exhibit other patterns including concentric LVH and 
apical hypertrophy (Figure 1.2). 
 
 
 
 
 
 
 
 
Approximately a third of HCM patients may have significant LVOT obstruction at rest24, a third 
develop a LVOT gradient on exercise, and a third have neither a resting nor  an exercise induced 
obstruction6. Obstruction of the LV outflow tract may be labile, characterised by spontaneous 
variability on a day to day basis affected by various factors that alter LV contractility and loading. 
Mechanical obstruction to the outflow of blood from the LV is produced by systolic anterior 
displacement of either the anterior26 or posterior leaflet, but sometimes by mid-cavity muscular 
apposition27.  The presence of a LVOT gradient, whether at rest or on exertion, is important to 
 Figure 1.1 : The Hypertrophic Heart 
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establish since it relates to the progressive development of heart failure symptoms31 and 
cardiovascular mortality28, 29. Furthermore, symptoms of heart failure may be treated successfully 
by LV outflow tract obstruction reduction30, 31.  
 Echocardiography is a relatively easy, non-invasive method of establishing the 
presence/absence of an out-flow tract gradient. The same technique applied immediately following 
exertion may demonstrate an LV outflow gradient previously not seen at rest 6.   
 Over time a subset of patients with HCM  may progress to a ‘burnt out stage’ with thinning 
of the LV walls, dilation of the LV, and progressive systolic dysfunction32. Other patients may 
have profoundly 'restrictive' physiology, with other members of their family sometimes presenting 
as restrictive cardiomyopathy without significant left ventricular hypertrophy.  
Natural History of Non-Obstructive Hypertrophic Cardiomyopathy 
 This subset of patients has been less intensively studied compared to obstructive HCM, so 
the natural history has been less clearly defined. Maron et al.33 prospectively followed up 249 HCM 
patients with NYHA symptom class I-II, who had no LVOT obstruction at rest or on exercise, over 
a time course of 6 years. They report that the vast majority (≈ 90%) of patients remained 
asymptomatic, with an average ejection fraction of 60%. These patients had a low risk of 
progressive heart failure symptoms (1.6%/year) and a mortality rate comparable to the general 
population (0.5%/year) with infrequency of sudden cardiac death. However over 6 years, 10% of 
HCM patients developed progressive HF symptoms, with approximately 3% requiring heart 
transplantation, in contrast no patients with obstructive HCM required transplantation.  Though 
HCM patients with obstruction have a fivefold greater risk of developing debilitating symptoms, 
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this group of patients has recourse to invasive obstruction relieving procedures, consequently the 
need for transplantation is avoided 
 Rowin et al.34 reported that  1% of HCM patients (20 out of 2100), requiring transplantation 
for refractory HF symptoms had no LV outflow obstruction (rest or exercise) and had preserved 
LV systolic function. The mean age at the onset of heart failure symptoms was 35years and at time 
of listing for transplant 41years.  Of interest mean pulmonary artery pressure was elevated at rest 
(31±11mmHg), with evidence of elevated LV end diastolic pressure at cardiac catheterisation, of 
note two patients at cardiac catheterisation had normal resting mean pulmonary artery pressure, but 
on exertion this increased to >30mmHg. HCM transplant candidates with reduced systolic function 
usually show diffuse (often transmural) LV myocardial scarring, in contrast this subgroup of 20 
patients with advanced HF symptoms showed no or minimal myocardial fibrosis on histology or 
on MRI imaging, which would suggest perhaps a more distensible myocardium in this subset.  It 
is of interest that almost half of these patients demonstrated a restrictive pattern of filling on 
echocardiography.  
 In summary, the vast majority of patients with NOHCM and preserved LV systolic 
function, have few symptoms and an excellent prognosis. Nevertheless, a small but not 
insignificant number develop debilitating heart failure symptoms at a relatively young age, for 
whom heart transplantation is currently the most effective form of therapy. 
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Prevalence 
Population studies have shown that HCM affects approximately 1 in 500 of the General 
population35, making it the commonest inherited cardiac condition. This may represent an 
underestimate as it is based exclusively on phenotype positive disease, ignoring genotype positive, 
phenotype negative patients. 
 
 
 
 
 
 
 
 
Figure 1.2 : Macroscopic Types of HCM3 
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Figure 1.4 :  Histology HCM. The normal histology (A) is perturbed in HCM, with marked 
enlargement and disarray of myocytes (B) with increased interstitial fibrosis (C)36.  
 
Genetics 
Although sporadic cases occur, heritable HCM is a Mendelian autosomal dominant trait 
with variable penetrance. The vast majority of families in whom a disease-causing mutation is 
identified have a mutation of a gene encoding a sarcomere protein. Thus far, 434 mutations in any 
of 10 genes encoding sarcomeric proteins have been identified, most of which are missense 
mutations1. Three HCM causing genes  have been found to account for over half patients 
genotyped17. Despite these advances all the genetic variations causing HCM have not been 
identified, with current genetic testing identifying a recognised disease causing mutation in 
approximately 50% of probands37. Phenotypic expression is myriad a genotype-phenotype 
  Figure 1.3 : The Sarcomere. Schematic demonstrating the components of the sarcomere.
(http://people.fmarion.edu/) 
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correlation rather poor and consistent with a interplay between modifier genes and environmental 
factors38. 
Clinical Presentation 
Given the varied natural history of HCM ( Figure 1.5), prognostication is difficult. Patients 
may experience few symptoms for long periods of time, with 25% of patients achieving a normal 
life span39. Patients frequently complain of breathlessness and exercise intolerance. In some the 
predominant cause is dynamic left ventricular outflow tract obstruction40, 41 in a small proportion a 
progressive impairment of left ventricular systolic function is responsible. In at least 50% an 
abnormality of LV relaxation and diastolic filling is the predominant mechanism42-44. 
 
  
 
 
 Sudden cardiac death (SCD) is the most feared complication of HCM, being the commonest 
cause of premature death in this condition.  HCM is arguably the commonest cause of SCD in 
young adults although it may also occur in later life but with lower frequency45. Ventricular 
Figure 1.5 : HCM Clinical presentation
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arrhythmia has been reported as the most common cause of SCD events, using data collected from 
implanted cardioverter-defibrillator units46. It is thought that ventricular arrhythmias arise from 
electrically unstable myocardial substrate resulting in the sudden loss of cardiac output and death.  
Patients may be risk stratified for SCD based on the presence or absence of several 
recognised risk factors for SCD. These include a history of unexplained syncope47, or a family 
history of SCD48, severe myocardial thickening (>30mm), significant LVOTO (>30mmHg), 
documented evidence of ventricular tachycardia (sustained or non-sustained) 49 and failure of the 
systolic blood pressure to rise by at least 25mmHg at peak exercise on stress testing50, 51, 
particularly in those less than 40 years of age. Patients with the presence of two or more risk factors 
(annual SCD rate of 3% (95% CI 2-7%) were traditionally offered prophylactic Implantable 
Cardioverter Defibrillator Therapy (ICD). More recently a model for risk stratification has been 
developed by O’Mahoney et al.52, has applied a more continuous weighting to risk factors for SCD, 
rather than a binary approach. This model has been validated as a risk prediction tool for SCD 
(http://doc2do.com/hcm/webHCM.html), allowing better identification of high risk patients, with 
avoidance of patient harm through unnecessary ICD implantation. 
Exercise Intolerance in HCM: The Role of Diastolic Function  
 Patients with HCM are often symptomatic and complain of exercise intolerance 41, 53. The 
underlying pathophysiology is multifactorial and complex. Diastolic dysfunction is one component 
that is traditionally cited as the cause for exercise intolerance in non-obstructive HCM7. 
 Subjective effort intolerance is now widely evaluated objectively by exercise testing. 
Aerobic exercise, progressively increasing to the maximal tolerance is a common physiological 
stress that can elicit cardiovascular abnormalities not present at rest, while aiding in the 
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determination of the adequacy of cardiac function. As exercise is initiated there is an increase in 
Oxygen requirement from the body in general, but primarily from working muscle 54. To supply 
these demands cardiac output is normally increased by a combination of stroke volume 
augmentation and increased heart rate. In health, given the skeletal muscles ability to utilize  
Oxygen far exceeding the capacity of the cardiovascular system to deliver Oxygen55 56, cardiac 
output becomes the limiting step in determining the bodies peak Oxygen consumption during 
exercise. Peak Oxygen consumption (VO2max) can be measured during the performance of dynamic 
exercise involving a large part of total muscle mass. Cardiac output explains 70-85% of the 
variance in VO2max with the remainder being determined by  peripheral Oxygen extraction57.  
VO2max  is considered to be one of the best measures of cardiovascular fitness and exercise 
capacity58. 
 In health, cardiac output can increase as much as 4-6 fold above basal levels during exercise 
59. Studies in patients with HCM have shown that the peak Oxygen consumption achieved is clearly 
related to peak cardiac output 42, 60. Given that cardiac output is the product of heart rate and stroke 
volume, both of these variables will have an influence on VO2max. This is clinically exemplified by 
the fact that almost 25% of HCM patients with chronotropic incompetence, have a reduced VO2max 
and greater symptom burden61, 62.  
 LV stroke volume (SV) (in the presence of competent valves) is the difference between 
end-diastolic (EDV), and end-systolic volumes (ESV) (SV = EDV - ESV). An increase in LV SV 
would mandate an increase in LV EDV and/or a reduction in LV ESV. Patients with HCM often 
have supranormal systolic function63, at rest, suggesting a limited role for further reductions in ESV 
on exercise42 to contribute to an increase in SV, even in health reductions in ESV on exercise are 
modest64.  
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 The volume of blood accommodated in the LV chamber during diastole is related to the 
functional characteristics of the LV myocardium and to filling pressures, the relative contributions 
of each being dynamic and interrelated throughout the course of the cardiac cycle.  
 On exertion, an increased HR reduces the duration of diastole65, abbreviating the time 
available for LV filling, ≈0.55 seconds at 70 beats min-1 to ≈0.12 seconds at 195 beats min-1 66. To 
augment LVEDV, or even to maintain it67, the rate of LV filling has to increase for a significant 
portion of the LV filling period 68, 69.  The acceleration of blood flow into the LV is determined by 
the pressure drop across the mitral valve (LA pressure -LV Pressure)70, which in turn is determined 
largely by LV diastolic function and LA pressure at the time of mitral valve opening. In health, LV 
diastolic function is in the main a reflection of a composite of LV intrinsic stiffness and its ability 
to relax, with extra-myocardial elements (e.g. pericardium) having a limited influence. A rapidly 
relaxing ventricle (reduced tau71), with negligible pericardial constraint, allows for the 
development of an increased gradient across the MV ('suction') in diastole, without necessitating 
an excessive increase in LA pressure 68.  
 Any mechanism then, that adversely affects LV diastolic function, will have repercussions 
seen in LA pressures and upstream in the pulmonary vasculature, and in reduced cardiac output 
augmentation, manifest clinically as dyspnea and exercise intolerance.  
 Invasive and non-invasive techniques have been used to characterize indices of global and 
individual components of diastolic function, and which have then been related to exercise tolerance 
and symptom burden in patients with HCM.  
 Measuring the characteristics of individual components of myocardial mechanics during 
diastole, on exercise, would appear to be the most direct approach at evaluating myocardial 
diastolic function. This has proven difficult, perhaps not so surprising given the diastolic 
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myocardium experiences a laminated wave front of thinning (radially), lengthening (longitudinally 
and circumferentially) and un-twisting, atop a distending force, all completed in just over a tenth 
of a second! Nevertheless, investigators have attempted to define measures of diastolic mechanical 
function, in particular using echocardiography, specifically tissue doppler imaging and more 
recently speckle tracking.  
 Patients with HCM have been reported to have reduced early diastolic longitudinal 
velocities (e'), even prior to the development of symptoms and overt hypertrophy 72. Early 
longitudinal diastolic velocity at the septal mitral annulus has been inversely related to tau (time 
constant of isovolumic relaxation)73 perhaps a reflection perhaps of reduced relaxation, and 
elasticity. However, the reduction in e' has been inconsistently related to a reduction in exercise 
tolerance and symptoms 8, 74-76. 
  Kato et al. 77 using TDI, reported a marked reduction in early diastolic longitudinal strain 
rate in patients with HCM, to less than half, compared to controls and patients with LVH secondary 
to hypertension. A strong correlation was reported by Mizukoshi et al. 78 between early diastolic 
longitudinal strain rate during exercise and peak Oxygen consumption (Figure 1.16). Of important 
note, no correlation was found at rest. 
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Figure 1.6 : Association between peak VO2max versus early diastolic longitudinal strain rate 
(LSRe) during exercise. (r = 0.63, p<0.001) 78 
 
 Untwist, a relatively load independent metric of diastolic function79, increases during 
exercise in healthy individuals80. The peak rate of untwist has been shown to be temporally and 
sequentially related to the development of the peak intraventricular pressure gradient80. Of 
important clinical relevance Rovner et al.81, observed a direct relationship between intraventricular 
pressure gradients("suction") to peak Oxygen consumption.    
 In patients with HCM untwist has been shown to be delayed 82 83 when compared to healthy 
volunteers, and to correlate, though weakly, (r=0.36 p=0.006) with peak Oxygen consumptions83. 
The underlying cause of altered twist/untwist in HCM may relate to regional abnormalities of 
systolic and diastolic function. Knudtson et al. 84 demonstrating degradation in untwisting function 
following myocardial ischemia. 
 Given the intrinsic limits of the information obtained from examining individual 
components of myocardial function, investigators have assessed markers of global diastolic 
function.  
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 Using radionuclide ventriculography Bonow et al.85 demonstrated that the LV peak filling 
rate (PFR) in patients with HCM at rest was increased by Verapamil, and that this increase 
correlated, reversibly, with an improvement in exercise capacity.  Though they observed a 
reduction in time to peak filling (TTPF) acutely following Verapamil (∆TTPF 23ms p<0.001), this 
appears not sustained at longer term follow-up (∆TTPF 5ms p=ns) however PFR remained 
increased. These findings suggest that improved diastolic function is related to an increase in 
exercise capacity.  Frenneaux et al.86 correlated exercise capacity in patients with HCM, measured 
using peak Oxygen consumption, with peak cardiac output, but observed no relation of peak 
exercise capacity with resting peak filling rate. Chikamori et al.60 reported that patients with 
NOHCM with marked exercise limitation (VO2max <70% predicted), had a reduced LV PFR, 
however they observed that the time to LV PFR (TTPF) did not discriminate between patient with 
and without marked exercise limitation. Though it needs pointing out that, studies by Chikamori et 
al. were carried out at rest.  
 Lele et al.42  demonstrated that compared to healthy controls, resting LV PFR was modestly 
lower (p=ns) in patients with HCM, but on exercise this difference was significantly more 
pronounced (p=0.001). The authors observed a strong inverse relationship between TTPF and 
VO2max in HCM patients.  A prolonged TTPF was noted both at rest and on exercise in patients 
compared to healthy controls. On exercise, both healthy controls and HCM patients experienced a 
reduction in the TTPF, however in health this was more than 50% but just over 33% in patients. 
Furthermore, in patients there was a loss of the normal inverse relation between HR and TTPF87, 
with some patients experiencing a paradoxical prolongation of TTPF on exercise.  
These finding suggest that for the LV to fill effectively during diastole on exercise, the LV has not 
only to have a greater filling rate, but for a duration sufficient to increase LVEDV. Not only does 
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this not happen in HCM, with evidence suggesting baseline dysfunction, but diastolic function may 
deteriorate further on exercise.  
 Given the ease with which LV filling velocity may be measured non-invasively using 
echocardiography, at first sight it would appear to have the potential to be a readily available index 
of global diastolic function. Though LV filling velocities have been demonstrated to be reduced at 
rest, using standard doppler, in HCM patients compared to healthy volunteers88, this was not related 
to exercise capacity89. The variance of LV filling velocity is dependent on LV loading conditions70, 
making it an unreliable indicator of LV myocardial function during diastole.  
 Left atrial volume has been suggested as a marker of the chronicity and severity of global 
LV diastolic dysfunction90. An increased LA size reflects the cumulative effect of LV filling 
pressure over time. Nishimura et al.91 demonstrated that increasing LA pressure positively 
correlated with doppler evidence of diastolic dysfunction, with Matsuda et al.92 showing that as 
diastolic function deteriorates, LA volume increases. Kjaergaard et al.93, using echocardiography 
to measure LA volumes in patients with HCM, observed an inverse correlation with peak Oxygen 
consumption.  Though the correlation was weak (r= -0.2 p=0.06), on multivariate linear analysis 
LA volume was an independent predictor of exercise capacity in patients with HCM. 
 The cause of diastolic dysfunction in HCM is likely multifactorial. Passive left ventricular 
stiffness is probably increased by hypertrophy, myocyte disarray, and interstitial fibrosis, 
compounded by microvascular ischemia94. However, Abozguia et al. have shown that the abnormal 
LV relaxation response to exercise is related to impaired cardiac energetics. Both were corrected 
by the metabolic modulator Perhexiline, which resulted in an increase in peak Oxygen 
consumption95. 
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 In summary, measuring diastolic function, particularly on exercise, has proven difficult, 
with many indices of diastolic function influenced by loading conditions, making interpretation 
difficult. However, though limited, there is direct and indirect evidence that suggests that diastolic 
function is impaired in patients with HCM, with consequential adverse effect on exercise tolerance 
and symptom status. 
Symptom Management  
Pharmacotherapy 
HCM with significant obstruction is commonly treated with Beta-blockers +/- 
Disopyramide17 symptomatic non-obstructive HCM is often first managed with calcium channel 
blockers. Beta blockers lower the heart rate, prolonging diastole with increased passive ventricular 
filling96, 97. However, beta blockers also slow the rate of LV active relaxation which may offset the 
beneficial effects of a slower heart rate98. The negative inotropic properties of beta blockers may 
lessen myocardial Oxygen demand and decrease the outflow gradient particularly during exercise99 
and potentially mitigate against arrhythmia100. Disopyramide, a sodium channel blocker, has also 
been used in patients with severe refractory symptoms in obstructive HCM, the reduction in the 
obstruction being due to its negatively inotropic properties101, and improved diastolic function 
being demonstrated102. However due to Disopyramides’ anticholinergic properties, and concern 
regarding potentially enhanced conduction through the AV node, it is often combined with a small 
dose of beta blocker. 
 Calcium channel blockers can be a therapeutic option, usually when beta blocker therapy 
is contraindicated, with Verapamil being the first in its class to be used 63, 103. It has been used for 
both obstructive and non-obstructive cardiomyopathy, particularly in those with chest pain104 in 
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addition to exercise limitation. Its strongly negatively chronotropic and inotropic properties 
improving ventricular relaxation, and ventricular filling, which probably have a beneficial effect 
on the myocardial Oxygen supply-demand ratio105, 106.  However, concern has been raised over 
deaths linked to Verapamil use in patients with severely obstructive HCM, who had severe 
symptoms (orthopnoea, paroxysmal nocturnal dyspnoea) with elevated pulmonary artery 
pressures.107 Hence, some clinicians advocate the use of Disopyramide combined with beta blocker 
therapy in such patients108. 
 The majority of patients with non-obstructive HCM do not develop symptoms of heart 
failure33. A small subset, 10%, may develop exertional dyspnoea (with persevered systolic 
function)33. In these patients management strategies, have been limited to beta blockers and 
calcium channel blockers, and diuretics for several decades 85, 109, 110. Beta-blocking drugs are 
recommended first line in patients who can tolerate them47, dose titration guided by heart rate, 
target heart rate of 60-65 beats per minute110. Verapamil63 is the calcium channel blocker that is 
recommended in patients with side-effects or with contraindications to beta-blockers110. If 
symptoms of heart failure persist despite rate limiting drugs, then diuretic therapy may be added109.   
More recently Abozguia et al.95 have demonstrated the effectiveness of the metabolic manipulator 
Perhexiline in improving exercise tolerance and symptom, in this group of patients.  A small but 
significant proportion of patients with NOHCM develop symptoms of heart failure refractory to 
medical management despite normal systolic function. For this group of patients heart 
transplantation currently is the most effective form of therapy34. 
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Figure 1.7 : A simplified flow chart detailing the management of HCM following diagnosis. 
 
 
Device therapy 
 
It was chance clinical observations in the 1960s and 1970s that suggested a role for 
ventricular pacing in patients with obstructive HCM. Investigators initially presented case reports, 
and small case series of ventricular pacing diminishing LVOT gradients in patients with obstructive 
HCM. 111-113  
In 1975 Johnson & Daily,114 published a case report in which they described  the co-
incidental abolition of the LV outflow tract gradient in a 71 year old man with HCM requiring 
atrioventricular pacing for high grade AV  block. Several observations they made are particularly 
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noteworthy and pertinent today. The authors report that elimination of the outflow tract gradient 
was only observed when atrial contraction preceded ventricular pacing (Figure 1.7), and when atrial 
contraction preceded a QRS complex there was associated increase in LV end diastolic dimension. 
Furthermore, the patient was haemodynamically intolerant of fixed rate ventricular pacing 
necessitating that he receives AV sequential pacing (A-V delay 175ms). These features suggest the 
importance of increasing LVEDV as mechanism of LVOT gradient reduction, and maintaining 
haemodynamic stability. Permanent pacing was delivered via right atrial and left ventricular 
epicardial (via sternotomy) electrodes. The authors state that the patient convalesced satisfactorily. 
 
 
Figure 1.8 :  Ventricular pacing HOCM. Left ventricular and left brachial artery pressures 
recorded during ventricular pacing. Beats preceded by a P wave (R1, R2, R7) have no systolic 
gradient. 114 
 
Ventricular pacing was used successfully by the original investigators to reduce LV outflow 
tract gradient, but compromised LV stroke volume and systolic pressures 111, 112. A subsequent 
small case series, using atrioventricular sequential pacing, demonstrated successful reduction in 
LV outflow gradient and importantly the preservation of stroke volume 115. The mechanism of 
improvement was not clear, the authors suggested that the altered sequence of ventricular activation 
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caused an enlargement of the LVOT (similar to the understanding we have today). The therapeutic 
potential of AV sequential pacing was highlighted in a case series by  McDonald et al., who 
reported improvement in exercise tolerance in 9 out of 11 patients implanted.116, though no mention 
is made on the impact of pacing on LVOT gradients in these patients. 
These initial reports of amelioration of underlying pathophysiology, and symptomatic 
benefit of AV sequential pacing were encouraging.  In 1992 Jeanrenaud et al. 117 published a small 
prospective non-randomised study which evaluated the acute and chronic (over 3years) effects of 
AV sequential pacing on the symptom status and haemodynamics of 13 patients with severely 
symptom limited obstructive HCM. The investigators reported an acute reduction in LVOT 
gradient of greater than 40% (with no loss of cardiac output), and over a period of 3 years 
symptomatic improvement.  The paced AV interval reported as the key determinant for LVOT 
gradient reduction. This both needed to be long enough to allow optimum filling of the LV and 
short enough to preserve apical pre-excitation. The authors suggested that RV apical excitation 
altered the ventricular pattern of contraction such that septal contraction was attenuated, delaying 
the onset of the mitral leaflet-septal contact mechanism of gradient generation during systole 40.  
Following the report by Jeanrenaud et al.117 a number of investigators 118-122 reported non-
randomised prospective cohort studies, suggestive of therapeutic benefit from AV sequential 
pacing with an associated reduction in LVOT gradients. 
Fananapazir et al.119 initially reported a non-randomised, non-blind, short term (3 months) 
study, examining the role of AV sequential pacing in 44 patients with obstructive HCM and severe 
symptoms (NYHA III-IV). Impressively, subjective symptomatic benefit was reported in all 44 
patients, and a substantial improvement in peak Oxygen consumption of 2ml/kg/min (p<0.005). 
LVOT gradient was reduced, acutely, by almost 60% together with an increase in systemic arterial 
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pressures. Of further interest, when AV sequential pacing was discontinued following 3 months of 
pacing, the reduction in LVOT gradient persisted.  The authors suggest this as evidence for 
remodelling.  
Two years later the same group of investigators 120  conducted a chronic (over 2 years) non-
randomised, non-blind, prospective study investigating the effect AV sequential pacing on 84 
patients with symptom limited (mean NYHA class 3.2) obstructive HCM (mean gradient 
96mmHg). Symptom reduction was again impressive, reported in almost 90% of patients, by the 
end of follow-up over a third of the original cohort required no pharmacotherapy. The authors 
reported a mean reduction in LVOT gradient of 60mmHg with complete elimination in 50% of 
patients. The severity of mitral valve SAM was reduced as was mitral regurgitation, with no 
reduction in cardiac output. Of particular clinical relevance was their observation of regression in 
LV wall thickness, consistent with earlier reports123. A statistically significant increase in LV end 
systolic dimension was reported (≈1.5mm, no change in LVEDD), though small, this would have 
a particular clinical significance if put in the context of a thinning LV wall. However, the authors 
point out that wall thinning was segmental, and there was no correlation with reduction in LVOT 
obstruction. This is reassuring, as the only other time when the wall thickness regresses in HCM is 
the end-stage phase, which preludes to transplantation.   Of interest this reduction in wall thickness 
has not been reported following reduction in LVOT gradient following myectomy or septal 
ablation. 
These initial pilot cohort studies made a powerful argument for the role of AV sequential 
pacing in symptomatic obstructive HCM. Nevertheless, it was noted that they were all non-
randomised, non-blind, uncontrolled, prospective studies, with inherent shortcomings. 
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Investigators subsequently conducted randomized crossover trials focusing on symptom reduction, 
improvement in exercise tolerance and relief of outflow obstruction.  
 In 1997 Kappenberger et al.121 reported the outcomes of a short-term, randomized, double 
blind, cross-over study. This group evaluated the effects of 3 months of AV sequential pacing in 
83 patients (mean age 53years) with obstructive HCM, who were symptom limited (NYHA II-III), 
with objective evidence of reduced exercise tolerance (VO2max ≤ 85%). All patients experienced 3 
months of AV sequential RV pacing and 3 months of sham pacing, in random order. No washout 
period was defined. The authors reported that following AV sequential pacing, on average a 1 class 
improvement in NYHA grading of symptoms was seen, but with no change in exercise tolerance. 
A marked (50%) reduction in LVOT gradient was observed, reassuringly no change in ejection 
fraction was reported. Kappenberg et al.121 reported that 20 patients experienced symptomatic 
benefit even during sham pacing, suggestive of a possible placebo effect. Of interest, they found 
no correlation between the acute reduction in LVOT gradient and reported reduction in symptoms, 
suggesting underlying mechanisms of symptom improvement following pacing, 124 125 126 other 
than LVOT gradient reduction. 
 Nishimura et al. 127 conducted a smaller (21 patients), short term, double-blind, randomized, 
cross-over study to evaluate the effect of AV sequential pacing in patients with obstructive (LVOT 
gradient>50mmHg) HCM who were severely symptomatic (NYHA III-IV) and exercise limited 
(meanVO2max 19.4ml/kg/min. Patients experienced a 3-month duration of AV sequential pacing 
and sham pacing, in random order, with no washout period.  Using temporary pacing studies at 
cardiac catheterisation, the AV interval (mean 70ms) to be programmed for chronic pacing was 
determined as the interval that allowed, at rest at least, the maximum reduction in LVOT gradient 
without compromising aortic pressure (as described by Jeanrenaud et al.117). The authors reported 
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that patient symptoms were significantly reduced following pacemaker implantation regardless of 
pacing mode (42% of patients reported symptom improvement during sham pacing), but no 
significant difference in symptom reports when comparing the periods of sham pacing and AV 
sequential pacing. Theses finding are strongly suggestive of a placebo component to the 
improvement in patient symptom experience. Similarly, neither exercise duration nor peak Oxygen 
consumption was significantly different between AV sequential pacing and sham pacing. LVOT 
gradient was reported as reduced, by 30%. Nonetheless the residual gradient was still substantial 
(55mmHg), meeting the criterion for surgical myectomy.  Though baseline LVOT gradient was 
greater in those patients who experienced symptom improvement, there was no correlation between 
reduction in LVOT gradient (acute pacing) and symptom improvement. Analyses of those patients 
that experienced AV sequential pacing first, because of concerns regarding a possible carry-over 
effect, again revealed no improvement in of symptom, exercise tolerance or LVOT gradient 
reduction.  
 Maron et al.128 Conducted a short-term (3month), randomized, cross-over study assessing 
the impact of AV sequential pacing in 48 patients with obstructive HCM.  Patients were severely 
symptomatic NYHA III-IV (≈80% of patients), exercise limited (VO2max 16.2±5ml/kg/min), and 
had a minimum peak resting LVOT gradient of ≥ 50mmHg. The AV delay (85±35ms) was 
determined during temporary pacing at cardiac catheterisation, similar to Jeanrenaud et al117.  The 
authors report no difference in symptoms, or in exercise tolerance (treadmill exercise time and 
VO2max) between AV sequential pacing and sham pacing. Although there was no washout period 
designed into the study, the results remain unchanged whether patients experienced AV sequential 
or sham pacing first. Of interest, patients reported a significant reduction in symptoms (p<0.001) 
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following pacemaker insertion compared to baseline, regardless of whether they were actively or 
sham paced, again suggestive of a placebo component to the benefit seen. 
 Maron et al.128 report that AV sequential pacing was associated with an average reduction 
in the LVOT gradient of  40%, comparable to Kappenberger et al. 121(50%), but modest when 
compared to Fananazapir et al.120 (60%), however over a third of patients experienced minimal to 
no change in LVOT gradient. Of particular note, no correlation was identified between a reduction 
in LVOT gradient, and exercise tolerance (r = -0.08) or change in symptoms (r = 0.14). A subgroup 
analysis suggested 6 patients experienced a non-placebo reduction in symptoms and improvement 
in exercise capacity following AV sequential pacing, of note all these patients were greater than 
65years old. 
 The initial findings in support of the beneficial effects on symptoms and exercise tolerance 
for AV sequential pacing were generated for the most part by non-randomized, uncontrolled, cohort 
studies. These findings have not been borne out in subsequent randomized, cross-over, studies 
which have suggested a significant placebo component to the symptomatic benefit seen.  Unrelated 
to changes in the underlying pathophysiology, except possibly in a subgroup of elderly patients. 
 Nevertheless, the magnitudes of reduction observed in resting LVOT gradient, following 
AV sequential pacing, has been statistically significant, with no placebo effect being reported. 
However, the clinical significance of this observation is questioned in light of no relationship 
between resting LVOT gradient reduction and symptom improvement.  
 At present sequential atrio-ventricular sequential pacing has been given a class IIb 
indication129  in patients with obstructive HCM who otherwise have a contraindication to septal 
alcohol ablation or septal myectomy.  
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Percutaneous alcohol septal ablation 
In patients with obstructive HCM with severe symptoms despite maximal medical therapy, 
an intracoronary injection of 1-4ml of alcohol may be given into a suitable septal perforator artery 
with the aim of producing a localised infarct in that area of myocardium with consequent reduction 
in septal thickness and resultant increase in LV outflow tract area31, 130. However, concerns have 
been raised about the long-term sequelae of an alcohol-induced myocardial infarction and 
associated scarring.  In particular, the possibility of the resultant scar tissue to behave as a substrate 
for potentially lethal arrhythmia131 132, 133. 
Surgical myectomy 
 This is the gold standard method with which to reduce left ventricular outflow tract 
obstruction in severely symptomatic patients who prove resistant to pharmacotherapy134, 135.  This 
procedure is associated with a substantial immediate and permanent reduction in the obstruction to 
outflow reported in the vast majority of patients136. As a consequence, excellent long-term 
symptomatic outcomes have been reported137.  In contrast to alcohol septal ablation surgical 
myectomy has not been shown to cause intra-myocardial scarring138. The risks associated with 
surgery  considered to be very low and in some of the most experienced centres mortality rates 
approach zero139.This is usually the final recourse in patients with obstructive HCM with drug 
refractory symptoms. 
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Dyssynchrony  
 
Dyssynchrony in Hypertrophic Cardiomyopathy   
 
Several studies have reported that HCM is characterised by dyssynchronous contraction 
and relaxation11, 140-143 which is presumably due to the patchy nature of both myocyte disarray and 
fibrosis, and possibly due to ischemia. Maron et al. found no correlation between the severity of 
myocardial thickening  and extent of myofiber disarray on histological examination144 suggesting 
that even myocardium that looks macroscopically normal may exhibit abnormal contractile 
patterns.  
 In the early 1990s Betocchi et al. using biplane ventriculography was able to assess regional 
systolic and diastolic asynchrony in 22 patients with hypertrophic cardiomyopathy11 of whom 12 
had significant LVOT obstruction. This method was used to create 12 sectors of the LV from which 
were derived time-volume curves. Systolic and diastolic dyssynchrony indices were derived from 
the standard deviation of the time taken for each sector from end-diastole to end-systole or from 
the time to peak filling rate for each sector. This method is similar to the more contemporaneous 
method of deriving the Yu index for quantifying ventricular synchrony (SD of time to peak systolic 
velocity for 12 segments of the LV). Betocchi et al.11 found systolic dyssynchrony in 50% of 
patients, but diastolic dyssynchrony in only 23% (5 patients). This is more prevalent than that 
reported in heart failure with a preserved ejection fraction (35-40%)145, but not quite as common 
as that seen in systolic heart failure with broad QRS (60-90%)146. Rather unfortunately, Betocchi 
et al. do not comment on ECG QRS durations in their cohort of patients.  
 Bonow et al.147 reported on diastolic dyssynchrony using radionuclide ventriculography in 
HCM patients. Compared to healthy volunteers they found a greater regional variation in time to 
peak filling. Furthermore, they found that Verapamil was able to smooth out this temporal variation 
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in diastolic function within the left ventricle (i.e. reducing diastolic dyssynchrony), with an 
attendant reduction in time to peak filling (TTPF), suggesting a mechanism for improvement in 
global diastolic function.  
Using contemporary Tissue Doppler Imaging (TDI) techniques both intra- and 
interventricular dyssynchrony has been reported in patients with HCM despite normal QRS 
duration on surface ECG148. Perhaps unsurprisingly, a direct positive correlation between systolic 
dyssynchrony and wall thickness (r=0.69) was reported but, counterintuitively a positive 
correlation with LVOT gradient(r=0.51) was observed (In contrast to diastolic dyssynchrony which 
was found to be inversely related to LVOT obstruction11). Clinically important, the presence of 
systolic dyssynchrony was found to be predictive of ventricular arrhythmia and sudden cardiac 
death 148, 149.  
 Echocardiographic Speckle tracking image analysis (STE) has suggested that the 
dyssynchrony seen in HCM may be more than just a function of hypertrophy alone12, consistent 
with the histological findings described by Maron et al.144. Using STE Nagakura et al. assessed 20 
patients with non-obstructive HCM with narrow complex QRS12. Using an 18 segment model of 
the LV and they derived a global dyssynchrony index from the SD of time to peak strain for all 18 
segments. This is similar to the Yu index, but theoretically at least appears more robust as it 
overcomes the shortcomings of tissue Doppler-derived longitudinal velocities and also includes the 
apex. They demonstrated that, as perhaps anticipated, patients with HCM had a greater degree of 
systolic dyssynchrony compared to controls but more interestingly that patients with hypertensive 
hypertrophy had no significant difference in dyssynchrony compared to age-matched healthy 
controls.  
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Using Magnetic Resonance Imaging (MRI), Schwammenthal et al.150 demonstrated that 
there were marked differences in contraction time between hypertrophied and non-hypertrophied 
segments of myocardium in patients with obstructive HCM, with hypertrophied segments ending 
contraction early in systole. 
  In summary, mechanical dyssynchrony has been identified in HCM by a number of 
investigators, with multiple modalities despite a narrow QRS duration of the surface 
electrocardiograph. This has been linked to global diastolic dysfunction, LV outflow tract 
obstruction and ventricular arrhythmia, and importantly that its amelioration with Verapamil was 
linked to improved global diastolic function. 
Dyssynchrony in Narrow QRS Heart Failure 
 
A QRS duration <120ms on the surface ECG suggests electrical synchrony, and intuitively 
might imply mechanical synchrony. This is of particular relevance to the current study, because 
the HCM patients we studied had a mean QRS duration of 98.82±4.05ms. However significant 
mechanical dyssynchrony has been shown to be present in patients with systolic heart failure 
despite a narrow QRS (<120ms) complex on the surface ECG by a number of investigators151-154. 
Ghio et al.152, examined 61 patients with systolic heart failure with a narrow QRS (<120ms) using 
TDI. They reported that intra-ventricular dyssynchrony was present in 29.5% of these patients 
despite a narrow QRS complex, and its presence an independent predictor of morbidity and all-
cause mortality. The investigators observed a correlation between the extent of systolic mechanical 
dyssynchrony and duration of the surface QRS complex, though this was weak(r=0.27). 
 Yu et al.153 studied 71 systolic heart failure (EF<50%) patients with narrow QRS 
(<120ms), using TDI (Ts-SD) to assess for both systolic and diastolic dyssynchrony. They 
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observed a greater prevalence of systolic dyssynchrony, (Ts-SD +2 SD of normal controls) in 43% 
of patients, compared to Ghio et al. (29.5%), and diastolic dyssynchrony (Te-SD +2 SD of normal 
controls) in 43% of these patients.  
 Shin et al.155 assessed 381 (340 with QRS<120ms) patients with significant LV systolic 
dysfunction following myocardial infarction.  Using STE, this group measured the dispersion of 
time to peak velocity and strain as indices of dyssynchrony. They report that the pattern of 
ventricular contraction (dyssynchronous contraction) was a predictor of death or heart failure 
independent of overall ventricular function and of regional wall motion abnormalities. Of particular 
note, only 7% of the patients with the greatest degree of dyssynchrony studied by Shin et al. had a 
prolonged QRS interval, emphasising the poor sensitivity of the surface ECG in detecting clinically 
significant cardiac dysfunction.  
The poor correlation of mechanical dyssynchrony with QRS duration may perhaps be due 
to the insensitivity of a surface electrocardiogram to represent electrical delay in all areas of the 
myocardium.  Notwithstanding this, in the presence of an intact His Purkinje network (narrow 
QRS) conceptualizing the origin of mechanical dyssynchrony is difficult. In myocardium, isolated 
from failing human hearts, alteration in calcium handing with disturbances in excitation contraction 
coupling have been demonstrated. These changes may partly explain the observation of mechanical 
dyssynchrony despite 'normal' electrical conduction as measured by a surface ECG156, 157. It may 
be that there is no significant impairment of electrical conduction, and so a narrow QRS complex,  
but despite this there is significant mechanical delay due to changes such as interstitial fibrosis, 
hypertrophy158, 159, or due to changes at the subcellular level160. Similarly, it is conceivable that the 
Purkinje network could be affected predominantly in its terminal portions, at the Purkinje myocyte 
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junction in limited areas of myocardium, so as to significantly alter mechanical activation 
sequence, without having a significant effect on the surface ECG recordings. 
Echocardiographic measures of dyssynchrony 
Three broad groups of mechanical dyssynchrony have been described i) Intraventricular 
dyssynchrony ii) Interventricular dyssynchrony and iii) Atrioventricular dyssynchrony.  
i) Intraventricular Dyssynchrony 
Tissue Doppler Imaging 
Tissue Doppler imaging (TDI) can be used to measure regional longitudinal velocities of 
the myocardium. Regional velocities can be related to a common fixed point in time, usually the 
onset of electrical activity (surface ECG derived QRS complex). This technique has been used 
extensively to derive indices to quantify clinically significant mechanical dyssynchrony14, 161-172. 
The advantage of color coded TDI and post processing, is that it allows simultaneous measurement 
of velocities in multiple segments of the same cardiac cycle, which diminishes variation in 
measurement due to differences in heart rate, respiration and loading conditions. The disadvantage 
is that it is angle of insonation dependent and unable to distinguish active from passive translational 
or tethering generated myocardial velocity.  
Using color coded-TDI initially, simple models looking at the differences in time to peak 
velocity in two basal segments, the basal-septal and basal-lateral wall were developed163.  A more 
comprehensive model of the LV was developed by Yu et al.173. This group measured time to peak, 
longitudinal systolic velocity in twelve segments of the LV, obtained from the apical window 4 
chamber, 3 chamber and 2 chamber views, basal and mid segments. A global dyssynchrony index 
was derived from the standard deviation of these 12 time intervals (Ts-SD Yu Index). A Yu index 
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of more than 31.4ms was shown to be predictive of reverse remodelling after CRT173. The Yu index 
correlated better with reverse remodelling than any of the other TDI-derived indexes. Recognising 
this, The American Society of Echocardiography suggests measuring opposing wall delay, using 
either apical 4-chamber or apical Long-axis views (cut off 65ms) or deriving the Yu index as 
measures of dyssynchrony using color coded TDI174. 
Speckle Tracking 
This is an angle of insonation independent, non-doppler technique (thereby overcoming the 
limitation of TDI), which utilizes information from 2D grey scale B-mode images to assess 
regional myocardial mechanics. This method tracks the displacement of unique speckle footprints 
through successive digitally stored 2d B-mode images175, 176. The distance between the speckles is 
measured as a function of time, from which parameters of myocardial velocity and deformation 
including strain, strain rate and rotational velocity can be derived177 178. Radial, circumferential 
and longitudinal strain can be easily measured in all segments and be temporally related to the 
QRS complex.  Good quality 2d B-mode images are required for adequate tracking of the speckles, 
however despite good quality images, tracking may be limited by out of plane motion, and lateral 
resolution in the far field and image drop out. 
 A number of indices of dyssynchrony have been derived using STE178-180. One of the more 
promising (ability to predict response to BiV pacing) has used STE to measure the time to peak 
radial strain for each of six myocardial segments at the mid left ventricular level, using the short 
axis view at the papillary level. A time interval of greater than 130ms between the first and last 
segment reaching peak systolic radial strain was found to be predictive of improvement in systolic 
function following Biventricular pacing178-180. The American Society of Echocardiography 
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suggests using STE to quantify LV radial dyssynchrony, with a cut-off of ≥ 130ms being suggested 
as indicative of clinically significant dyssynchrony174. 
ii) Interventricular dyssynchrony 
Interventricular mechanical dyssynchrony can be defined as the delay in time between the 
onset of blood being ejected from the right and left ventricles. This can be measured using pulsed 
blood flow doppler traces obtained from the right and left ventricular outflow tracts, using the 
onset of the QRS complex as a common temporal reference point. The difference between these 
intervals (Qp-Qs) is taken as a measure of interventricular dyssynchrony152, 181, 182. A delay of  > 
44ms was found to be an independent predictor of response to CRT therapy181. 
The technique of TDI has been applied to quantify interventricular dyssynchrony181 14, 167, 
183. The time delay between the basal RV wall and basal lateral LV wall attaining peak systolic 
velocities has been used as a measure of interventricular dyssynchrony (Ts LV-RV).  
iii) Atrioventricular dyssynchrony 
A LV filling time of < 40% of the cardiac cycle (R-R interval) is suggestive of 
atrioventricular dyssynchrony184. Ventricular filling time can be obtained using echocardiography, 
from the transmitral blood flow Doppler trace. Filling time may be reduced because of 
intraventricular dyssynchrony with a resultant increase in isovolumic time periods during the 
cardiac cycle (R-R interval). A reduction in effective filling time may be seen in patients with a 
prolonged PR interval which results in sufficient decay in the atrioventricular filling gradient to 
allow consequential backflow of blood into the atrium during diastole (pre-systolic mitral 
regurgitation), this phenomenon may be further exacerbated in the presence of elevated end 
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diastolic pressures. Reducing the PR interval by RV pacing to any value below physiological has 
been shown to reduce pre-systolic mitral regurgitation, and thus, prolong effective filling time185. 
Hypertrophic Cardiomyopathy: Twisting, Untwisting and Strain 
 
The contraction of obliquely-oriented, helically-arranged left ventricular myocardial fibers, 
from a right hand helix in the subendocardium, through to a left-hand helix in the subepicardium,  
results in  a ‘wringing’ motion responsible for left ventricular twist seen during systole186. During 
the cardiac cycle, when viewed from the apex, counterclockwise twist develops during the systolic 
period, whereas the clockwise recoil of untwisting occurs during diastole,  largely  during the 
period of isovolumic relaxation187 188.  This ‘twist’, plays an important role in left ventricular 
ejection and in the storage of elastic potential energy at the end of the systolic period. Studies have 
shown that some of this elastic energy may be stored during systole in a giant spring-like molecule 
found in the sarcomere, Titin (3-3.7MDa).  The abrupt release of this elastic energy contributes to 
restoring forces189, 190, manifesting as the rapid untwisting of the LV seen during the diastolic 
isovolumic relaxation period, with a resultant suction effect191 enhancing left ventricular filling192, 
193. Both twist and untwist of the left ventricle has been reported as being altered in HCM. Twist 
has been reported as increased80, 194 147 and diastolic untwist as delayed83, 195, 196. The significant 
contribution of ventricular untwisting to diastolic function has been demonstrated197, 198. Speckle 
tracking (STE) has been shown to be a feasible non-invasive method with which to measure these 
parameters177, 199. Furthermore, the measurement of untwisting may present an index of diastolic 
dysfunction that is largely load independent79, 200.  
Myocardial strain (Figure 1.7) is a dimensionless measure of tissue deformation. In health, during 
systole, the left ventricular myocardium shortens longitudinally and circumferentially, measured 
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strain being negative in value, but thickens radially, producing positive strain. Strain rate represents 
the local velocity of this deformation. Using STE, Serri et al. have shown that in patients with non-
obstructive HCM, the longitudinal, circumferential and radial strain were all reduced, when 
compared to healthy volunteers201. The demonstration of a reduction in longitudinal strain has been 
repeated by other groups202, 203, though data on circumferential strain has been variable80, 204. 
Clinically very pertinent, these deformation parameters may be abnormal even prior to the 
development of overt hypertrophy17, 205 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.9 : Strain. A dimensionless measure of the extent of tissue deformation.  
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Diastolic Ventricular Interaction (DVI) 
 
 In health the right ventricle is wrapped around the left ventricle and both are contained 
within a predominantly, closely-apposed fibrous sac, the pericardium, which exhibits a J shaped 
stress-strain relation206  (Figure 1.8).  
 
 
Figure 1.10 : Short axis section through the ventricular mass. Showing how the right ventricle  
wraps itself around the left ventricle, sharing a common septum, enclosed by pericardium. 
 
 The ventricles close proximity to one another allows changes in pressure or volume of either 
chamber to influence the functional characteristics of the other207, 208. This interaction between the 
ventricles occurs directly across the shared interventricular septum and via shared myocardial 
fibres in the outer muscle layers. This interaction is potentiated by both ventricles sharing an 
acutely non-distensible volume (created by the pericardium). Furthermore, the pericardium couples 
stresses from one part of the heart to the other. In effect, any change in the volume, or pressures 
within one ventricular cavity, has the ability to influence the pressure/volumes of the other, given 
the largely non-compressible nature of myocardial tissue.  This ability for ventricles that are in a 
series relationship, to directly interact, offers a form of feed-forward control209 between the 
ventricles, which may be passive during rest in health, and become dynamic during exercise; and 
in sickness become pathological. Direct interaction between the ventricles during systole, has been 
Interventricular Septum 
Pericardium 
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termed systolic ventricular interaction, and that during diastole, diastolic ventricular interaction 
(DVI). 
 Almost half a century ago Laks et al.210 demonstrated in an elegant study using explanted,  
isolated canine hearts with pericardium removed, how the compliance of each ventricle was 
dependent upon the state of filling of the contralateral chamber, clearly demonstrating the concept 
of direct ventricular interaction ( Figure 1.10). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  In their work, they emphasised that the ventricles were able to accommodate more fluid 
when filled in isolation, then when filled simultaneously. This ability for the ventricle to increase 
its volume is of  crucial importance, if the ventricle is to utilise Starling law of the heart, which 
states that the more the left ventricle fills with blood, the more volume it ejects211.  
 
 
 
Figure 1.11 : Pressure volume relationship of the right and left ventricle explanted canine 
heart. Curve 1 refers to pressure volume curve produced after simultaneous biventricular 
continuous injection of fluid, followed in time by curve 2, injection of fluid into right ventricle 
alone and then by curve 3, simultaneous biventricular injection. Right hand panel represents 
the left ventricle2. 
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The Right Ventricle 
 
  In a beating, perfused, isovolumic, rabbit heart Santamore et al.212  demonstrated  the 
presence of ventricular interaction by showing that the diastolic pressure volume relationship of 
either ventricle could be changed by altering the volume of the other ventricle. Evidence for the 
right ventricle (RV) affecting the contractile properties of the left ventricle (LV), was demonstrated 
by Moulopoulos et al.213 using canine hearts. During experimental   pressure-loading of the right 
ventricle, LV  function was reduced213 and LV rate of contraction (dp/dt) decreased.  This 
relationship was found at higher RV filling pressures, and may have been a reflection of reduced 
LVEDV with leftward shift along the Starling curve. However, by using isolated beating canine 
hearts Bemis et al.214 found that alteration of RV filling pressures over the entire range, was able 
to affect alterations in LV geometry, (a leftward shifting of the interventricular septum). Of note, 
in the study by Bemis et al., the pericardium was retained intact whereas in the study of 
Moulopoulos et al. it was not. This would suggest a very significant role for the pericardium in 
modulating the interaction between RV and LV.  In contrast to these findings, Maughan et al.215 
have reported, in the  pericardium-free,  isolated canine heart that the right ventricle had little 
influence on LV diastolic pressures.  
 Kass et al.216 have  shown (Figure 1.10) in humans at rest, including patients with left 
ventricular hypertrophy (n=5), that acutely reducing pressure in the right ventricle, using inferior 
vena cava occlusion, resulted in a sudden decrease in left ventricular diastolic pressures with 
minimal change in filling volumes (represented as downward displacement of the LV end diastolic 
pressure volume curve of the left ventricle), before any reduction in cardiac output was seen. They 
reported that as much as 40% of the resting left ventricular diastolic pressure was due to factors 
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that are extrinsic to the left heart, the right heart and the pericardium being the two major sources 
for generation of external forces on left ventricular diastolic pressure.  
 
 
 
 
 
 
 
 
 
 
The Pericardium 
 
The importance of the pericardium in enhancing direct diastolic ventricular interaction 
comes as no major surprise given that it provides, at least acutely, a non-distensible volume 
enclosing both ventricles. Since the turn of the 20th century it had been suggested that the 
pericardium plays a protective role, in shielding the heart from over-distending itself217. The fibrous 
nature, mostly collagen bundles, of the pericardium make it a suitable candidate for this role. The 
physiological effect of this construct is demonstrated by the J-shaped relationship of its pressure 
volume curve206. That the pericardium does enhance diastolic ventricular interaction has now been 
demonstrated by a number of investigators218-220. Initially, using in vivo canine hearts, Glantz et 
Figure 1.12 : Relation between initial resting left ventricular diastolic pressure (LVPd) and 
the component of this pressure that is due to external forces (∆Pd). Four groups of patients 
are shown. The data fell along a single relation that was well fit by linear regression. The 
slope of (0.38) indicating that 38% of the resting LVEDP was due to forces external to the 
left ventricle1 
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al.218 demonstrated that a correlation existed between left and right ventricular diastolic pressures, 
but that this correlation was tighter with the pericardium intact, and increasingly so at higher 
diastolic pressures on the steep part of the pericardial pressure volume curve, where the 
predominant contributor to end diastolic pressure generation becomes the pericardium. In effect, 
with increasing ventricular volumes, there is a gradual move away from them behaving as two 
individual chambers, towards them behaving as one chamber (created by the pericardium).  
 This work was followed by Janicki and Weber220, who, by using isolated canine hearts, 
studied DVI with and without the pericardium. The presence of DVI was suggested by the increase 
in diastolic pressures in either ventricle, following an increase in volume of the other. This 
relationship was much more marked with the pericardium intact.  Furthermore, in health, Kroeker 
et al.209 showed that the pericardium may modulate beat-beat diastolic ventricular interaction. By 
using canine hearts, they demonstrated acute changes in the output of the two ventricles in opposite 
directions when filling of the ventricles was changed by acute atrial volume loading and unloading. 
This compensatory, homeostatic, mechanism was absent at low ventricular pressures (<5mmHg) 
and absent with the pericardium opened.  
 The role of the pericardium in health, in limiting maximum exercise capacity was suggested 
by Robinson et al.221, following a study in healthy human males. They looked at central venous 
filling pressures, SV and cardiac output, both at rest and during maximal exercise, before and after 
acute volume loading. In the upright resting state, a small increase in central venous filling pressure, 
following volume loading, was associated with marked increases in SV and cardiac output. 
However, during exercise, volume loading produced a more marked increase in central venous 
filling pressures, but with little increase in stroke volume and a failure to increase LV end diastolic 
volume (LVEDV) which they proposed reflected pericardial constraint. Later work by 
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Higginbotham et al.222 demonstrated that at higher exercise workloads, it is HR that drives the 
increase in cardiac output, with no further increase in LVEDV, despite increasing LV filling 
pressures. Pericardial constraint, as suggested by Robinson et al. would again explain this 
observation.  
 The role of the pericardium in relation to exercise capacity was assessed directly by Stray-
Gunderson et al.223 in a canine model. This group looked at exercise performance (peak Oxygen 
consumption) before and after removal of the pericardium in untrained dogs. They reported that 
following pericardiectomy, dogs developed greater increases in stroke volume and cardiac output 
on exercise (maximal heart rates unchanged) and in peak Oxygen consumption. These findings 
would suggest that the pericardium plays an important role in limiting exercise capacity. 
Unfortunately, this study did not measure LV volumes, so was unable to comment whether it was 
in increase in LVEDV, or a reduction in LV end systolic volume that gave rise to the increase in 
SV seen following pericardiectomy. However as discussed earlier, investigators have224 suggested 
improved LV compliance following removal of the pericardium, making it more likely that it was 
an increase in LVEDV that led to the increase in SV seen following removal of the pericardium. 
 More recent work by Fujimoto et al.225, suggests the presence of diastolic ventricular 
interaction and pericardial constraint to be a mechanism that is present even at rest. They studied 
50 healthy volunteers, applying supine lower body negative pressure (LBNP) to transiently volume 
unload the right ventricle, and then immediately following relief of LBNP, measured beat-beat 
changes in SV and LV transmural filling pressure (Pulmonary Capillary Wedge Pressure (PCWP) 
- Right Atrial Pressure (RAP)). They demonstrated that during the first 7 beats immediately 
following relief of LBNP, the increase in RAP was greater than the increase in PCWP, resulting in 
an acute decrease in LV transmural filling pressures, and an associated fall in SV, whilst HR and 
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pulse pressure remained constant. This suggests that pericardial constraint is apparent even at low 
cardiac filling pressures, and is significant enough to cause a reduction in SV. However, a 
pericardium that is compliant, such as is present in the young may prevent this phenomenon, and 
conversely, a stiff pericardium may exacerbate it. Of interest the pericardium in health 
demonstrates organised wavy bundles of collagen, which straighten when stretched226. 
Unfortunately, a literature review did not reveal the histological nature of the pericardium in 
patients with hypertrophic cardiomyopathy, the muscle of which demonstrates fibre disarray and 
fibrosis. A pericardium which demonstrates similar loss of architectural organisation may lend 
itself to DVI.  
Diastolic Ventricular Interaction in the Clinical Context 
 
Otto Frank described the relation between the diastolic stretch of the left ventricle (preload) 
and the force of contraction227.  In cardiological practice, changes in left ventricular preload are 
usually assessed by measuring changes in direct, or indirect left ventricular end diastolic pressure 
(LVEDP), as described originally by Starling228, based on the assumption that changes in LVEDP 
correlate with changes in left ventricular diastolic stretch.  In health, the latter assumption is correct, 
but in certain pathophysiological states it is erroneous. 
 In health, the effective left ventricular (LV) distending pressure is close to the measured 
LVEDP because pericardial and right ventricular pressures at end diastole are both close to zero 
and there is therefore minimal external constraint to LV filling.  However, the pericardium exhibits 
an exponential stress-strain relation229-232 in experimental, and pathological situations e.g. 
pulmonary embolism  (Figure 1.11) where there is an acute RV pressure and volume overload, 
such that as it becomes stretched, the surrounding pericardial pressure increases.  Right ventricular 
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end-diastolic pressure is usually almost identical to pericardial pressure because the relatively thin 
walled RV does not maintain a significant transmural gradient 233.  In this setting, LV filling is 
impeded by the pericardium (pericardial or external, constraint) and from the RV, across the shared 
inter-ventricular septum (diastolic ventricular interaction – DVI).  The effective distending pressure 
in these circumstances is not the LVEDP, but the LVEDP minus the additional external constraint 
from the pericardium and right ventricle. This phenomenon is highlighted by Glantz et al.218 who 
reported that acute right ventricular distension by pulmonary artery constriction, though elevating 
both ventricular diastolic pressures, was associated with a reduction in LV size suggesting a 
reduction in LV distending pressures; by contrast, a reduction in LV size following acute RV 
distension was not seen with the pericardium open (i.e. a loss of pericardial constraint).  
 Similarly, a small MRI study conducted by Holverda et al.234 looking at the effects of 
submaximal exercise in patients with idiopathic pulmonary hypertension, reported a small decrease 
in LVEDV and an increase in RVEDV (with total end diastolic volumes, RV and LV, remaining 
the same during rest and exercise) with  failure to augment SV on exercise. They hypothesised that 
in the presence of a closed volume created by the pericardium, increased RV pressures may have 
directly impaired LV filling by enhancing ventricular interaction and shifting the septum to the left. 
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Figure 1.13 : DVI following pulmonary embolism, and relief following embolectomy235.  
Note the enlarged RV compressing the LV and leftward bowing of the ventricular  
septum pre-pulmonary embolectomy. 
 
Diastolic Ventricular Interaction in Chronic Heart Failure 
 
Chronic heart failure (CHF) is a disorder often associated with elevated RV pressure and 
RV volume overload.  Frenneaux et al. have shown that there is significant DVI in approximately 
40-50% of patients with CHF4, 216.  In such patients, blood volume unloading  achieved by applying 
lower body negative pressure, resulted in a 'paradoxical' increase in LV end-diastolic volume  
(Figure 1.12 and Figure 1.13), despite a fall in measured LV  'filling pressures'.  Further, in a canine 
model of heart failure, they showed that as LVEDP was lowered by IVC occlusion, the pressure in 
the pericardium and RV fell to an even greater extent, so that the effective LV distending pressure 
increased.  Changes in LV diastolic volume and stroke work were completely predictable on the 
basis of changes in the LV transmural pressure gradient (i.e. the effective distending pressure). In 
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patients with CHF, the presence of this abnormal LV volume response was strongly predicted by 
a restrictive trans-mitral Doppler profile, providing a simple non-invasive marker of DVI236. 
 
 
 
 
 
 
 
 
 
 
 
 Figure 1.14 : Change in LVEDV during LBNP, in controls and patients  
 with chronic heart failure4. Vertical bars indicate mean (SD) 
 
Figure 1.15 : Ventricular volume changes with LBNP4 
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Diastolic Ventricular Interaction in Hypertrophic Cardiomyopathy 
Frenneaux et al. have previously shown that patients with HCM have a markedly impaired 
ability to utilise the Starling mechanism to increase stroke volume during exercise i.e. LVEDV 
fails to increase despite a substantial increase in pulmonary capillary wedge pressure 10, 42.  
Intrinsic abnormalities of myocardial compliance, and of active relaxation due to myocyte 
hypertrophy, fibrosis and ischaemia237 are likely to contribute to this phenomenon.  However 
diastolic ventricular interaction (DVI) might provide an additional or alternative explanation for 
the inability to utilise the Starling mechanism during exercise. 
Ong et al.238, using echocardiography, identified pulmonary hypertension in over a third 
(138 patients out of 373) of patients with NOHCM with an EF >50%. The presence of pulmonary 
hypertension in this subgroup was related to an increase in mortality, not seen in patients with 
obstructive HCM. Losse et al.239 have shown that over a quarter of patients with NOHCM, failed 
to increase SV on exercise, which was associated with a pathological increases in pulmonary artery 
pressures (Figure 1.15). The largest increment in pulmonary pressures noted to occur at the lower 
workloads. Though a pathological increase in pulmonary artery pressure was correlated to 
symptom severity, a number of patients exhibited pathological rises in PA pressure, but denied 
symptoms (NYHA I), perhaps suggesting adjustment to exercise limitation.   
In patients who experience pathological increases in right ventricular pressure on exercise, 
DVI may become physiologically relevant. This concept has been supported by animal studies. 
Belenkie et al.240 induced acute pulmonary hypertension (result of pulmonary artery constriction) 
in a closed pericardium canine model.  Pulmonary artery constriction, as might be anticipated, 
reduced stroke volume (by 50%), right ventricular diameter increased with an associated reduction 
in LV area. Of note, opening of the pericardium, during pulmonary artery constriction, resulted in 
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an increase LV area, a left ward shift of the ventricular septum, and increase in stroke volume. 
These investigators demonstrated that though a series interaction accounts for much of the 
reduction in cardiac output during acute pulmonary hypertension, pericardial constraint and 
leftward septal shift were also important.  
Acute pulmonary embolism increases pulmonary vascular resistance, as a consequence the 
mean pulmonary artery pressure can double241, under extremis it may even exceed systemic arterial 
pressure. An increased right ventricular afterload, may lead to right ventricular dilation and 
displacement of the ventricular septum to the left.  Belenkie et al.242 volume loaded closed chest 
dogs, pericardium intact, before and after pulmonary embolization with autologous clot. Prior to 
embolization, volume loading increased the left to right transeptal pressure, and importantly 
increased LV transmural pressure gradients, and stroke work. Following embolization of the 
pulmonary artery, volume loading failed to increase the trans-septal gradient, the ventricular 
septum shifted to the left at the end of diastole with an associated reduction in stroke work. 
Transmural LV diastolic pressure failed to increase despite an increase in LVEDP. 
Pericardiectomy corrected this 'paradoxical' response243. 
 Some patients with HCM have raised LVEDP and right ventricular end diastolic pressure 
(RVEDP) at rest. During exercise, the increase in both LVEDP and RVEDP is often very marked 
in these patients42, 244.  Based on observations in patients with CHF4, DVI might be anticipated to 
be present at rest in some patients but to develop in many, during exercise.  If this is so, then the 
effective distending pressure in the LV might not increase in spite of an increase in measured 
LVEDP during exercise, resulting in an impaired stroke volume response during exercise245-247.  
There are, however, two theoretical reasons why patients with HCM might not have significant 
DVI despite markedly elevated LVEDP and RVEDP.  First, the abnormally thickened 
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interventricular septum may limit interaction between the ventricles.  Secondly, right ventricular 
hypertrophy is present in a minority of patients with hypertrophic cardiomyopathy248 and this may 
permit the generation of a significant right ventricular trans-mural pressure gradient, i.e. pericardial 
pressure may not be elevated despite a markedly raised RVEDP. 
 
 
Figure 1.16 : Mean changes in stroke volume index (SVI) and mean pulmonary artery 
pressure (PPA), during exercise in 19 patients with non-obstructive hypertrophic 
cardiomyopathy classified according to New York Heart Association criteria for clinical 
severity. The mean values are designated with the respective number of patients in each 
group. Adapted from Losse et al.239 
 
 
 
 
 
 
 
 
 
 
 
51 
 
Biventricular Pacing 
 The idea that electrically stimulating the myocardium may be of clinical benefit occurred 
when it was noticed that patients with systolic heart failure often had prolonged PR and QRS 
intervals on surface ECG (25-50%), and that patients with more severe heart failure have a greater 
prevalence of broad QRS and often an ECG pattern consistent with left bundle branch block (15-
27%)249. Atrioventricular dyssynchrony secondary to a prolonged PR interval was reported in up 
to a third of patients with heart failure250. The acute hemodynamic benefit of cardiac pacing was 
then demonstrated using simple right ventricular (RV) pacing with a short AV delay, in an attempt 
to reduce pre-systolic mitral regurgitation185, 251 secondary to atrioventricular dyssynchrony. 
Despite this technique substantially reducing pre-systolic regurgitation, it did not translate into long 
term improvement252, 253, probably because the benefit of improved AV synchrony was countered 
by increased mechanical dyssynchrony caused by the RV pacing254. 
 Observations in the late 1980s showed that left bundle branch block had a deleterious 
impact on left ventricular contractile function 255 with an associated increase in mortality256.  The 
attempted amelioration of this pattern of electrical and consequential intraventricular mechanical 
dyssynchrony followed. A series of studies then demonstrated that simultaneous pacing of the left 
and right ventricle improved cardiac function in patients with heart failure and electrical conduction 
delay257-259. Initially, placement of the LV lead required a thoracotomy, understandably making 
patient-acceptability limited. However once transvenous pacing of the LV was possible, there 
followed a slew of randomised controlled trials which demonstrated symptomatic benefit184, 260-263 
and objective improvements in exercise capacity  demonstrated by improvements in peak Oxygen 
consumption of 10-15%15. These smaller trials were followed by large landmark trials that 
demonstrated that BiV pacing therapy improves cardiac structure and function, reduces morbidity, 
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hospitalization and importantly is associated with a 10% reduction in risk of death in addition to 
the benefit gained from standard therapy264, 265. Of note, the CIBIS-II trial was stopped prematurely 
following a 5.5% reduction in mortality in HF patients treated with Bisoprolol. The magnitude of 
the benefit from BiV pacing was as great and in addition to, the established pharmacological 
therapies. As a result, biventricular pacemakers are now a Class 1 indication, with level of evidence 
A, therapy for heart failure in the European Society of Cardiology Guidelines. 
 A subset of patients with HCM develop LV systolic dysfunction, with wall thinning and 
LV dilation266. In this group of patient, the presence heart failure symptoms, reduction in systolic 
function and ECG evidence of LBBB, case reports 267 and one prospective, non-randomised, non-
blinded cohort study 268 suggested that BiV pacing may improve symptoms and induce reverse 
remodelling of the LV in this subset of HCM patients, consistent with the findings of larger, 
randomised controlled trials in patients with systolic heart failure.262, 264 
 In patients with HCM with heart failure symptoms in the presence of normal systolic 
function, there are case reports, and small case series which suggest symptomatic and 
hemodynamic improvement following BiV 269 270 and LV pacing 271 272.  
 Yufu et al. 272 report the case of a 55-year-old female with symptom limited obstructive 
HCM (resting LVOT gradient 198mmHg) refractory to pharmacotherapy. Echocardiogram showed 
asymmetric septal hypertrophy, with systolic anterior motion of the anterior mitral valve leaflet, 
and mild mitral regurgitation. During cardiac catheterisation studies, temporary AV sequential 
pacing of the RV resulted in no reduction in LVOT gradient. The patient then underwent AV 
sequential pacing of the LV, via an epicardial lead. This resulted in a dramatic reduction in the 
LVOT gradient from 198mmHg to 10mmHg. The authors report that a month later, the patient was 
asymptomatic, with a reduction of mitral regurgitation and a LVOT gradient of 10mmHg. 
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Unfortunately, no comment is made on the LVEDD.  The authors postulate that the mechanisms 
underlying the improvement seen following LV pacing but not RV pacing, involve modification 
of ventricular excitation contraction coupling sequences, that alter LV wall movement, and 
consequently reduce systolic anterior motion of the mitral valve leaflet. An alternate mechanism 
of improvement has been suggested by Kass et al.273 This group of investigators have suggested 
that pacing increases LV end-systolic volume, which would open up the LVOT, with a consequent 
decrease in LV outflow tract velocities and with an attendant reduction in the Venturi phenomenon.  
 Rinaldi et al. 274 examined the role of BiV pacing, in a series of  8 symptomatic HCM 
patients with preserved LV systolic function, with a mean QRS interval of 132ms, as a 'cardiac 
resynchronisation' therapy. Of the 8 patients, 5 patients had obstructive HCM, 2 patients having 
already undergone alcohol septal ablation, and 1 having had a myectomy.   The authors reported 3 
patients experiencing symptomatic benefit following 4 weeks of BiV pacing with an attendant 68% 
reduction in LVOT gradients. However, over 5 years, 2 of these 3 patients developed progressive 
LV failure, of which one died 43 months following implantation. The third patient developed atrial 
arrhythmia and pacemaker infection, requiring explantation. The authors did not report any 
measure of   mechanical dyssynchrony.  This small case series suggests short term benefit from 
BiV pacing. But over the longer term at best no benefit, and at worst a deleterious effect on LV 
function. At present no guidelines 108 129 advocate the use of BiV pacing in patients with HCM, 
obstructive or non-obstructive, with normal systolic function. 
 The mechanisms involved in producing benefit from BiV pacing in patients with systolic 
heart failure have not been completely elucidated. At present, approximately 70% of patients 
selected, who meet all the current implantation criteria I) symptoms of heart failure refractory to 
optimal medical therapy, II) objective evidence of systolic heart failure ejection fraction <35%, 
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III) surface electrocardiographic QRS duration >120ms, derive benefit. Extensive work has been 
done over the last decade to try to elucidate the mechanisms involved in producing this benefit, 
with the goal of improving patient selection. This has been hampered because the benefits of the 
response to BiV therapy have no universal definition.  Benefit defined in terms of reverse 
ventricular remodelling (a benchmark metric of 'response') has been shown to be tenuously 
associated with symptom benefit, if at all 275, 276. Because of difficulties in elucidating both the 
mechanisms at work and the patients response, refinement to the guidelines for BiV therapy have 
been limited, and broadly stand today as they did 15 years ago277. 
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Postulated mechanisms involved in producing benefit from BiV pacing therapy: 
 
I Restoration of electrical synchrony 
 
It might be intuitive to think that if a broad QRS is harmful, then its correction would result 
in benefit. This is incorrect. It has been shown that correction of the QRS interval does not correlate 
with haemodynamic benefit or mechanical resynchronisation278. Furthermore, LV pacing, which 
produces a wider QRS complex than BV pacing, was demonstrated by Kass et al. to result in acute 
hemodynamic improvement259 and by Gasparini et al. 239 and others,  to confer as much clinical 
benefit as BiV pacing in patients with refractory heart failure279, 280. Thus, it appears that electrical 
resynchronisation, as determined by surface ECG, is not mandatory for benefit. 
II Restoration of mechanical synchrony 
 
That biventricular pacing can ameliorate dyssynchrony was shown in man decades before 
clinical application281 . Mechanical dyssynchrony has been demonstrated in patients with systolic 
heart failure by using MRI282, echocardiography, radionuclide techniques and invasively, with 
conductance catheters283, but the vast majority of work has been done using echocardiographic 
techniques. Delays in timing of contraction between the right and left ventricle (interventricular 
dyssynchrony) and intersegmental temporal variation in contraction within the left ventricle 
(intraventricular dyssynchrony) have been demonstrated in patients with heart failure. Patients 
with the widest QRS complexes often demonstrate the greatest degrees of mechanical 
dyssynchrony, however a normal QRS does not always confer mechanical synchrony and 
conversely, patients with LBBB may have relatively normal mechanical synchrony153. A large 
number of studies have suggested that the identification of mechanical dyssynchrony is a more 
sensitive and specific indication for BiV pacing therapy than the duration of the QRS complex and 
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particularly, that the correction of mechanical dyssynchrony is a prerequisite for benefit to be 
realized284. Further, highlighting the importance of the role of mechanical dyssynchrony, 
investigators have shown that  heart failure patients with evidence of mechanical dyssynchrony  
gain benefit from BiV pacing despite a narrow surface QRS complex ( electrical synchrony) 285 
286, demonstrating LV reverse remodelling, improved systolic function and overall functional 
improvements. However, initial enthusiasm for BiV therapy in patients with systolic heart failure 
and a narrow QRS duration has recently been tempered by multicentre, randomized, controlled 
studies which have failed to demonstrate a benefit in mortality 287. Of concern one study was 
brought to a premature halt due to safety concerns; of note this study had no dyssynchrony 
inclusion criteria288. The difficulties in reliably measuring mechanical dyssynchrony has recently 
been brought into focus by the results of the PROSPECT trial, highlighting particularly the 
shortcomings in the echocardiographic techniques 289.  
III Reverse remodelling and the amelioration of mitral regurgitation 
 
Reverse remodelling has been shown to occur with Angiotensin converting enzyme 
inhibitors, Angiotensin receptor blockers, and beta receptor blockers. Furthermore, the 
improvement in ventricular geometry is positively correlated with reduction in morbidity and 
mortality. Biventricular pacing has been shown to promote sustained reverse remodelling with 
reductions in LV end-systolic, end diastolic volumes and improvement in ejection fraction15, 290-
293. Discontinuation of pacing resulting in reversal of improvement294. A number of studies have 
shown that BiV pacing may ameliorate the degree of mitral regurgitation295, 296. Multiple 
mechanisms may be at play.  In the original studies, reduction in atrioventricular(AV) conduction 
delay reduced presystolic mitral regurgitation with acute hemodynamic improvement185. 
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Biventricular pacing not only shortens AV delay, but restores intraventricular mechanical 
synchrony, resulting in a more rapid increase in transmitral pressure gradients with the effective 
pushing together of the mitral leaflets and thus further reducing pre-systolic regurgitation295.  
BiV pacing-induced changes in ventricular geometry, with reductions in LVEDD and 
LVESD297, are likely to reduce the mitral regurgitation that is associated with a failure of coaptation 
seen in the dilated failing ventricle. 
IV Augmented diastolic filling 
 
The effective diastolic filling period can be prolonged by a reduction in pre-systolic mitral 
regurgitation, by using short AV delay pacing185. This has been clearly demonstrated at rest, but 
whether this benefit is sustained during exercise is unknown. Restoring systolic synchrony may 
shorten systole and increase the diastolic filling period. A synchronously relaxing ventricle might 
be expected to improve the rate of relaxation and so reduce the time wasted in ‘isovolumic’ phase 
of the cardiac cycle allowing more time for filling and ejection. Despite these theoretical 
considerations, the effect of BiV pacing on parameters of LV relaxation (tau or passive left 
ventricular compliance), have been mixed 259, 298.  
 Frenneaux et al. have previously shown that a substantial proportion of the acute 
hemodynamic benefits seen with LV and BiV pacing may be a result of a reduction in the external 
constraint to left ventricular filling. In patients with CHF, almost 50% had impediment of left 
ventricular filling by a) external constraint from the right ventricle, via the shared interventricular 
septum (direct diastolic ventricular interaction) and b) from the stretched pericardium (pericardial 
constraint)4. Left ventricular pacing temporally shifts left ventricular contraction to be earlier then 
right ventricular contraction: consequently, LV filling occurs before RV filling. Given that the 
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pericardial volume is relatively fixed, a smaller RV volume would allow greater LV filling both 
via reductions in direct DVI, and reductions in pericardial constraint. Subsequently, an increase in 
LVEDV and by the Frank-Starling mechanism, a greater left ventricular stroke work would have 
to be matched with increased RV stroke work.  Following LV pacing, Frenneaux et al. showed that 
despite measured LVEDP remaining unchanged (a finding consistent with Kass et al.259)  the 
effective  LV filling pressure  increased and suggested this may result from of a reduction in 
external constraint to LV filling, with  a consequent significant increase in LV filling10. 
Furthermore, QRS duration was not predictive of response to LV pacing. Bleasdale et al.10 showed 
that acute hemodynamic improvement with LV pacing was predictable in the presence of elevated 
left ventricular filling pressures. Perhaps not surprising given that external constraint to left 
ventricular filling is related linearly to left ventricular end diastolic pressures.  
V Transcriptome 
 Initial work demonstrated that in patients and in animal models of dyssynchronous heart 
failure there were regional variations in myocardial protein expression299 300. Subsequent studies 
have found marked regional variation in gene expression, corroborating the variation in protein 
expression301. More importantly, work done in canine heart, demonstrated that BiV pacing can 
reverse these variations in gene expression301. 
VI Mitochondrial subproteome 
 
From canine dyssynchronous heart failure models treated with BiV pacing, mitochondria 
were isolated and analysed 302. This work demonstrated up regulation of enzymes involved in key 
pathways such as pyruvate carboxylation and branched amino acid oxidation. In this way, BiV 
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pacing seems to behave as a metabolic therapy, altering energy metabolism in the mitochondria. 
This may be another mechanism by which BiV pacing is able to improve work performance. 
VII Beta adrenoceptor regulation 
 
 Biventricular pacing has been shown in canine heart models to enhance myocyte beta-
adrenergic responsiveness. Some of this enhancement is due to upregulation of beta1-
adrenoreceptor abundance, increased adenylate cyclase activity, and reduction of inhibitory G-
protein activity303. 
Future direction 
 
The management of drug-refractory symptoms in patients with non-obstructive 
hypertrophic cardiomyopathy remains challenging, with few options outside of a cardiac 
transplant. Obstruction to outflow, in patients with drug refractory symptoms, can be ameliorated 
with invasive strategies including septal myectomy or percutaneously with alcohol septal ablation.  
Many of the pathophysiological abnormalities that contribute to symptoms in non-
obstructive HCM are common to patients with chronic heart failure secondary to systolic left 
ventricular impairment. A number of recently published studies have shown that Biventricular 
pacing can improve exercise capacity, quality of life, and substantially reduce hospitalization and 
mortality in patients with drug-refractory NYHA Class III/IV CHF. The mechanism of 
improvement has been thought to be predominantly related to a reduction in intra-ventricular 
contractile dyssynchrony.  However, the studies of Frenneaux et al.  have shown that at least some 
of the acute haemodynamic benefit of Biventricular pacing in CHF is due to a reduction in the 
external constraint to LV filling by the pericardium and right ventricle, a phenomenon known as 
diastolic ventricular interaction. 
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 In view of the findings discussed above, the objective of this PhD was to examine the role 
of Biventricular pacing in patients with non-obstructive Hypertrophic Cardiomyopathy (HCM) 
with drug refractory symptoms. The study had an acute and chronic component. The acute 
component examined the role of diastolic ventricular interaction, impaired diastolic filling and 
dyssynchrony at rest and on graded exercise, in patients with drug refractory symptoms of exercise 
intolerance, and the acute impact of Biventricular pacing on these parameters. The chronic 
component of the study consisted of a double-blind, cross-over, sham-controlled trial, which 
examined the impact of Biventricular pacing on echocardiographic parameters of cardiac function, 
symptoms and exercise capacity (VO2 max) over a period of 4 months. 
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Study Objectives 
First Objective  
I) To assess the impact of acute Biventricular pacing on myocardial dyssynchrony in patients with 
non-obstructive Hypertrophic Cardiomyopathy (HCM). 
Hypothesis: Biventricular pacing will improve parameters of dyssynchrony. 
Second Objective  
II) To measure, diastolic myocardial function at rest and on exercise in patients with non-
obstructive HCM and the effects of acute Biventricular pacing on diastolic myocardial function at 
rest and exercise in patients with non-obstructive HCM. 
Hypothesis: We hypothesised that diastolic ventricular interaction may be present at rest in 
some patients with HCM and may develop during exercise.  We hypothesised that 
Biventricular pacing would acutely improve myocardial filling parameters at rest/on exercise 
in patients with HCM 
Third Objective  
III) To investigate the impact of right ventricular unloading on left ventricular diastolic filling by 
using lower body negative pressure in patients with non-obstructive HCM, with and without 
Biventricular pacing. 
Hypothesis: We hypothesised that in patients with HCM, right ventricular unloading would 
improve diastolic filling via relief of diastolic ventricular interaction, and that Biventricular 
pacing may relieve diastolic ventricular interaction. 
 
 
 
 
62 
 
Fourth Objective   
IV) To assess the effects of chronic Biventricular pacing on dyssynchrony, ventricular strain, twist 
and untwist parameters in patients with non-obstructive HCM. 
Hypothesis: We hypothesised that chronic Biventricular pacing would improve 
dyssynchrony, twist and untwist rates in patients with HCM  
Fifth Objective   
V) Primary end point: To assess impact of Biventricular pacing on peak Oxygen consumption (VO2 
max). To assess the impact of Biventricular pacing on symptomatic status using the Minnesota 
Living with Heart Failure Questionnaire; the secondary outcome measure of the chronic component 
of this study. 
Hypothesis: We hypothesised that Biventricular pacing would reduce myocardial 
dyssynchrony, improve diastolic function, and thereby improve exercise capacity (Primary 
end point) and improve symptomatic status (Secondary end point) in patients with drug 
refractory symptomatic HCM 
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Chapter 2 	
 
General Methods	
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i) Study design  
 We used the University of California, Los Angeles (UCLA) power calculator to determine 
that a sample size of 23 patients would have a power of 90% to detect an increase in VO2max of at 
least 3ml/kg/min (primary end point) with a standard deviation of 3ml/kg/min, and an alpha equal 
to 0.05. In our experience, technical problems in the placement of pacemaker and in invasive 
studies would precludes analysis in approximately 25-30% of patients, hence at the outset of the 
study we aimed to recruit approximately 30 patients.   
 The crossover methodology has been suggested to be the gold standard for evaluation of 
therapeutic effectivness304. Each patient is able to act as their own control, this allows reduction in 
bias associated with variances in known and unknown confounders. This method allows between 
and within group analysis305. A further major advantage of crossover methodology is statistical 
efficiency306, compared to non-crossover designs, fewer patients are required. Crossover trials are 
particularly suited to chronic conditions, with effect of intervention that is of short duration and 
reversible.  Methodological difficulties include allocation concealment, patient drop out, and issues 
related to potential carryover effects307 (sequence order effect). Allocation concealment refers to 
the technique used to implement the randomisation sequence308. Ideally the person allocating 
treatment should not be involved with the trial e.g. a pharmacist or technician.  
 Even a well conducted crossover trial, is prone to weakness.  when the patient drops out 
after the first intervention period, and declines subsequent treatment, within-subject comparison is 
then not possible. This is of particular clinical relevance should the patient have dropped out 
because of adverse effects related to treatment. 
 A carry-over effect suggests that the observed difference between treatments has been 
influenced by the order in which the treatment was received; hence the estimated overall treatment 
 
 
65 
 
effect will be affected (usually resulting in the treatment effect being under estimated, leading to a 
bias towards the null). Argument has been put forwards against consistent testing for carryover 
effects of interventions across periods as carry-over effects are rare and statistical manipulation 
after the fact cannot address the impact of a carry-over effect.  A common sense approach to 
crossover trials is suggested, where no carry-over is assumed and thus, not tested for 309. Instead it 
is recommended that the washout period be sufficient to prevent carry-over effects. 
The complete study was performed on a total of 29 patients from 31 enrolled into the study 
(Figure 2.1). Two patients discontinued at the crossover phase of the chronic component of the 
study these two patients were excluded from all analysis. One of these patients became extremely 
symptomatic when crossed over to the sham pacing arm of the study, and declined further 
participation. The second patient developed intractable diaphragmatic twitching and was unable to 
continue. Therefore 29 patients took part in both the acute haemodynamic study and completed 
both arms of the chronic cross over study. Data are presented for the 29 patients that completed the 
study. There were no deaths or major adverse events during the study period. The study was 
approved by the South Birmingham Research Ethics Committee and conformed to the principles 
outlined in the Declaration of Helsinki. All participants provided written informed consent.  
Patients were recruited nationally. Biventricular pacemaker implant took place at the Queen 
Elizabeth, University Hospital Birmingham (n=9) and at the Heart Hospital, London (n=22). 
Following implantation, devices remained in sham pacing mode (VVI30), eliminating any active 
Biventricular (BiV) pacing. Patients were seen 2 weeks following implantation of BiV pacemaker, 
when they underwent the acute component of the study. The acute component of the study took 
place over a period of one day. Following completion of this patients were then randomized into a 
double-blind cross over trial (4 months in each limb) to assess the effects of chronic BiV pacing 
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vs. sham pacing (VVI30). In order to assign participants to either BiV pacing first or Sham pacing, 
a random allocation sequence was generated using the block randomization method 310, with 8 
blocks of size 4. A cardiac pacing physiologist, not part of the research team, programmed the 
device according to the allocation, at entry into the trial and at cross-over. 
 The primary end point was peak Oxygen consumption (VO2max) achieved during treadmill 
ergometer testing. The secondary end point was of symptom status, assessed using Minnesota 
living with heart failure questionnaire. At the end of each 4-month period patients also underwent 
transthoracic echocardiographic studies as outlined below. All patient who completed the study, 
experienced 4 months of BiV pacing, and 4 months of sham pacing. A period of 4 months was 
selected to eliminate any carry over effect161. Patients and investigators were blind to the mode of 
pacing.  
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Figure 2.1 : Study Flow Chart 
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ii) Patient selection 
 Patients were consecutively recruited from cardiomyopathy clinics at the Heart Hospital, 
University College London Hospitals, London and Queen Elizabeth Hospital, Birmingham, UK 
between 2006 and 2008.  
Inclusion criteria:  
i) Fulfilled conventional echocardiographic criteria for the diagnosis of HCM  
(LV wall thickness greater than 1.5 cm in the absence of another cause for hypertrophy)311 
ii) Absence of LVOT obstruction at rest or on provocation (peak gradient < 30mmHg). 
iii) Age 18 to 80 years.  
iv) Exertional symptoms (NYHA ≥ 2b) 
v) Normal sinus rhythm.  
vi) Peak VO2 < 75% of predicted for age and gender. 
Exclusion criteria:  
i) Presence of epicardial coronary artery disease. 
ii) Conventional indications for pacing 
iii) Women of childbearing potential 
iii) Biventricular pacemaker implant	
Patients who fulfilled the entry criteria underwent implantation of a biventricular pacing 
device, with the right ventricular electrode placed at the apex of the right ventricle, and the left 
ventricular electrode via the coronary sinus in a lateral position, using a standard technique      
(Figure 2.2). 13 Guidant, 10 Medtronic and 6 St Jude devices were implanted 
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Figure 2.2 : Biventricular pacemaker 
 
iv) Biventricular pacemaker programming 
 
At implant the pacemaker was programmed for sham pacing (VVI30). During the acute 
and chronic components of the study the pacemaker was programmed to one of two modes either 
(i) Active Biventricular pacing (BiV) or (ii) Sham pacing mode(VVI30), in effect no pacing.  On 
the day of the acute component of the study, the pacemaker had its lead stability, integrity, pacing 
thresholds and sensitivities measured to ensure consistent ventricular pacing when active. For 
active pacing the pacemaker was programmed to BiV pacing mode. When in BiV pacing mode an 
atrioventricular delay (A-V delay) was set to 90ms together with LV and RV pacing lead outputs 
and vectors set to ensure consistent capture of the ventricles whilst avoiding Phrenic nerve 
stimulation.  When active BiV pacing, the delay between the LV and RV pacing (V-V delay) was 
set to the minimum possible 0-4ms. For the chronic component of the study identical pacemaker 
settings were used for active BiV and for sham pacing (VVI30) as were used in acute component, 
with a complete pacemaker check at crossover. 
LV Lead 
RV Lead 
Atrial Lead 
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v) Exercise gated radionuclide ventriculography 
Within two weeks of pacemaker implantation patients completed a protocol of graded semi-
supine exercise gated radionuclide ventriculography with and without BiV pacing (Figure 2.3). 
 
 
 
Figure 2.3 : Flow chart Acute Study: Exercise Radionuclide Ventriculography. This protocol was 
completed, within one session, as part of the Acute study component. 
 
Patients undertook two levels of semi-supine workloads i) Rest or at ii) 50% of heart rate reserve 
(based on a prior maximum exercise test, see Inclusion criteria - peak metabolic exercise test) in 
random order. These were undertaken in BiV and sham pacing modes, in random order. The 
patient’s brachial blood pressure was manually measured during the final minute of scintigram 
acquisition. A set of four, gated ventriculograms were acquired per patient. 
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 Red blood cells were labelled by means of a modified in-vivo technique312: in brief, 10 
minutes after intravenous injection of stannous pyrophosphate (0.02 mg/kg), 5 mL blood were 
drawn into a heparinised syringe and agitated for 20 minutes with 750MBq of Technetium-99m-
pertechnetate before reinjection.  
Left ventricular end systolic, and end diastolic volumes, ejection fraction and rates of 
diastolic filling were assessed by equilibrium R-wave gated blood pool scintigraphy. We used a 
small field of view gamma camera fitted with a parallel hole, general purpose, low energy 
collimator (camera Olivetti Modulo-M-200ESL) which was linked to a dedicated microprocessor. 
Studies were carried out at rest and during graded semi-erect exercise (achieving 50% of heart rate 
reserve) on a cycle ergometer (Lode B.V medical technology, Groningen, Netherlands)313 as 
previously described by our group42 with and without active BiV pacing. With the patient on the 
cycle ergometer, the detector was adjusted for the left anterior oblique view with the best 
ventricular separation and 10 to 15 degrees of caudal tilt. Each RR interval was divided into 32 
equal frames throughout with a 20% tolerance window was set about the patient's heart rate. A 
constant number of frames per RR interval ensured consistent temporal resolution during diastole 
at all heart rates.   
Data from each beat were acquired into a memory buffer in a 64x64 "word" matrix and if 
accepted were reformatted with two-thirds forward, one-third backward gating. 3 minutes of data 
was acquired during rest and on exercise following a 60 second period for stabilization of heart 
rate (RR interval). In order to be able to make the volumes derived from each scintigram 
comparable, the physiological (during exercise mobilisation of red cells from the spleen results in 
a reduction in radioactive counts per ml of blood4) and physical decay was corrected for, by taking 
a 5ml sample of blood into a preweighed tube at the beginning of each acquisition. The composite 
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cycle derived from each stage was spatially and temporally filtered. Left ventricular counts in each 
frame were determined by a semi-automated edge-detection algorithm. Data were analysed using 
Link Medical MAPS software, Sun Microsystems (Figure 2.4). 
 
 
 
 
 
 
 
 
 
 
The following volumes were measured, LV end-diastolic volume, LV end-systolic volume, and 
stroke volume. LV end-systolic elastance index was calculated from ESP/end-systolic volume ratio 
314. Changes in volume are expressed as a percentage of baseline. From the LV time activity curve 
filling fractions were derived by splitting the diastolic filling phase of the LV time activity curve 
(minimum volume to maximum volume) into 3 equal tertiles. The proportion of filling occurring 
during each tercile of diastole expressed as a percentage of total filling (Figure 2.5). 
 Figure 2.4 : Time activity curve/Ventriculogram 
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vi) Lower body negative pressure with gated radionuclide ventriculography 
Changes in ventricular volume were assessed before (LBNP0) and following the application 
of lower body negative pressure (LBNP30)4, 315 whilst measuring LV function using gated 
radionuclide ventriculography as described above. The patient lay supine in a specially constructed 
Perspex lower-body negative pressure tank, encased from below the iliac crests in an airtight seal. 
Lower body negative pressure of 30mmHg (LBNP30) was applied in order to volume off load the 
right ventricle. A scintigram was acquired in the left anterior oblique view, prior to and following 
the application of Lower-body negative pressure of 30mmHg for six minutes; during the final 4 
minutes of which the scintigram was acquired. The patient’s brachial blood pressure was manually 
measured during the final minute of scintigram acquisition. Gated ventriculograms were acquired 
during sham pacing and in BiV pacing mode (Figure 2.6). Each pacemaker mode was given a five-
minute run in period before image acquisition. A 5ml sample of blood was taken, into a previously 
  Figure 2.5 : Time activity curve derivation of filling thirds 
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weighed tube, at the beginning of each image acquisition in order to correct for physical and 
physiological decay, so as to make volumes measured comparable. A set of four, gated 
ventriculograms were acquired per patient. This protocol was completed the same day as the 
exercise gated radionuclide ventriculography studies. 
 
 
 
Figure 2.6 : Flow chart Acute Study: LBNP Radionuclide Ventriculography. 
Ventriculograms were acquired when lower body negative pressure applied was 0mmHg 
(LBNP0), then repeated with a lower body negative pressure of 30mmHg (LBNP30). This 
was done following sham (VVI30) and active pacing (BiV). 
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vii) Normalised ventricular septal radius of curvature (Rs) 
  This measurement is based on methodology described by Dong et al.316. From the gated 
radionuclide ventriculography end diastolic frame (Figure 2.7), the ventricular septum was traced. 
The septal radius of curvature (R) was measured over the middle 60% of the ventricular septum. 
This was then normalised for LV area as follows. The end diastolic LV region was measured, from 
which a radius (r) is calculated based on the assumption of the LV profile being a circle. The 
normalised radius of curvature (Rs) is then calculated by calculated by dividing R by r. The flatter 
the septum, the greater the normalised radius of curvature (Rs). 
 
 
 
Figure 2.7 : Gated radionuclide ventriculography end diastolic frame.  
Using this image ventricular septal radius of curvature measurements (R) were made. 
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viii) Transthoracic Echocardiography 
These studies were carried out during the Acute study component, then following 4 months 
of active BiV pacing and again following 4 months of sham pacing (VVI30). 
a) Two-Dimensional Echocardiography 
Standard Echocardiography, including tissue doppler studies were performed with patients 
in the left lateral decubitus position (Vivid 7, GE Vingmed Ultrasound, Horten, Norway). Images 
were acquired using a 2.5MHz transducer. From the parasternal window, short axis views were 
acquired from 3 levels (basal, papillary muscle and apical levels (distal LV cavity where papillary 
muscle is not visible) 177) and a standard long-axis view was recorded. From the apical window 
standard two-chamber, four-chamber, and long axis views were acquisitioned. Blood flow velocity 
profiles were assessed using standard doppler. Two-dimensional gray scale images were acquired 
at a minimum 60 frames per second (fps). Pulsed wave tissue doppler images were acquired at a 
minimum of 150fps, with sector width and depth being adjusted to obtain the highest frame rate.  
2D gray scale and color coded tissue doppler images were saved as 3 consecutive cycles, triggered 
to the QRS complex in a digital format for analysis post-acquisition. Mitral annulus velocities 
(pulse wave tissue doppler imaging [PW-TDI]) were recorded from basal anterolateral and basal 
inferoseptal segment in apical 4-chamber view.  Left atrial volumes were calculated using the area 
length method from apical 2 and 4 chamber views as has been previously described 317 calculated 
LA volumes were indexed to body surface area to derive LA volume index (LAVI).  LV mass was 
calculated by the area length method and then indexed to body surface area to determine the LV 
mass index as previously described 318. The greatest thickness measured in the LV wall at any short 
axis parasternal view was considered to represent maximal wall thickness in HCM patients 319. 
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LV volumes were calculated using Simpsons biplane method, using the apical four and 
two- chamber planes, and LV ejection fraction was derived from LV volumes in diastole and 
systole using a modified Simpson’s formula 317. Stroke volume was calculated from the product of 
time velocity integral and cross sectional area of the left ventricular outflow tract. Cross sectional 
area of the LVOT was measured from the parasternal long axis view, immediately beneath aortic 
annulus, midsystole, inner edge to inner edge. Cardiac output320 was derived from stroke volume 
and heart rate. LV Myocardial performance index was calculated as the sum of isovolumic 
contraction and relaxation time divided by LV ejection time321. All measurements were taken from 
3 consecutive beats and an average derived. Transmitral blood flow was assessed by placing a pulse 
wave doppler sample volume at the mitral valve tips, 3 cardiac cycles were recorded.   
b) Speckle Tracking  
 
Speckle tracking (STE) is a direction independent, non-doppler method which utilizes 
information from 2d gray scale images to assess myocardial mechanics. This method temporally 
tracks  the displacement of unique speckle footprints through successive digitally stored two-
dimensional B-mode  images175.  The distance between the speckles is measured as a function of 
time, from which parameters of myocardial velocity and deformation including strain, strain rate 
and rotational velocity can be derived177 178. 
To allow high quality STE analysis, high definition standard B-mode images, at a minimum 
frame rate of 60fps were acquired. Images were acquired from the apical 2-, 4-, and long axis 
views, as well as the parasternal short axis views at the basal level (identified with the mitral valve), 
the mid-level (identified with papillary muscles) and apex (below the papilla), obtaining images 
which by eye had the most circular geometry in order to try and avoid oblique views178. Speckle 
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tracking analysis was carried out using Echopac software (version 4.2.0). From an end-systolic 
single frame, a region of interest was traced on the endocardial cavity interface by a point and-
click approach. Then an automated tracking algorithm followed the endocardium from this single 
frame throughout the cardiac cycle. Further refinement of the region of interest was performed to 
ensure that all of the myocardial regions of interest were included in STE analysis. Adequacy of 
two-dimensional image tracking was verified in real time. A tracking score of ≥ 2.5 was accepted. 
This method has been validated with MRI, the current gold standard methodology for non-invasive 
assessment of myocardial deformation322, to be accurate in providing measures of myocardial 
strain176, 323. Left ventricular peak, longitudinal, radial and circumferential strain and strain rate in 
each view were calculated with the use of the entire length of the LV myocardium.  
c) Echocardiographic Assessment of Intraventricular Synchronicity 	
Colour coded Tissue Doppler Images (TDI), (with sector width, depth, gain settings, pulse 
repetition frequency, and color saturation optimization to acquire a minimum frame rate of 90 
frames per second (fps)) were obtained from the apical four, two and long axis views. At least three 
consecutive beats were stored and post image acquisition analysis was done using a customized 
software package (Echo Pac version 4.2.0 for PC, GE Vingmed Ultrasound). To assess left 
ventricular systolic intraventricular synchronicity myocardial pulse tissue doppler velocity profile 
signals were reconstituted from each of 12 segments of the left ventricle, using a six basal and six 
mid-segmental model derived from apical 4, 3 and 2 chamber images. With use of the onset of 
QRS complex as the reference point, the time to peak myocardial systolic velocity (S wave) and 
peak early diastolic velocity (E wave) were measured for each of the 12 segments. From these time 
interval the following indices of dyssynchrony were derived i) The standard deviation of the time 
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to onset of peak longitudinal systolic velocity for twelve segments173 (Yu Index) (LTs-SD)  and 
likewise for early diastolic velocity (LTe-SD) 151 , ii) Basal septal to lateral delay in time to peak 
velocity (LTs(S-L)) 163  and iii) Maximum difference of time to peak systolic velocity for the basal 
six segments left ventricle289(LTs-peak[basal]), iv) Maximum delay between peak systolic 
velocities among the four walls (4c and 3c views) at the basal level14. The left ventricular pre-
ejection time (>140ms) was measured as marker of global left ventricular synchrony (QRS onset 
to start of Doppler flow in the aortic outflow tract)184. 
 Indices of dyssynchrony, as derived using color-coded tissue doppler measures of velocity, 
were similarly, derived from Speckle tracking data. From Speckle tracking derived longitudinal 
and radial strain, the following indices of dyssynchrony were derived174 i) Standard deviation of 
time to peak longitudinal systolic strain 12 segment model of LV(LTε-SD) ii) Radial dyssynchrony 
was measured from the short axis mid-left ventricular (papillary) view. The short axis view was 
divided into 6 standard segments. Standard deviation of time to peak systolic radial strain for these 
six segments178was derived as an index of radial dyssynchrony (SDt6s ) and time delay between the 
peak strain in the anteroseptal and inferolateral segments and time difference between the earliest 
and latest segments (AS-P delay )179 were used as  measures of dyssynchrony324. 
d) Echocardiographic Assessment of Interventricular Synchronicity 
 
Colour coded tissue doppler imaging was used to assess Interventricular dyssynchrony. The 
delay in time to peak systolic velocity between basal free wall of the right ventricle and the basal 
LV lateral segments161 was measured (Ts LV-RV).  To further assess inter-ventricular 
dyssynchrony pulse wave doppler images of aortic and pulmonary flow velocities were used. 
Interventricular mechanical delay was calculated as the difference between the ECG derived Q 
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wave and the onset of the LV outflow (Aortic pre-ejection time) and the onset of RV outflow 
(Pulmonary pre-ejection time) (Qp-Qs)184. 
e) Echocardiographic Assessment of Atrioventricular Synchrony 
Atrioventricular synchrony was assessed by measuring the proportion of the RR interval 
occupied by left ventricular filling. LV filling duration was measured as the time from the onset of 
the E wave to the end of the A wave on transmitral pulsed wave doppler. A LV filling time of less 
than 40% percent of R-R interval, was suggestive of atrioventricular dyssynchrony184, 325, 326. 
f) Echocardiographic Assessment of Diastolic Function 
 
This was assessed indirectly by looking at blood flow patterns through the heart, with 
standard doppler and directly by assessing myocardial tissue velocities with pulsed wave tissue 
doppler, and by combinations of the two. 
 A trans-Mitral blood flow velocity profile was acquired by placing a pulsed waved doppler 
sampling volume at the mitral valve leaflet tips in the apical 4 chamber view. This profile has an 
early component, the E wave, and a late filling component the A wave. The ratio of these (E/A), 
and the deceleration time(DT) of the early filling wave (E) were measured327.  To assess early 
diastolic filling, the isovolumic relaxation time (IVRT) was measured. This was acquired  by 
placing a pulsed wave doppler sample volume  between the aortic and mitral valve, in the apical 4 
chamber view328. Myocardial tissue velocities were measured, as a direct measure of LV 
relaxation, using pulsed wave tissue doppler imaging. Pulsed wave tissue velocities are measured 
during image acquisition from the Mitral valve annulus, lateral and septal sites. These have 
characteristic profiles, consisting of a systolic velocity (s'), early diastolic velocity (e') and a late 
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diastolic velocity (a'). The ratio E/e' was derived from blood flow and tissue velocity profiles to 
provide a more preload independent estimate of LV filling pressures329.  
f) Echocardiographic Assessment of Myocardial Rotation 
Rotation of the LV base and apex was measured using STE analysis. Speckle tracking 
analysis was applied to 2d gray scale images acquired from the basal and apical short axis views, 
to derive basal and apical LV global rotation (rot) and LV rotational rates (rot-r) respectively 
(Figure 2.8).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 2.8 : STE derived rotation. This is an example of STE measured
myocardial rotation(degrees) of the Apex (top image) and Base (lower image).
Aortic Valve Closure (AVC). 
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These data were first exported to a spreadsheet program (Excel 2010, Microsoft Corp, 
Seattle, Washington) and then exported to DPlot Graph Software (2001-2008 by HydeSoft 
Computing, Inc) to allow calculation of LV twisting and untwisting rates177. To adjust for variance 
in heart rate that may occur between basal and apical image acquisition and so allow isochronous 
comparison of basal and apical rot/rot-r the R-R interval was converted to 100%. Left ventricular 
twist (twist rate) was calculated as the isochronous net difference between apical and basal rotation 
(rotation rate) (Figure 2.9). 
 
 
 
 
 
 
 
 
 
 
 
	
ix) Symptom status assessment 
 
 An assessment of symptoms was made at baseline (0 months), at cross over (4 months) and 
at completion of study (8 months), patients scoring their symptoms by completing the Minnesota 
Living with Heart Failure questionnaire (Figure 2.10). 
 
 
Figure 2.9 : Twist. Each point (red box) represents an isochronal difference  
between apical and basal rotation, thus giving a twist value. 
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Figure 2.10 : Minnesota Living with Heart Failure Questionnaire 
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x) Cardiopulmonary exercise testing 
 Patients underwent an erect treadmill test, symptom limited, using a standard ramp protocol 
with simultaneous respiratory gas analysis330, 331(Schiller CS-200 Ergo-Spiro exercise machine). 
This test was carried out as part of the inclusion/exclusion criteria screening, then at the cross over 
point of the chronic study (4 months), then at study exit (8 months) (Figure 2.1).   All patients 
underwent spirometric studies prior to each exercise test.  During the treadmill test samplings of 
expired gases was performed continuously, and data expressed as 30s means. Minute ventilation, 
Oxygen consumption, Carbon Dioxide production and the respiratory exchange ratio (RER) were 
measured. Peak Oxygen consumption, expressed in ml/kg/min (Peak VO2), was defined as the 
greatest VO2 attained by the patient during the exercise test. Cardiac monitoring by ECG was 
continuous throughout the exercise test. Blood pressure at the brachial artery was measured 
manually using a cuff sphygmomanometer every minute throughout the test. Active 
encouragement was given to patients to continue exercising till exhaustion, achieving a minimum 
RER of at least 1.  
xi) Statistical analysis 
 Randomised and controlled trial outcome data may be examined by conducting an intention 
to treat (ITT) or Per-protocol (PP) analysis. The ITT approach,  includes all randomized patients 
in the groups to which they were assigned, regardless of their adherence to entry criteria, of the 
treatment they actually received, and regardless of subsequent withdrawal from treatment or 
deviation from protocol332. In brief a 'once randomized, always analysed' approach to trial data 
analysis. ITT reflects real-life clinical scenario more closely, as it acknowledges variable 
compliance, and protocol non-adherence. An ITT analysis maintains the balance generated from 
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the original randomisation. ITT analysis preserves sample size and hence statistical power333. It 
minimizes type I error and allows for greater generalizability of subsequent trial outcomes334. 
However, if a patient who actually receives no treatment is included in the analysis as a subject 
who received treatment, in particular for mechanistic studies, then the information it provides about 
effect of treatment on the mechanism under scrutiny will be limited, if not incorrect. Furthermore, 
ITT analysis is prone to under-estimate of treatment effect because of dilution due to non-
compliance. Interpreting the outcomes of an ITT analysis may become difficult if a large number 
of patients break with protocol, and cross over to the opposite limb of the study335. ITT analysis 
may then fail to reject the Null hypothesis (Type II error).   
 A  Per Protocol (PP) analysis of data, could be defined as the examination of the subset of 
the ITT population who completed the study without any protocol violation336. Also, known as an 
"on-treatment" analysis, as those "off-treatment" are excluded. The PP analysis answers the 
question as to whether the treatment works among those that comply, allowing retention of clarity 
when investigating underlying mechanisms of disease, in so doing a PP approach is a more 
sensitive approach then ITT analysis in determining the biological effect of the new treatment 
modality.  It should, perhaps, be the preferred analysis for purely mechanistic studies337.  
 However, when considering treatment effect of a new therapy excluding patients who do 
not comply makes PP analysis more likely to reject the Null hypothesis (Type I error), and the 
result less generalisable when considering the real world practical value of the new therapy.  
Data were analyzed using SPSS version. 17.0 for Window and Microsoft Office Excel 2010, 
and expressed as mean ± standard error (sem).  Comparisons of variables were determined by 
Student’s t-test (2-tail) if variables were normally distributed and the Mann-Whitney U-test if the 
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data were non-normally distributed.  Categorical variables were compared with the Pearson chi-
square test. A difference of p < 0.05 was taken to indicate statistical significance. 
During the chronic component of the study, comparison of the measured variables between 
BiV pacing, and sham pacing was performed using repeated measures analysis of variance. Statistical 
significance was set at p< 0.05.  
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The Acute Study 
 
 
 
Chapter 3) The effects of acute biventricular (BiV) pacing on left ventricular dyssynchrony in 
patients with Hypertrophic Cardiomyopathy (HCM) at rest. 
 
Chapter 4) The effects of acute BiV pacing on myocardial function during exercise in HCM. 
 
Chapter 5) The impact of right ventricular volume unloading, using Lower Body Negative 
Pressure (LBNP), on Left ventricular diastolic function in patients with HCM,    
with and without Biventricular pacing. 
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Chapter 3   
 
 
 
The Acute Study  
 
 
 
The effects of acute Biventricular pacing on left ventricular dyssynchrony, in patients with 
Hypertrophic Cardiomyopathy at rest. 
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Introduction 
 As discussed in the General Introduction (section Dyssynchrony in Hypertrophic 
Cardiomyopathy) several  investigators have reported dyssynchronous contraction and relaxation 
in patients with HCM11, 140-143, which is probably related to the loss of normal architecture of the 
underling substrate with myocyte disarray, fibrosis and microvascular ischemia (Figure 1.4).   A 
number of techniques have been used to demonstrate this discoordinate functioning of the 
Hypertrophic cardiomyopathic myocardium. The current gold standard in myocardial imaging, 
MRI, has also been used to demonstrate and quantify the presence of myocardial dyssynchrony in 
patients with HCM.  Importantly Bonow et al.147 demonstrated that amelioration of diastolic 
dyssynchrony using Verapamil was associated with improved global diastolic function. This 
study, though over 25 years old, is still cited today for the current use of Verapamil in patients 
with HCM.  
 Using contemporaneous ultrasound echocardiography techniques, (as discussed in the 
General introduction section Measuring dyssynchrony using echocardiography) a number of 
investigators have demonstrated that despite a normal QRS interval (an electrical synchrony 
surrogate) in patients with HCM, there is evidence for the presence of mechanical dyssynchrony.  
Dyssynchrony has been demonstrated to be present both intra- and interventricular, and to be 
directly correlated with wall thickness. 
 Biventricular pacing (as discussed in Chapter 1 Biventricular Pacing) has been shown to 
be life prolonging in patients with systolic heart failure. Of the several postulated mechanisms 
involved in producing benefit from BiV pacing, one that has been suggested is the attenuation in 
dyssynchronous myocardial contraction. Numerous studies have demonstrated exactly this using 
contemporary ultrasound imaging techniques. The correction of intraventricular dyssynchrony 
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using BiV pacing has been correlated with parameters of improved global cardiac function 161, 
reduction in symptom status, and improved exercise tolerance163. 
 However, to date no studies have addressed the possible effects of BiV pacing on 
dyssynchrony in patients with symptomatic non-obstructive hypertrophic cardiomyopathy. Thus, 
the aim of this study was to answer this specific question. We hypothesized that BiV pacing would 
acutely improve echocardiographic parameters of dyssynchrony in patients with HCM. 
Methods 
29 HCM patients (20 males mean age 55years), were selected according to the inclusion 
and exclusion criteria described in Chapter 2 (section ii). Two sets of Echocardiographic studies 
were carried out on these patients at rest, during sham pacing and then after 1 hour of BiV pacing, 
as described in Chapter 2 (section iii). 4 measures of myocardial systolic synchrony and 1 measure 
of diastolic synchrony, and 2 measures of interventricular synchrony were assessed using 
conventional doppler, tissue doppler and STE echocardiographic techniques as described in 
Chapter 2 (section viii). 
Statistical analysis 
In brief data were analysed using SPSS v17.0 and Microsoft Excel. Comparisons of 
variables were determined by the Students paired t test. A difference of p<0.05 was taken to 
indicate statistical significance (see Chapter 2 section xi for details). Using SPSS retrospective 
observed power calculations were carried out for results with p > 0.05.  
Results 
The clinical and cardiopulmonary characteristics of the study population are shown in Table 
3.1. 29 patients were able to tolerate active Biventricular (BiV) pacing. Patients had a lower 
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exercise capacity as compared to healthy controls338, with significant symptoms. Baseline QRS 
interval was not prolonged.  
Over half the patients were on rate limiting medications (beta blockers and/or calcium 
channel blockers). These were continued throughout the study period. 
LV ejection fraction on echocardiography was unchanged following acute BiV pacing, with 
no change observed in LV filling time, E/A ratio or in E/E' (Table 3.2). 
Speckle Tracking 
Speckle tracking derived measures of systolic intraventricular dyssynchrony are show in 
Table 3.3. SDt6S and AS-P delay both demonstrated a tendency towards reduction, though 
statistical significance was not achieved. 
Tissue Doppler Imaging 
Both indices of systolic intraventricular dyssynchrony measured using TDI were reduced 
following BiV pacing. The Yu index of systolic dyssynchrony was significantly reduced (p=0.005) 
following application of acute BiV pacing,(Table 3.3, Figure 3.1). Similarly, the basal systolic 
intraventricular dyssynchrony as measured using TDI, was reduced (p=0.05). Diastolic 
intraventricular dyssynchrony measured using TDI did not show any significant change following 
acute BiV pacing (p=0.941), (Table 3.3). 
Parameters of interventricular dyssynchrony as measured using TDI did not show any 
significant change following acute biventricular pacing (p= 0.81) similarly, interventricular 
dyssynchrony measured using conventional pulse wave doppler, did not demonstrate any 
significant change following BiV pacing (p= 0.36), (Table 3.3). 
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Table 3.1 Baseline characteristics of study population 
Age (Years) 55±2.11  
Heart Rate (bpm) – Baseline Resting 67.82±2.7 
Systolic BP (mmHg)- Baseline Resting 129.48±3.47 
Diastolic BP (mmHg)- Baseline Resting 77.07±1.69 
VO2 max ml/kg/min (% predicted) 17.89±0.76 (45.93±3.20) 
Peak Heart rate achieved bpm 119±4.44 
Exercise duration(Sec) -Baseline 422±25 
Minnesota QOL score- Baseline 49.07±4.08 
ECG QRS (ms)- Baseline Resting 98.82±4.05 
    
Drug therapy n 
Beta-blocker 15 
Ca2+ Channel Blocker 15 
Diuretic 6 
ACE inhibitor 7 
Warfarin 3 
    
Echocardiography   
Mean Wall Thickness (MWT) (mm) 18.65±0.88 
Left Atrial Volume Index ml/m2 - Baseline 35.42±1.87 
LV EF, % 61.68±1.22 
Mitral E velocity, m/s 0.73±0.04 
Mitral A velocity, m/s 0.71±0.04 
Mitral E/A ratio 1.16±0.10 
TDI S velocity, cm/s 0.05±0.003 
TDI  E’ velocity m/s 0.05±0.003 
TDI A’ velocity cm/s 0.04±0.006 
E/E’ 15.67±1.87 
LV EF Left Ventricle Ejection Fraction; TDI Tissue Doppler Imaging 
Values are mean ± sem (standard error mean) 
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Table 3.2 Effect of Acute Biventricular (BiV) pacing on echocardiographic variables. 
At Rest Whole Group n=29 VVI30 Acute BiV p 
LVEF, % 62.54±1.28 65.30±1.43 0.13 
LAV Index (ml/m2)  35.07±1.73 30.08±2.12 0.11 
RV Tei Index 0.39±0.07 0.32±0.05 0.86 
Isovolumic Relaxation Time (ms) 118.44±4.31 120.18±5.84 0.71 
Isovolumic Contraction Time (ms) 11.65±23.22 11.17±28.16 0.75 
LV Tei index 0.43±0.07 0.35±0.08 0.25 
AoV Peak Gradient (mmHg) 11.83±2.53 7.69±0.96 0.05 
Cardiac index l/min/m2 3.57±0.27 3.46±0.19 0.25 
LV Filling time (s) 0.52±0.02 0.53±0.02 0.55 
Mitral E velocity (m/s) 0.71±0.03 0.71±0.04 0.92 
Mitral A velocity (m/s) 0.68±0.04 0.68±0.04 0.87 
E/A ratio 1.16±0.09 1.13±0.08 0.70 
Mitral DT (ms) 235.25±9.81 262.75±15.45 0.16 
E/E’antlat 15.01±1.66 12.42±1.10 0.06 
Total Isovolumic time s (60s) 12.58±1.59 13.50±2.22 0.74 
Total LV ejection time s (60s) 17.80±0.75 17.05±0.89 0.55 
Total LV filling time s (60s) 29.61±1.48 29.44±1.87 0.94 
Effective LV Filling Time(FT) 
(FT/RR) 0.49±0.02 0.49±0.03 0.94 
TAPSE (mm) 14.27±1.74 14.48±1.78 0.75 
 Values are mean ± sem. p values are for BiV vs. VVI30. 
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 Table 3.3 Effects of Acute BiV pacing on dyssynchrony at rest n=29. mean ± sem 
 Acute Pacing Mode 
Intraventricular dyssynchrony n=29 VVI30 BiV p 
178SDt6s (s) (ste) 0.058±0.007 0.039±0.01 0.14 
178AS-P delay by RS (s) (ste) 0.11±0.01 0.053±0.018 0.078 
173Yu index by TDI (s) 0.07±0.009 0.038±0.007 0.005 
14Basal systolic dyssynchrony TDI (s) 0.10±0.01 0.084±0.017 0.053 
151Diastolic dyssynchrony Te-SD TDI (s) 0.049±0.006 0.051±0.034 0.941 
Interventricular dyssynchrony n=29    
Qa-Qp (ms) 14.27±3.24 15.90±3.35 0.36 
Ts LV-RV TDI (s) 0.08±0.01 0.09±0.02 0.81 
 
ste: speckle tracking 
SDt6s: Standard Deviation time to peak systolic radial strain for six segments papillary level 
AS-P delay by RS: Anteroseptal – Posterior wall delay in time to peak Radial Strain. 
Te-SD: Standard deviation 12 segments to peak early diastolic velocity (e). 
Basal systolic dyssynchrony TDI: Maximum delay between peak systolic longitudinal 
velocities basal level four walls. 
Qa-Qp: Pre-ejection interval difference aortic and pulmonary flow. 
Ts LV-RV: Time interval (Ts) to peak longitudinal systolic velocity basal wall lateral left 
ventricle (LV) and basal free wall right ventricle (RV). 
Values are mean ± sem. p values are for BiV vs. VV130.  
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Figure 3.1 : Box-whisker plot showing data collected in 29 patients. TDI derived Yu index 
during sham pacing (VVI) and following Acute active pacing (BiV).  Open circles show 
individual patients, bold line is median. **p = 0.005; BiV vs. VVi.  
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Discussion 
 
Hypertrophic cardiomyopathy potentially harbors the correct substrate to produce clinically 
significant dyssynchronous myocardial contraction, with patchy myocyte disarray and fibrosis339, 
340.  Even with an intact rapid conduction network, the myocardium may still demonstrate 
mechanical dyssynchrony due to fibrosis, differential wall stresses, microvascular ischemia, and 
myocyte mal-alignment, all seen in hypertrophic cardiomyopathy340, 341. The duration of the QRS 
complex is often used as a surrogate marker for dyssynchronous myocardial contraction, however 
the relationship between the width of the QRS complex and response to BiV pacing is poor342. This 
may in part be explained by up to a third of patients with prolonged QRS not demonstrating 
mechanical dyssynchrony343, 344. Conversely mechanical dyssynchrony is not infrequently reported 
in heart failure patients with a narrow width QRS complex345.  In patients with heart failure the 
presence of dyssynchrony is detrimental to both morbidity and mortaliy346 
Acutely, biventricular pacing has been shown to be able to restore coordinate contraction 
in patients with systolic heart failure, with an immediate positive impact (in a heartbeat) on 
ventricular performance259 and chronically on mortality and morbidity264 with most benefit seen in 
patients with basal dyssynchrony347, 348. Rogers et al.268 report that BiV pacing in patients with end-
stage non-obstructive HCM (mean EF 41±14%), and left bundle branch block, improves symptoms 
and induces reverse remodeling of the left ventricle. However, comment on the impact of BiV 
pacing on measures of dyssynchrony is not made. As discussed earlier, Rinaldi et al.274 reported a 
case series of 8 patients with obstructive HCM and preserved systolic function, experiencing varied 
clinical outcomes following BiV pacemaker implantation, with no comment made regarding 
dyssynchrony parameters. A literature review did not reveal any previously published work 
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examining the impact of BiV pacing on indices of dyssynchrony in patients with non-obstructive 
HCM with preserved systolic function.  
In the present study, we investigated the acute effects of BiV pacing, at rest, on several 
measures of dyssynchrony, in patients with non-obstructive exercise limited HCM. Despite a 
narrow QRS complex, at baseline, the order of magnitude of dyssynchrony when measured using 
STE and tissue doppler, was similar to that described in patients with systolic heart failure173, 178. 
We observed that following acute BiV pacing there was a tendency for a reduction in LV 
intraventricular systolic dyssynchrony, similar to that reported in patients with systolic heart 
failure.  However, we found that it was only the TDI-derived measures that reached statistical 
significance. A tendency towards a reduction in intraventricular dyssynchrony was seen using STE 
techniques, however statistical significance was not achieved. Though the sample size was small, 
a retrospective analysis of observed power was calculated at 80%, which would suggest lack of a 
true biological effect.  
These are conflicting results. Tissue doppler imaging derived measures of dyssynchrony 
utilise data from the longitudinal motion (note, not contraction) of the myocardium data. However 
due to the orientation of epicardial and subendocardial fibers, myocardial contraction in principally 
radial349. Helm et al.350 have demonstrated that in the failing heart, longitudinal derived indices are 
poorly sensitive to mechanical dyssynchrony. In contrast to TDI, speckle tracking derived measure 
of myocardial dyssynchrony are based on radial contraction. Suffoletto et al.179 and others178 have 
shown using STE, radial strain derived indices to be powerful predictors of response to BiV pacing 
in patients with systolic heart failure. Furthermore Chung et al.289 showed that TDI derived 
measures of dyssynchrony suffer moderate to high intra- and inter-observer variability, as 
compared to STE derived measures of radial dyssynchrony351. STE derived strain overcomes some 
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of the inherent short comings of TDI, as discussed earlier, and may provide a more accurate 
measure of myocardial mechanics. 
We found that measures of interventricular dyssynchrony were essentially unchanged by 
BiV pacing, perhaps unsurprising given that pre-pacing values were similar to post-pacing values 
reported in the literature352. The measure of diastolic dyssynchrony was unaffected following BiV 
pacing, similar results have been reported in systolic heart failure studies284, 353. If systolic 
contraction was more synchronous following BiV pacing one might anticipate that diastolic 
relaxation would as consequence be more synchronous, however given that only approximately a 
third of systolic heart failure patients have both systolic and diastolic dssycnhrony354, suggests 
mechanisms more than just mechanical dyssynchrony at play.  
In this study, all measures were carried out using 2-dimensional echocardiography at rest, 
with the patient supine. However, it is when erect and on exertion that most patients experience 
symptoms. This is a serious limitation of the current work, as it may be during exercise related 
myocardial stress when clinically significant myocardial mechanical dyssynchrony is prevalent. 
Furthermore, echocardiography was carried out 1 hour following initiation of BiV pacing. It is 
possible that this is not a duration long enough to have an impact significant enough on 
myocardium in HCM to be detected by speckle tracking.  
Future studies performed using 3D speckle tracking  echocardiography355, on exercise, 
maybe able to provide a more comprehensive assessment of LV mechanics, overcoming some of 
the shortcomings of two-dimensional imaging at rest,  and thus be able to make a more accurate 
assessment of the impact of BiV pacing on myocardial mechanics. 
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The question of whether the improvements seen acutely in systolic TDI measures of 
dyssynchrony are sustained chronically, and perhaps more importantly whether this translates into 
a clinically significant response will be addressed in the chronic component of this study.   
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Chapter 4 	
 
 
The Acute Study 
 
 
The effects of acute Biventricular pacing on myocardial function during exercise in Hypertrophic 
Cardiomyopathy. 
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Introduction 
 
Patients with HCM often complain of exertional breathlessness. In those patients who do 
not have obstruction to outflow at rest or on exercise6 and who have normal systolic function, the 
symptoms of  breathlessness and reduced exercise tolerance are attributed to diastolic dysfunction8, 
40, 356, 357, as discussed in Chapter 1. The suggested mechanisms contributing towards impaired 
diastolic function include altered ventricular relaxation, filling and compliance, producing 
symptoms of heart failure. As discussed earlier in Chapter 1, it has been shown in patients with 
systolic heart failure, with volume overload, and pulmonary hypertension, that restricted filling of 
the LV by pericardium and right ventricle may too have a part to play4 in generating diastolic 
dysfunction. In patients with non-obstructive HCM, the established management options are 
largely limited to diastole prolonging pharmacotherapy108, though Frenneaux et al. have recently 
demonstrated the benefit of metabolic energy modulation using Perhexiline95  
A number of studies have now shown that BiV pacing can improve exercise capacity, 
improve the quality of life, and reduce mortality in patients with NYHA III/IV systolic heart failure 
with broad QRS complex. The mechanism of improvement has been thought to relate primarily to 
an amelioration of ventricular contractile dyssynchrony, giving rise to the commonly used term 
cardiac resynchronisation therapy. However reliable measures of dyssynchrony that may be used 
to predict response to BiV pacing have been frustratingly difficult to find, with almost innumerable 
indices described163, 165, 167, 171, 173, 179, 181, 184, 358-361, this predicament is highlighted by current 
guidelines advocating no parameter of mechanical dyssynchrony when considering BiV pacing 
therapy362, 363.   
However our group has shown that at least some of the acute hemodynamic benefit seen by 
LV and BiV pacing in systolic heart failure is due to a reduction in the external constraint to LV 
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filling by the pericardium (pericardial constraint) and by the right ventricle through the 
interventricular septum, a phenomenon known as diastolic ventricular interaction (DVI) 10, as 
discussed in Chapter 1. We proposed that this benefit may be due to an alteration in the relative 
timing of LV vs. RV filling.  
As discussed in the introduction there is reason to postulate that DVI may occur commonly 
in patients with Hypertrophic Cardiomyopathy who are very symptomatic. On exercise pulmonary 
artery pressure commonly rises markedly in patients with HCM239(Figure 1.15), with the most 
marked increase seen at the lower exercise levels. This increase in PA pressure might be expected 
to cause enlargement of the RV on exercise, with leftward ventricular septal shift, and pericardial 
stretch, resulting in pericardial constraint and DVI. Animal studies 240, 242, 243, with increased 
pulmonary artery pressures, either via embolization or pulmonary artery constriction, support the 
concept of consequential deleterious diastolic ventricular interaction and loss of stroke work. Of 
important note in the animal studies, pericardiectomy contributed to an improvement in diastolic 
ventricular interaction.  Then Biventricular pacing might be expected to affect a reduction in 
external constraint to LV filling by altering the relative timing of LV and RV filling, restoring the 
ability to utilize the Starling mechanism on exercise. 
The goal of the present study was to look at ventricular function of HCM patients at rest 
and on exercise, with and without biventricular pacing specifically looking of LV end diastolic 
volumes, stroke volumes and ventricular filling patterns. We hypothesised that DVI may be present 
in some patients at rest, develop further on exercise, and may be relieved by BiV pacing. 
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Methods	
This study was performed on the 29 HCM patients (20 males mean age 55years), selected 
according to the inclusion and exclusion criteria described in Chapter 2 section ii.  
In brief changes in ventricular volume, and patterns of filling were measured, using gated 
radionuclide ventriculography, at rest and during semi-supine bike exercise (at 50% heart rate 
reserve) (as described in detail in Chapter 2 section v), with and without BiV pacing (as described 
in Chapter 2 section iv).  
10 patients had images of paired studies of sufficient quality to allow normalised ventricular 
septal radius of curvature (Rs) measurements (as described in detail in Chapter 2 section vii). The 
ventricular septal radius of curvature was measured (normalised for LV area), at rest and during 
exercise with and without BiV pacing. 
Statistical analysis 
Data were analyzed using SPSS version. 17.0 for Windows and Microsoft Office Excel 
2010, and expressed as mean ± standard error (sem), described in detail in Chapter 2 section xi. 
Results 
The clinical and cardiopulmonary characteristics of the patient cohort are shown in Table 
3.1 (see Chapter 3). 29 patients were able to tolerate active Biventricular pacing. Patients had a 
significantly reduced exercise capacity, with significant symptoms. Baseline QRS interval was not 
prolonged. Over half the patients were on rate limiting medications (beta blockers and/or calcium 
channel blockers). 
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i) LVEDV response to exercise (Table 4.1  and Figures 4.1  and  4.2) 
In the group, as a whole (n=29), during sham pacing, there was a failure of LVEDV to 
increase with exercise (-1.79±4.92% p=0.53) (Table 4.1). Patients were divided into two groups 
based on LVEDV response to exercise during sham pacing.  Those in whom LVEDV fell during 
semi-supine exercise, suggestive of more marked diastolic dysfunction, (Group 1) (n=15) than 
those in whom LVEDV increased during semi-supine exercise (Group2) (n=14). 
For the whole group (n=29) the change in LVEDV during exercise did not significantly 
differ between BiV pacing and sham pacing (p=0.18), (Figure 4.1). However, in Group 1 patients, 
there was a significant difference in LVEDV response to exercise between BiV vs. sham pacing 
with a modest increase in mean LVEDV with BiV pacing (p=0.004) (Figure 4.2). For differences 
between sham vs. BiV pacing see Table 4.1. 
ii) Stroke volume (Table 4.1, Figures 4.3 and  4.4)  
Stroke volume fell on exercise in Group 1 patients (-21.04±5.31%) during sham pacing, 
but increased during BiV pacing (5.80±7.66% p=0.008).  In contrast, stroke volume increased 
during exercise in Group 2 patients (24.46±5.02%) with sham pacing and the response was similar 
during BiV pacing (p= 0.28), (Figure 4.4).  
iii) Heart Rate (Table 4.3) 
During sham pacing in the whole group, heart rate increased significantly in patients on 
exercise and in both Groups 1 and 2. Peak exercise heart rates were comparable in Groups 1 and 
2 (p= 0.49). During sham pacing resting heart rate, though lower in Group 1(58±2.09) compared 
to Group two (63±2.61), was not significantly different (p=0.23), and may be a reflection of greater 
beta blocker and calcium channel blocker use in Group 1. Blood pressure increased appropriately 
 
 
105 
 
in patients in both Groups with no significant difference between the Groups 1 and 2 of peak 
pressure achieved (p=0.54). 
iv) Left Ventricular contractile function at rest and during exercise (Tables 4.1and 4.3)  
In the whole group, LV end systolic (es) elastance, a measure of LV contractile function, 
was similar at rest (p=0.80) and on exercise (p=0.41) during BiV vs. sham pacing. This was so in 
both Group 1 and Group 2 patients (Table 4.3). During sham pacing on exercise in Group 1 patients, 
LV end systolic elastance was statistically greater than in Group 2 (p=0.01) but this difference was 
largely driven by a single individual without whom p=0.07.  
Similarly, LV ejection fraction did not significantly differ between BiV pacing and sham 
pacing at rest or on exercise (Table 4.3). However BiV pacing was associated with a significant 
shortening of the duration of systole at rest (p=0.03), and on exercise (p=0.002) vs. sham pacing, 
in the whole group (Table 4.3). In the two subgroups this tendency for a reduction in duration of 
systole with BiV pacing was maintained, but was most marked in Group 1 on exercise (p=0.02) 
(Table 4.3). 
v) Diastolic Filling (Table 4.4, Figures 4.5-4.10) 
In the whole group the percentage of total filling occurring in the first third of diastole was 
reduced both at rest and on exercise (p< 0.005) during BiV pacing vs. sham pacing (Figure 4.7). 
This effect was significant for Group 1 (p=0.02 rest, p=0.002 exercise), and for Group 2 (p= 0.01 
rest p= 0.04 exercise) (Figure 4.9). The percentage of filling occurring in the final two thirds of 
diastole was accordingly increased in the whole group at rest (p< 0.005),  (Figure 4.5), and during 
exercise (p< 0.005) (Figure 4.8), with significant increases in both Group 1 and Group 2 at rest, 
(Figure 4.6) and on exercise, (Figure 4.10). The diastolic filling period was substantially increased 
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on exercise in Group 1 patients, less so in Group 2 patients during BiV vs. sham paced mode, 
(Tables 4.3, and 4.5).  
vi) Normalised ventricular septal radius of curvature (Rs) (Table 4.2) 
In 10 patients, the radionuclide ventriculograms were of sufficient quality during both 
studies (BiV and sham pacing) to allow ventricular septal radius of curvature measurements, (5 
from Group 1 and 5 from Group 2). Unpaced, during exercise there was a trend for an increase in 
Rs (p=0.08), this was more marked in Group 1 (1.75±1.09) patients as compared to Group 2 
(1.09±0.03) patients. During BiV pacing, on exercise, the increase in Rs was less marked when 
compared to sham pacing (BiV Rs Exe 2.27±0.27 vs. VVI30 Rs Exe 3.64±0.81 p=0.16). The 
attenuation in the increase in Rs on exercise, during BiV pacing, was more marked in Group 1 
patients (∆ Rs (BiV Exe - VVI Exe) -1.96±0.98) compared to Group 2 patients (∆ Rs (BiV Exe - 
VVI Exe) -0.79±0.36). However, all of these differences were non-significant. 
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Exercise vs. 
Rest 
 
Whole Group 
n=29 
 
Group 1 
n=15 
 
Group 2 
n=14 
 
Gp1 vs. Gp2 
 
Pacing 
Mode   
VVI30 
 
∆ LVEDV % 
 
-1.79±4.92 
 
-22.32±4.29 
 
20.2±3.86 
 
p < 0.005 
 
∆SV % 
 
0.929±5.6 
 
-21.04±5.31 
 
24.46±5.02 
 
p < 0.005 
 
∆ end systolic 
Elastance % 
 
 
16.09±13.60 
 
 
27.23±26.44 
 
 
4.17±4.57 
 
 
p=0.41 
 
BiV 
 
∆ LVEDV % 
 
8.09±5.31 
 
3.40±7.00 
 
13.13±8.09 
 
p=0.347 
 
∆SV % 
 
9.20±5.94 
 
5.80±7.66 
 
12.84±9.39 
 
p=0.55 
 
∆ end systolic 
Elastance % 
 
 
4.89±6.81 
 
 
6.12±12.45 
 
 
3.57±5.25 
 
 
p=0.85 
 
BiV vs. VVI30 
 
 
∆ LVEDV 
 
p=0.18 
 
p=0.004 
 
p=0.43 
 
 
∆SV 
 
p=0.31 
 
p=0.008 
 
p=0.28 
 
∆ end systolic 
Elastance 
 
p=0.442 
 
p=0.443 
 
p=0.932 
Table 4.1 Semi-supine exercise data during, sham pacing (VVI30) and active pacing (BiV). delta 
Left Ventricular End Diastolic Volume (∆LVEDV %), delta Stroke Volume (∆SV %). Active 
pacing (BiV), Sham pacing (VVI30).  Group 1 and Group 2 as defined in Chapter 4. All values 
expressed as mean±sem. 
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Table 4.2 Effect of semi-supine exercise and Biventricular (BiV) pacing on normalised ventricular 
septum radius of curvature (Rs) measurements. Sham pacing (VVI), Active pacing (BiV), Semi-
supine exercise (Exe). Group1 (Gp1) and Group2 (Gp2) as defined in Chapter 4. mean ± sem. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Normalised ventricular septal radius of curvature (Rs)  
 n=10 Gp1 n=5 Gp2 n=5 p (Gp1vs. Gp2) 
VVI30 
Rest 2.21±0.15 2.45±0.15 1.98±0.14 0.16 
Exe 3.64±0.81 4.20±1.71 3.08±0.16 0.54 
p (Rs VVI Rest vs. Rs VVI Exe) 0.08 0.32 0.43  
BiV 
Rest 2.07±0.19 2.03±0.24 2.12±0.15 0.86 
Exe 2.27±0.27 2.24±0.32 2.29±0.23 0.93 
p (Rs BiV Rest vs. Rs BiV Exe) 0.45 0.36 0.73  
p (Rs VVI Exe vs. Rs BiV Exe) 0.16 0.53 0.11  
∆ Rs (BiV Exe -VVI Exe) -1.37±0.72 -1.96±0.98 -0.79±0.36 0.45 
∆ Rs (VVI Exe - VVI Rest)             +1.42±0.73 +1.75±1.09 +1.09±0.03 0.68 
∆ Rs (BiV Exe - BiV Rest)              +0.19±0.25 +0.21±0.14 +0.17±0.34 0.94 
p (∆Rs VVI30 vs. ∆ Rs BiV) 0.14 0.36 0.15  
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Group 1 n=15    
 
Rest 
HR (Heart Rate) bpm 58.97±2.09 63.63±2.65 0.18 
SBP mmHg 135.73±5.43 134.93±5.05 0.91 
EF (Ejection Fraction) % 71.03±3.37 71.73±2.46 0.87 
LV end systole elastance 67.21±20.79 60.83±20.79 0.83 
Duration systole (s) 0.38±0.03 0.34±0.02 0.14 
Duration of diastole(s) 0.61±0.05 0.56±0.06 0.19 
 
Exercise 
HR 86.97±4.6 87.12±4.58 0.98 
SBP 163.73±5.04 156.6±5.27 0.34 
EF % 71.17±3.11 73.02±2.70 0.66 
LV end systole elastance 94.43±23.76 66.96±23.76 0.42 
Duration of systole (s) 0.33±0.01 0.27±0.01 0.02 
Duration of diastole(s) 0.34±0.02 0.44±0.03 0.002 
 
Group 2 n=15     
 
Rest 
HR (Heart Rate) bpm 62.99±2.61 67.28±3.59 0.29 
SBP mmHg 130.42 ±4.24 128±5.03 0.72 
EF (Ejection Fraction) % 73.79±3.04 75.97±2.37 0.58 
LV end systole elastance 47.05±8.39 45.51±8.39 0.89 
Duration systole (s) 0.37±0.02 0.32±0.02 0.13 
Duration of diastole(s) 0.57±0.05 0.59±0.04 0.81 
 
Exercise 
HR 91.21±3.96 93.65±4.49 0.69 
SBP 159.43±4.95 152.57±5.52 0.36 
EF % 76.493.57 75.38±3.41 0.85 
LV end systole elastance 51.23±8.24 49.08±8.24 0.85 
Duration of systole (s) 0.32±0.01 0.26±0.02 0.05 
Duration of diastole(s) 0.35±0.04 0.38±0.04 0.47 
 
Table 4.3 Semi-supine exercise data following sham pacing (VVI30) and active 
pacing (BiV). SBP mmHg. Patients are divided into Group1 and Group2 as defined in  
Chapter 4. Values are shown as mean ±SEM. p values are for BiV vs. VV130. 
  VVI30 BiV p 
Whole Group n=29       
 
Rest 
HR (Heart Rate) bpm 60.91±1.6 65.33±2.18 0.09 
SBP (Systolic Blood Pressure) 133.17±3. 131±3.57 0.75 
EF (Ejection Fraction) % 72.37±2.25 73.78±7.73 0.62 
LV end systole elastance 57.48±11.43 53.44±11.43 0.80 
Duration systole (s) 0.38±0.02 0.33±0.02 0.03 
Duration of diastole(s) 0.61±0.03 0.58±0.03 0.35 
 
Exercise 
HR 89.02± 3.03 90.21±3.21 0.78 
SBP 161.66±3.5 154.66±3.76 0.18 
EF % 73.74±2.37 74.16±2.13 0.90 
LV end systole elastance 73.58±13.07 58.33±13.07 0.41 
Duration of systole (s) 0.32±0.01 0.27±0.01 0.002 
Duration of diastole(s) 0.35±0.03 0.42±0.02 0.002 
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Table 4.4 Effect of sham pacing (VVI30) and active pacing (BiV), on Diastolic filling thirds 
during semi-supine exercise, whole group n=29, and by Groups (Gp) as defined in Chapter 4. 
Values are shown as mean ±SEM 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 VVI30 BiV BiV vs. VVI30 
 1st Third 
filling % 
Final 2/3 
filling % 
1st Third 
filling % 
Final 2/3 
filling % 
1st Third 
filling 
Final 2/3 
filling 
Whole Group  
Rest n=29 48.32±3.04 51.67±3.04 32.53±2.93 67.46±2.93 p<0.005 p<0.005 
Gp2 Rest n=14 49.01±4.35 50.98±4.35 33.79±3.47 66.20±3.47 p=0.01 p=0.01 
Gp1 Rest n=15 47.62±4.42 52.37±4.42 31.18±4.92 68.81±4.92 p=0.02 p=0.02 
  
Whole Group 
Exercise n=29  36.26±2.71 63.70±2.69 22.03±2.18 77.96±2.18 p<0.005 p<0.005 
Gp2 Exercise n=14 34.27±3.73 65.65±3.72 23.61±3.04 76.38±3.04 p=0.04 p=0.04 
Gp1 Exercise n=15 38.40±3.99 61.88±4.32 20.44±3.18 79.55±3.18 p=0.002 p=0.003 
  
Gp1 vs. 
Gp2  
Rest p=0.82 p=0.82 p=0.66 p=0.66   
Exercise p=0.46 p=0.46 p=0.47 p=0.47   
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Pacing Mode  
 VVI30 BiV BiV vs. VVI30 
Duration diastole rest (s)      
Whole Group (s) n=29  0.61±0.03 0.58±0.03 p=0.35 
Group2 (s) n=14 0.57±0.05 0.59±0.04 p=0.81 
Group1 (s) n=15 0.61±0.05 0.56±0.06 p=0.19 
Group1 vs. Group2  p=0.91  p=0.47   
Duration diastole exercise (s)      
Whole Group n=29 0.35±0.03 0.42±0.02 p=0.002 
Group2 (s) n=14 0.35±0.04 0.38±0.04 p=0.47 
Group1 (s) n=15 0.34±0.02 0.44±0.03 p=0.002 
Group1 vs. Group2   p=0.81 p=0.38  
Table 4.5 Effect on the duration of diastole in seconds(s) at rest and on semi-supine exercise, 
during sham pacing (VVI30) and during active pacing (BiV). Group 1 and Group 2 as 
defined in Chapter 4. Values are shown as mean ±SEM.  
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Figure 4.1 : Box-whisker plot showing delta LVEDV on exercise, during sham pacing (VVI) and 
following acute active pacing (BiV), n =29. Open circles show individual patients, bold line is 
median.  There was no significant difference between VVi and BiV. 
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Figure 4.2 : This box-whisker plot shows delta LVEDV on exercise, during sham pacing (VVI) 
and following acute active pacing (BiV). Patients have been separated into two groups. Patients 
who during sham pacing demonstrate a reduction in LVEDV on exercise were collated into 
Group1 and those who do not are in Group 2. Group1 n=15, Group2 n=14.  Open circles 
represent individual patients; bold line is median. **p=0.004; BiV vs. VVi in Group 1, p=0.43 
for BiV vs. VVi in Group 2.  
 
** 
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Figure 4.3 : Box-whisker plot showing delta stroke volume(SV) on exercise, during sham pacing 
(VVi) and following acute active pacing (BiV) n=29. Open circles represent individual patients, 
bold line is median. p=ns: BiV vs. VVi. 
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Figure 4.4 : Box-whisker plot showing delta SV on exercise, during sham pacing (VVI) and 
following acute active pacing (BiV), by group. Group1 n=15, Group2 n=14. Open circles 
represent individual patients, bold line is median. **p=0.008: BiV vs. VVi in Group 1; 
p=0.28: BiV vs. VVi in Group 2. 
 
 
 
** 
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Figure 4.5 : Box-whisker plot showing percentage of total diastolic filling occurring in the final 
two-thirds of diastole at rest, during sham pacing (VVi) and following active (BiV) pacing 
(n=29). Open circles represent individual patients; bold line is median. *p<0.05: BiV vs. VVi.  
 
 
* 
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Figure 4.6 : Box-whisker plot showing percentage of total diastolic filling occurring in the final 
two-thirds of diastole at rest, during sham pacing(VVi) and following active(BiV) pacing by 
Group (n=29). Open circles represent individual patients; bold line is median.  Group 1 (n=15) 
*p= 0.02: BiV vs. VVi, Group 2 (n=14) **p=0.01: BiV vs. VVi.  
 
 
 
* 
** 
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Figure 4.7 : Box-whisker plot showing percentage of total diastolic filling occurring in the 
first third of diastole on exercise, during sham pacing(VVi) and following active(BiV) pacing 
(n=29). Open circles represent individual patients; bold line is median. **p<0.005: BiV vs. 
VVi. 
 
 
** 
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Figure 4.8 : Box-whisker plot showing percentage of total diastolic filling occurring in the 
final two-thirds of diastole during exercise, during sham pacing (VVi) and following active 
(BiV) pacing (n=29) Open circles represent individual patients, bold line is median. 
**p<0.005: BiV vs. VVi. 
 
 
** 
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Figure 4.9 : This box-whisker plot shows percentage of total diastolic filling occurring in the first 
third of diastole during exercise, during sham pacing (VVi) and following active (BiV) pacing by 
Group. Group1 n=15, Group2 n=14. Open circles represent individual patients; bold line is 
median. **p=0.002: BiV vs. VVi for Group 1; *p=0.04: BiV vs. VVi for Group 2.  
 
 
 
Figure 4.10 : This box-whisker plot shows percentage of total diastolic filling occurring in the 
final two-thirds of diastole during exercise, during sham pacing (VVi) and following active (BiV) 
pacing by Group. Group1 n=15 Group2 n=14 Open circles represent patients; bold line is median. 
**p=0.003: BiV vs. VVi for Group 1, *p=0.04: BiV vs. VVi for Group2. 
 
** 
* 
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Discussion 
The purpose of the present study was to investigate the systolic and diastolic behaviour of 
the heart in patients with HCM on exercise, with and without BiV pacing.  Focusing in particular 
on LV end diastolic volumes, ventricular filling patterns, stroke volume, ejection fraction, end 
systolic elastance and ventricular septal curvature at end diastole. 
On exercise, we observed two contrasting changes in the LVEDV. In 14 patients (Group2), 
we noted an, as might be expected, increase in LVEDV on exercise, however in over half (n=15) 
(Group 1) of patients we observed an inappropriate reduction in LVEDV. A failure to increase, and 
more so a reduction in LVEDV on exercise reveals within the cohort of exercise limited HCM 
patients a subset with marked diastolic dysfunction. Furthermore, the subset of patients that 
experienced a fall in LVEDV on exercise had more severe exercise limitation at baseline. We 
focused on this group, examining the mechanisms underlying the diastolic dysfunction seen on 
exercise, and the effect of BiV pacing. 
The results showed that BiV pacing resulted in a greater increase in LV stroke volume on 
exercise, an effect that was almost exclusively observed in Group 1 patients, i.e. those patients with 
the most marked diastolic dysfunction. The effect did not appear to be explained by an increase in 
LV contractility (as assessed by LV end systolic elastance and LV ejection fraction). Instead the 
effect appeared to be mediated by LV preload recruitment. In health, LV end diastolic volume 
increases during exercise, and thereby the Starling mechanism contributes to the increase in stroke 
volume364. This increase in LV end diastolic volume is usually a consequence of both an increase 
in the rate of LV active relaxation during exercise280, 365 and the shifting of blood from the venous 
compartment to the central compartment due the effects of the muscle pump and to active 
vasoconstriction in the intestinal and splenic venous capacitance beds366. It has been shown that 
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the rate of LV active relaxation paradoxically slows during exercise in many patients with HCM 
on exercise, and that amelioration of the marked cardiac energetic impairment with the metabolic 
modulator Perhexiline reverses this abnormality95.  In approximately 50% of the patients in this 
study, during sham pacing, there was an abnormal fall in LV end diastolic volume during exercise, 
and an associated fall in stroke volume (Group1) and unchanged ejection fraction. This abnormal 
fall in LVEDV, seriously attenuates the ability to increase cardiac output on exercise in our 
otherwise chronotropically competent cohort of patients. Given that the augmentation of cardiac 
output during exercise is the predominant determinant of peak exercise capacity42, it is not 
unexpected that this pattern was associated with more severe exercise limitation and with worse 
symptoms than in those patients in whom LVEDV increased on exercise (Group2).  
Biventricular pacing substantially corrected these abnormal responses in Group 1 patients 
(indeed overall there was a modest mean increase in LVEDV during exercise during biventricular 
pacing) with no significant effect observed on the increase in LVEDV during exercise seen in 
Group 2 patients. This was associated with a significant increase in LV stroke volume during 
exercise by biventricular pacing in Group 1 but not in Group 2 patients.  
How might Biventricular pacing have effected this change in ventricular filling? 
Possibilities might include an increase in the rate of LV active relaxation on exercise or a reduction 
in intrinsic left ventricular stiffness, an increase in diastolic filling time or a reduction in external 
constraint to left ventricular filling. Diastolic dyssynchrony has been reported in HCM11, 367 and a 
reduction in the degree of diastolic dyssynchrony by biventricular pacing (especially on exercise) 
might translate into more rapid LV active relaxation and reduced LV stiffness.  However at least 
at rest we observed no significant effect of biventricular pacing on measures of diastolic 
dyssynchrony (see Chapter 3). Furthermore, we observed that biventricular pacing was associated 
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with a reduction in first third filling fraction at rest and on exercise and a marked increase in filling 
during mid and late diastole. External constraint to left ventricular filling by the pericardium368 
(pericardial constraint) and by the right ventricle through the interventricular septum (diastolic 
ventricular interaction, DVI) may be an explanation. DVI has been observed in experimental 
models associated with acute RV volume and/or pressure overload216 214. We have shown that these 
phenomena are seen in an experimental model of chronic heart failure367 and in those patients with 
chronic heart failure who have elevated left ventricular end diastolic pressures (typically 
>15mmHg)4. We have previously shown that in patients with severe CHF both biventricular and 
left ventricular pacing reduced this external constraint to left ventricular filling and thereby 
recruited LV preload, presumably by shifting the timing of LV vs. RV filling10. It is possible that 
this is again the common mechanism at play, and being seen in this patient cohort. DVI is typically 
associated with a restrictive LV filling pattern236 in which rapid early filling then ceases with the 
onset of external constraint. Consistent with the alleviation of DVI would be our observation of 
biventricular pacing reducing the rate of early filling but markedly increasing the filling in the latter 
part of diastole during exercise, with prolonged duration of diastole (potentially contributed to by 
a reduction in pre-systolic mitral regurgitation, although we have no assessment of this), and 
consequent improvement in the ability to utilize the starling mechanism, to increase stroke volume.  
As a result of its anatomical site, the position, and curvature of the ventricular septum is a 
reflection of the interaction it mediates between the right and left ventricle369. In the healthy beating 
heart the septum is shaped concave to the left, its position determined by the transeptal pressure 
gradient it is exposed to, with Kingma et al.370 observing an excellent correlation between end 
diastolic septal position and trans-septal gradient (r=0.98 p<0.001).  Dong et al.316 have further 
described that the left shift of the ventricular septum, during RV pressure loading, was associated 
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with an increase in Rs, even after correcting for LV cross sectional area, indicating a true 
relationship between ventricular septal position and Rs. Using the Mueller maneuver in man to 
volume load the RV, Guzman et al.345 and others371 have demonstrated ventricular septal flattening, 
with an increase in Rs in diastole, associated with a leftward shift, that persists during systole.  
Though our numbers are small (n=10) we see, on exercise, a strong trend for an increase in 
normalised interventricular septal radius of curvature on exercise (p=0.08), indicating septal 
flattening, with this effect being more marked in Group 1 vs. Group 2 patients, suggestive of 
increased RV pressures causing a left shift of the septum. Importantly we found that BiV pacing 
tended to ameliorate this septal flattening during exercise, restoring septal curvature. These data 
though requiring confirmation with larger numbers provide support to the concept that DVI may 
be the mechanism at play in the failure to utilize the Starling mechanism on exercise in HCM 
Furthermore, these findings indicate that correction of this phenomenon may underlie at least some 
of the observed effects of BiV pacing. Of interest, when Kingma et al. induced LBBB (pacing from 
the RV outflow tract), they reported a resultant end diastolic transeptal pressure gradient reversal 
(RV pressure > LV pressure) due to earlier pressure development in the RV, perhaps due to a 
temporal phase shift in ventricular filling (RV filling before LV), we suggest the converse is 
occurring with BiV pacing (LV filling before RV).  
In Group 2 patients, an appropriate increase in LVEDV on exercise, would be suggestive 
of, appropriate RV and LV filling and the absence of significant diastolic ventricular interaction. 
Hence temporally shifting LV filling prior to RV filling, with BiV pacing is unlikely to add further 
volume to an already appropriately filled, unrestricted LV. This is consistent with our observations 
of BiV pacing having a negligible effect on LVEDV or SV on exercise in Group 2 patients (Figure 
4.2, Figure 4.4). 
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In summary, we have shown that over half of patients with symptom limited HCM 
demonstrate very severe diastolic dysfunction on exercise, with deleterious effects on stroke 
volume, but with preserved chronotropy and contractility. Furthermore, we have shown that BiV 
pacing may be able to improve LV diastolic function, and we suggest that this is through the 
amelioration of diastolic ventricular interaction, with consequent improved utilization of the 
starling curve. However, the question of whether this improvement in myocardial function 
translates into improved exercise tolerance and symptomatic benefit is not yet answered and is 
addressed in the chronic component of this study. 
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Chapter 5  
 
 
The Acute Study 
 
 
The impact of right ventricular volume unloading, using lower body negative pressure, on Left 
ventricular diastolic function in patients with Hypertrophic Cardiomyopathy, with and without 
Biventricular pacing. 
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Introduction 
In the normal healthy heart the effective left ventricular (LV) distending pressure is close 
to the measured LV end diastolic pressure (LVEDP) because pericardial and right ventricular 
pressures at end diastole are both close to zero, there is therefore minimal external constraint to LV 
filling. As discussed in Chapter 1, Right ventricular (RV) end-diastolic pressure is usually almost 
identical to pericardial pressure (because the relatively thin walled RV does not usually maintain a 
significant transmural gradient). However, the pericardium exhibits a J shaped stress-strain 
relation229-232and in experimental models associated with acute RV pressure and volume overload, 
as the thin walled RV becomes stretched, pericardial pressure increases.    In this setting of acute 
RV pressure and volume overload,  LV filling is impeded by external constraint to filling from the 
pericardium (pericardial constraint) and from the RV, across the shared inter-ventricular septum242 
(diastolic ventricular interaction – DVI).  The effective distending pressure in these circumstances 
is no longer the measured LVEDP, but the measured LVEDP minus the external constraint from 
the pericardium and right ventricle, giving result to the 'effective' LVEDP. 
As discussed in the Chapter 1, the right ventricle is often volume and pressure overloaded 
in patients with chronic heart failure (CHF).   It has previously been shown by our group that there 
is significant DVI in approximately 40-50% of patients with CHF4, 216.  In such patients blood 
volume unloading (by applying lower body negative pressure) results in a 'paradoxical' increase in 
LV end-diastolic volume, (Figure 1.14, Figure 1.15), despite a fall in measured LV 'filling 
pressures'.  In a canine model of heart failure Frenneaux et al. have shown that as LVEDP was 
lowered by inferior vena cava occlusion, the pressure in the pericardium and RV fell to an even 
greater extent, so the effective LV distending pressure increased.  Changes in LV diastolic volume 
and stroke work were completely predictable on the basis of changes in the LV transmural pressure 
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gradient (i.e. the effective distending pressure). In patients with CHF the presence of this abnormal 
LV volume response was strongly predicted by a restrictive trans-mitral doppler profile 236. 
Bleasdale et al.10 have reported that LV pacing is able to improve diastolic function in patients with 
CHF, and that much of this benefit is via a reduction in external constraint to LV filling372.  
  Thus, in the present study we looked for evidence of constraint to LV filling by the RV, as 
suggested by a 'paradoxical' increase in LVEDV following application of RV volume offloading 
(LBNP), in patients with HCM. Furthermore, we looked at the impact of acute Biventricular pacing 
on diastolic function, in particular looking for correction of 'paradoxical' increases in LVEDV.  
  We hypothesised that in some patients, at rest, with HCM, RV volume unloading (using 
LBNP) would improve diastolic filling via the relief of DVI, which we would observe as a 
'paradoxical' increase in LVEDV.  We further hypothesised that BiV pacing, by analogy to LV 
pacing in CHF, may then relieve the external constraint to LV filling in patients with non-
obstructive HCM, which we would then see as an appropriate decrease in LVEDV following LBNP 
(i.e. correction of the 'paradoxical' response). 
Methods 
29 HCM patients (20 males mean age 55years), were selected according to the inclusion 
and exclusion criteria described in Chapter 2 (section ii). Baseline patient characteristics are given 
in Table 3.1 (Chapter 3).   In brief, a set of 4 gated radionuclide ventriculography studies were 
acquired per patient, (Figure 2.6).  Gated radionuclide ventriculography studies were carried out 
during sham pacing (VVI30) following the application of Lower Body Negative Pressure (LBNP) 
0mmHg and 30mmHg and then the same repeated during BiV pacing (as described in Chapter 2 
section iv).  
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Statistical analysis 
 In brief data were analysed using SPSS v17.0 and Microsoft Excel. Comparisons of 
variables were determined by the Students paired t test. A difference of p<0.05 was taken to 
indicate statistical significance (see Chapter 2 section xi for details) 
Results 
The clinical characteristics and cardiopulmonary exercise test characteristics of the patient 
cohort are shown in Table 3.1. Patients had a significantly reduced exercise capacity, with 
significant symptoms. Baseline QRS interval was not prolonged. Over half the patients were on 
rate limiting medications (beta blockers and/or calcium channel blockers). All 29 patients were 
able to tolerate the application of lower body negative pressure. 
Effect of LBNP on LVEDV during sham pacing and BiV paced modes 
In the whole group, during sham pacing, following the application of LBNP there was a 
significant reduction in LVEDV (-16.59±3.80% p<0.001), (Table 5.1 and Figure 5.1), with an 
associated reduction in SV (-18.31±3.78%). Following BiV pacing, the reduction in LVEDV           
(-21.08±3.42%) and SV (-21.65±4.06%) were more marked (Table 5.1 and Figure 5.2). Four 
patients experienced a paradoxical increase in LVEDV (19.81±4.23%) following the application 
of LBNP in sham pacing mode. This response was reversed following BiV pacing, resulting in a 
reduction in LVEDV (-23.89±10.12%) on application of LBNP in three of these patients. Unpaced 
patients from Group 1 (as defined in Chapter 4) also experienced a reduction in LVEDV following 
LBNP (-12.11± 6.35), but notably less so than Group 2 (as defined in Chapter 4) (-21.42± 3.80). 
This reduction in LVEDV, in Group 1 patients, became markedly more pronounced following BiV 
pacing (-20.97±6.19), (Table 5.1 and Figure 5.3). 
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Table 5.1 Effect of LBNP 30mmHg on LVEDV and SV following sham pacing (VVI30)  
and active (BiV) pacing. Group 1 and Group 2 as defined in Chapter 4. 
Values are mean±sem. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 VVI30 BiV 
BiV vs. 
VVI30 
BiV vs. 
VVI30 
 
LBNP30 – LBNP0 
 
∆ LVEDV 
 
∆SV 
 
∆ LVEDV 
 
∆SV ∆ LVEDV  ∆SV  
Whole Group n=29 -16.59±3.80% 
(p<0.001) 
-18.31±3.78% 
(p<0.001) 
-21.08±3.42% 
(p=0.003) 
-21.65±4.06% 
(p=0.025) 
p=0.39 p=0.36 
Group2 n=14 -21.42± 3.80 
(p<0.001) 
-21.35±4.26 
(p<0.001) 
‐ 23.01±3.32 
(p<0.001) 
-23.51± 3.61 
(p=0.004) 
p=0.74 p=0.68 
Group1 n=15 -12.11± 6.35 
(p<0.001) 
-15.5±6.18 
(p<0.001) 
-20.97±6.19 
(p<0.001) 
-21.81± 7.37 
(p=0.43) 
p=0.31 p=0.51 
Group1 vs. Group2 p=0.224 p=0.465 p=0.86 p=0.996 
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Figure 5.1 : This is a box whisker plot showing delta LVEDV following application of Lower 
Body Negative Pressure (LBNP) 30mmHg, with Sham (VVI30) pacing, as a whole group n=29 
(figure on left) and by Group (figure on the right). Group1 n=15 Group2 n=14. The majority of 
patients show a reduction in LVEDV following application of LBNP 30mmHg, except 4 (red 
solid circles), and this reduction in LVEDV following LBNP30mmHg is more consistent in 
Group 2 patients. Groups1 and 2 as defined in Chapter 4. Open circles are patients, bold line is 
median. 
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Figure 5.2 : This is a box whisker plot showing delta LVEDV following application of Lower 
Body Negative Pressure (LBNP) 30mmHg for the whole group, n=29. during sham pacing (VVi) 
and following active pacing (BiV). 
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Figure 5.3 : This is a box whisker plot showing delta LVEDV following application of 
Lower Body Negative Pressure (LBNP) 30mmHg during sham pacing (VVi) and 
following active pacing (BiV) by Group, Group 1 n=15, Group 2 n=14  
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Discussion 
 In health, lower body negative pressure reduces left ventricular end-diastolic volume and 
stroke volume by approximately 20%, with no significant effect on end-systolic volumes373. Thus, 
in health LBNP significantly reduces preload and stroke volume, producing a Starling effect. In 
contrast, Atherton et al4. observed a paradoxical increase in LVEDV and, as might be expected, a 
decrease in RVEDV on application of LBNP in almost half of patients with severe chronic heart 
failure (Figure 1.14). These patients had evidence of increased right atrial (a surrogate for 
pericardial pressure233), pulmonary hypertension, and left sided filling pressures, at rest, which 
would set the scene for deleterious diastolic right and left ventricular interaction. It is suggested 
that volume off-loading the RV by LBNP, precipitates relief of diastolic ventricular interaction, 
suggested as the key mechanism underlying the paradoxical increase in LVEDV following LBNP 
in this group of patients. 
 We have shown for the first time, that following the application of LBNP in a group of 
highly symptomatic patients with non-obstructive HCM at rest, the majority of patients do not 
experience a paradoxical rise in LVEDV. This suggests that, at rest and when supine at least, the 
degree of deleterious diastolic ventricular interaction and pericardial constraint is not sufficiently 
marked as to impair LV filling sufficiently that it may be amenable to correction by LBNP.  
However, we identified 4 patients who did demonstrate this paradoxical increase in LVEDV 
following application of LBNP. In these 4 patients, it may be the relief of DVI and pericardial 
constraint by RV volume offloading by LBNP that results in increased preload recruitment of the 
LV, with an increase in measured LVEDV. Furthermore, we have shown, for the first time, that 
BiV pacing was able to correct this paradoxical increase in LVEDV in response to RV volume 
unloading in 3 of these 4 patients.   
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Previous studies by Frenneaux et al. has shown that patients with HCM have a markedly 
impaired ability to utilise the Starling mechanism to increase stroke volume during exercise (i.e. 
LVEDV fails to increase despite a substantial increase in pulmonary capillary wedge pressure) 10, 
42, 244 and we see over half of our patients experiencing a fall in LVEDV on exercise (i.e. Group 1, 
see Chapter 4). Thus, the exercise data (Chapter 4) is suggestive of DVI development on exercise 
in many, but the LBNP data suggests its absence at rest in the majority of patients. All 4 patients 
in whom LVEDV paradoxically increased during application of LBNP (inferring presence of DVI 
at rest) were from Group 1.  
Unpaced and on application of LBNP, Group 1 patients (i.e. who experienced a reduction 
in LVEDV on exercise, see Chapter 4), exhibited a lesser reduction in LVEDV as compared to 
those in Group 2 (i.e. who experienced an appropriate increase in LVEDV on exercise) (Table 5.1 
and Figure 5.3), consistent with greater ventricular interaction in Group 1 patients. 
Although the number of patients in which the overt 'correction' of the paradoxical increase 
in LVEDV to LBNP following BiV pacing was small (n=3), it is of note that during BiV pacing 
following application of LBNP, patients in Group 1(n=15) tended towards a similar reduction in 
LVEDV as that seen in Group 2, suggestive of amelioration of DVI by BiV pacing in this Group 
of patients (Table 5.1).   
Left ventricular and BiV pacing has been shown to improve diastolic function in patients 
with heart failure in part by reducing the external constraint to LV filling with increased LVEDV 
with concomitant improvement in LV stroke volume10.  The explanation suggested for this 
reduction in external constraint by LV pacing has been the thought that LV pacing induces a phase 
shift in LV filling relative to RV filling, as demonstrated in the LV pacing canine model374, in 
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which LV relaxation and filling occurred relatively early compared with RV filling, allowing 
unimpeded LV filling.  
On application of LBNP, we assume a reduction in RVEDV. It would have been ideal if 
we had demonstrated a decrease in RVEDV associated with an increase in LVEDV, with correction 
following BiV pacing. Unfortunately, due to decay of radionuclide activity, image quality was not 
sufficient to allow RV volume analysis. Increasing the dose radiation would be ethically difficult 
to justify. 
Perhaps, lesser degrees of DVI may not have been observed because LBNP of -30mmHg 
may not have been great enough to sufficiently volume off load the right ventricle. Increasing the 
LBNP further causes nausea, making the procedure intolerable. A more acute reduction in central 
blood volume and RV pressure may be achieved by invasive inferior vena cava occlusion, using 
the balloon catheter method10.  
These studies were performed supine and at rest, we have shown earlier that it may be on 
exercise that this group of patients develops physiologically significant DVI. Volume off-loading 
the right ventricle, during exercise, may then manifest as a decrease in RVEDV and increase in 
LVEDV. Achieving this mechanically would be challenging. Pharmacological reduction in central 
volume maybe possible375. 
We report for the first time in the present study, that the majority of patients with HCM 
have an appropriate reduction in LVEDV following RV volume unloading, suggesting perhaps the 
absence of overt DVI in the majority of HCM patients at rest. However, our data suggests that in a 
small group of HCM patients there is an overt 'paradoxical' increase in LVEDV following LBNP, 
and that this response may be corrected by BiV pacing. 
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The Chronic Study 
 A randomized double blind cross-over trial 
 
Chapter 6) Effects of chronic biventricular (BiV) pacing on left ventricular dyssynchrony 
twist/untwist and strain in patients with non-obstructive Hypertrophic 
Cardiomyopathy (HCM)  
 
Chapter 7) Effects of chronic BiV pacing on peak Oxygen consumption and quality of life in 
patients with exercise limited non-obstructive HCM. 
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Chapter 6 	
 
 
The Chronic Study 
 
 
 
The effects of chronic Biventricular pacing on left ventricular dyssynchrony, twist/untwist and 
strain in patients with non-obstructive Hypertrophic	Cardiomyopathy. 
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Introduction 
Dyssynchronous contraction in patients with HCM has been demonstrated using TDI13 and 
Speckle tracking 12, as discussed in Chapter 1. A dyssynchronously contracting LV in patients with 
systolic heart failure portends an increased risk for developing ventricular tachyarrhythmia’s and 
sudden death. In patients with systolic heart failure, myocardial dyssynchrony further impairs 
systolic function, perpetuates chamber inefficiency, increases morbidity and mortality.  
Diastolic dysfunction is common in HCM patients and is manifest as a reduction in exercise 
capacity and breathlessness42  commonly seen in the presence of normal or supranormal systolic 
function and absence of obstruction to outflow. Active relaxation is slower with typically reduced 
rates of diastolic filling at rest376. Frenneaux et al. have shown previously that there is a failure of 
the normal increase in the rate of active relaxation (as measured by TTPF) on exercise, indeed in a 
high proportion of patients there was a paradoxical slowing of active relaxation on exercise42 i.e. 
deteriorating diastolic function just when needed most. 
As discussed in Chapter 1 (Device Therapy) in the 1990s a pacemaker based therapy 
(Biventricular pacing) was introduced as a possible method with which to restore cardiac 
synchrony, by electrically stimulating both the right and left ventricles together. Biventricular 
pacing appears to have immediate effects on measures of dyssynchrony, reducing mitral 
regurgitation, and increasing cardiac output, all this without an increase in myocardial Oxygen 
consumption377, 378. Over a longer period of time, reverse remodeling ensues with a reduction in 
chamber size. BiV pacing therapy in patients with systolic heart failure has now been shown, 
repeatedly, to improve quality of life, exercise capacity262 and most importantly reduce 
mortality264, with this effect being most marked in those with evidence of dyssynchrony at 
baseline347, 348. Of note and particular relevance to the present study is that the ventricle pattern of 
 
 
140 
 
contraction and relaxation may be dyssynchronous even when there is apparently normal electrical 
conduction (narrow QRS complex)  because of regional variation in myocardial function379 , a 
feature which is particularly true of patients with HCM.   
As discussed in the Chapter 1, a number of investigators have suggested the importance of 
the contribution made by myocardial twist and untwisting mechanics towards the efficient 
functioning of the myocardium380. During systole, myocardial deformation generates potential 
elastic energy, stored within the tissue of the myocardium, at end of active contraction this stored 
elastic energy is converted to kinetic energy, manifest as rapid untwisting80, 188 that is seen in early 
diastole. This untwist contributes to the generation of a pressure gradient from atria to ventricle, so 
‘sucking’ blood in during diastole, contributing to more efficient diastolic myocardial function.   
Speckle tracking has been recently been validated, by comparison with MRI, as a feasible, 
relatively easily applicable non-invasive method with which to measure myocardial strain and 
rotation199. When viewed from the apex, the left ventricle twists as a result of counter clockwise 
rotation of the apex and clockwise rotation of the base, and the opposite during diastole, resulting 
in untwisting.  Further work has suggested that the rate of untwist may be a measure of diastolic 
function that is largely independent of preload 187.  
 A synchronously contracting and relaxing ventricle may then conceivably result in 
improvement of systolic parameters including twist and strain, and likewise a mechanically 
synchronous diastolic phase may result in improvement in untwist.  In this study, we hypothesised 
that chronic BiV pacing would improve systolic and diastolic dyssynchrony, with concomitant 
improvements twist and untwist rates and strain in patients with symptom limited non-obstructive 
HCM.    
 
 
141 
 
Methods 
 See Chapter 2 (section i) Study design, and Figure 2.1. 
This was a randomised, double blind, cross-over study of active Biventricular pacing vs. 
sham (VVI30) pacing (4 months in each limb). 31 HCM patients (20 males mean age 55years), 
were selected according to the inclusion and exclusion criteria described in Chapter 2 (section ii). 
In brief transthoracic echocardiographic studies were carried out at rest, lying in the left lateral 
decubitus position, at cross over and at completion of study. To allow retrospective speckle tracking 
analysis B mode images, at a minimum frame rate of 60fps were acquired from the apical and 
parasternal short axis windows, as described in Chapter 2, section viii. Color coded tissue doppler 
images with a minimum frame rate of 90fps were obtained from the apical long axis and four and 
two chamber views, as described in Chapter 2 section viii.  
Speckle tracking software was used to measure radial strain, and time to peak radial strain. 
From which 2 indices of radial dyssynchrony were derived as described in Chapter 2 (section viii). 
Speckle tracking software was used to measure rotation and rotation rates at the apex and base. 
From which were calculated LV twist and untwisting rates, as described in Chapter 2 section viii. 
Post image acquisition analysis of color coded tissue doppler images from the apical 
window, was carried out to measure the time to peak systolic and diastolic velocity in twelve 
segments of the LV. From this data, 2 indices of systolic and 1 of diastolic dyssynchrony were 
calculated, as described in Chapter 2 (section viii). These analyses were carried out for the 29 
patients who completed the trial. The programming of the biventricular pacemaker was as 
described in Chapter 2 (section iii).  
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Statistical analysis 
See Chapter 2 (section xi) Statistical analysis Data were analyzed using SPSS version. 17.0 
for Window and Microsoft Office Excel 2010, and expressed as mean ± standard error (sem).  
Comparison of the measured variables between active pacing (BiV), and sham pacing (VVI30), was 
performed using repeated measures analysis of variance. Statistical significance was set at p< 0.05.  
A retrospective analysis for inequality of carry-over effects was carried out using a repeated 
measures analysis of variance 381, P >0.05 suggests no significant carry-over. 
Results 
The clinical and cardiopulmonary characteristics of the patient cohort are shown in Table 
3.1. Of the 31 patients enrolled, 29 patients were able to complete the study. 
  As indicated in Chapter 2 (section ii), these patients had a significantly reduced exercise 
capacity, with significant symptoms. Baseline QRS interval was not prolonged. Over half the 
patients were on rate limiting medications (beta blockers and/or calcium channel blockers). 29 
patients were able to tolerate active BiV pacing. 1 patient was unable to tolerate sustained BiV 
pacing because of diaphragmatic twitching, despite attempts at LV lead repositioning and a further 
patient was unable to tolerate cross over from active BiV pacing to sham pacing. Both patients have 
been excluded from all analysis. 
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Dyssynchrony 
  See Table 6.1. Using TDI two indices of LV systolic dyssynchrony were derived, the global 
Yu index, and a more basal focused systolic dyssynchrony index. Both demonstrated a trend towards 
reduction following BiV pacing but neither achieved statistical significance.  
  A measure of diastolic intraventricular dyssynchrony using TDI (Te-SD) did not 
significantly change following chronic BiV pacing. Interventricular dyssynchrony was measured 
using two different techniques with conventional pulse wave doppler and TDI. Neither measure 
demonstrated any significant change following BiV pacing (Table 6.1). Analysis for inequality of 
carry-over effect, suggests no significant sequence-order effect (Figure 6.1). 
 Speckle tracking has advantages over TDI in being a direction independent, non-doppler 
method of measuring ventricular mechanics. Using this technique 2 different speckle tracking 
indices of systolic intraventricular dyssynchrony were derived. SDt6S, a more global index and AS-
P delay, both showed a tendency towards reduction in dyssynchrony (Table 6.1). Neither index 
achieved statistical significance.  
Strain 
See Table 6.2. Chronic BiV pacing (4months) did not significantly alter apical radial strain 
(p=0.13) and strain rate (p=0.29), papillary radial strain (p=0.83) or strain rate (p=0.76) or basal 
radial strain (p=0.24) or basal strain rate (p=0.81). Similarly, circumferential peak strain and strain 
rates were not significantly altered by BiV pacing at apical, papillary or basal levels. Longitudinal 
peak strain and strain rates, measured from the apical 4 chamber view, were not significantly altered 
by chronic BiV pacing (Table 6.2). 
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Twist 
See Table 6.3. Following 4 months of BiV pacing no significant effect was seen in basal 
peak rotation (p=0.18) nor peak rotation rate (p=1.00). No significant change was seen in apical 
peak rotation (p=0.82), nor peak rotation rate (p=0.72). Four months of active BiV pacing (BiV) 
did not significantly alter peak twist (p=1.00), time to peak twist (p=1.00), peak twist rate (p=1.00) 
and time to peak twist rate (p=1.00).  Peak untwist rate and time to peak untwist was unchanged 
following BiV pacing (p=0.89 p=0.58 respectively).  Despite peak untwist rates being unaffected, 
untwist was more rapidly completed, with a significant reduction in time taken to complete 25% 
untwist (p=0.015) and 50% untwist (p=0.009) (Table 6.3, Figure 6.2, Figure 6.3).  
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Table 6.1 Effect of Chronic BiV pacing on inter and intraventricular dyssynchrony 
 
SDt6s: Standard Deviation time to peak systolic radial strain for six segments papillary level. 
ste: speckle tracking. AS-P delay by RS: Anteroseptal – Posterior wall delay in time to peak 
Radial Strain. Basal systolic dyssynchrony TDI: Maximum delay between peak systolic 
longitudinal velocities basal level four walls. Te-SD: Standard deviation 12 segments to peak 
early diastolic velocity (e). Qa-Qp: Pre-ejection interval difference aortic and pulmonary flow. 
Ts LV-RV: Time interval (Ts) to peak longitudinal systolic velocity basal wall lateral left 
ventricle (LV) and basal free wall right ventricle (RV). Values are mean ± sem. p values are 
for BiV vs. VV130. 
 
 
 
 
 
 
 
 
 
 
  
Chronic Pacing Mode 
 Baseline VVI30 BiV p 
Intraventricular dyssynchrony n=29     
178SDt6s (s) (ste) 0.058±0.007 0.045±0.009 0.037±0.007 1.00 
178AS-P delay by RS (s) (ste) 0.11±0.01 0.08±0.02 0.05±0.01 0.58 
173Yu index by TDI (s) 0.07±0.009 0.048±0.003 0.04±0.004 0.25 
14Basal systolic dyssynchrony TDI (s) 0.10±0.01 0.08±0.009 0.07±0.01 0.84 
151Diastolic dyssynchrony Te-SD (s) 0.049±0.006 0.051±0.008 0.04±0.006 1.00 
Interventricular dyssynchrony n=29  
Qa-Qp (ms) 14.27±3.24 16.69±4.98 16.50±2.56 0.976 
LV-RV asynchrony by TDI(s) 0.08±0.01 0.049±0.009 0.058±0.012 0.504 
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Table 6.2 Effects of Chronic BiV pacing on STE derived measures of myocardial strain and   
strain rates. Values are mean±sem. P values are for BiV vs. VV130. 
 
Whole group n=29 Baseline VVI30 BiV p 
Base Peak Radial strain % 19.55±2.49 22.35±2.49 18.01±2.53 0.24 
Radial  
strain rate s-1 
S 1.49±0.12 1.49±0.12 1.53±0.13 0.81 
E -0.92±0.09 -1.12±0.09 -1.40±0.10 0.10 
A -1.00±0.11 -1.06±0.11 -0.72±0.11 0.02 
Peak Circumferential Strain % -12.85±0.92 -13.722±0.92 -13.85±0.93 0.92 
Circumferential  
strain rate s-1 
S -1.35±0.07 -1.34±0.06 -1.46±0.07 0.29 
E 1.23±0.08 1.29±0.08 1.37±0.08 0.36 
A 0.69±0.05 0.72±0.05 0.61±0.05 0.16 
PM 
(Papillary 
Muscle) 
Peak Radial Strain % 20.17±2.19 20.00±2.15 19.38±2.19 0.83 
Radial  
strain rate s-1 
S 1.30±0.45 1.40±0.51 1.46±0.82 0.76 
E -1.11±0.103 -1.35±0.10 -1.36±0.10 0.97 
A -1.13±0.09 -0.85±0.09 -0.77±0.09 0.50 
Peak Circumferential Strain % -14.44±1.02 -17.90±1.00 -17.19±1.02 0.62 
Circumferential  
strain rate s-1 
S -1.38±0.07 -1.50±0.07 -1.45±0.07 0.66 
E 1.22±0.09 1.59±0.09 1.41±0.09 0.19 
A 0.86±0.06 0.93±0.07 0.71±0.06 0.03 
Apex Peak Radial strain %  14.16±2024 13.60±2.20 8.79±2.28 0.13 
Radial  
strain rate s-1 
S 1.10±0.11 1.15±0.11 0.96±0.11 0.29 
E -1.01±0.14 -1.06±0.13 -0.98±0.13 0.66 
A -0.59±0.45 -0.60±0.57 -0.37±0.46 0.10 
Peak Circumferential Strain % -15.26±1.30 -17.13±1.30 -17.77±1.35 0.74 
Circumferential  
strain rate s-1 
S -1.37±0.09 -1.45±0.09 -1.48±0.09 0.85 
E 1.26±0.14 1.48±0.14 1.50±0.15 0.94 
A 0.79±0.07 0.81±0.07 0.71±0.08 0.33 
Longitudinal Peak Strain % -12.25±0.077 -11.92±0.77 -11.07±0.78 0.43 
Strain Rate s-1 
S -0.93±0.03 -0.90±0.03 -0.93±0.04 0.52 
E 0.90±0.05 0.88±0.05 0.93±0.06 0.55 
A 0.82±0.05 0.78±0.05 0.71±0.05 0.31 
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Whole group n=29 Pacing Mode  
 Baseline VVI30 BiV p 
Rotation Apex  Rotation Peak (deg) 6.30±1.17 6.84±1.09 7.08±0.993 0.82 
 
Rotation Rate 
(deg/s) 
S 50.26±9.71 47.25±8.21 50.73±7.42 0.72 
E -42.26±9.67 -40.11±8.76 -48.39±9.45 1.00 
A -20.95±6.18 -27.17±6.49 -22.76±3.91 1.00 
 
Base  Rotation Peak (deg) -4.17±1.13 -6.37±0.70 -5.38±0.78 0.18 
 
Rotation Rate 
(deg/s) 
S -46.84±9.00 -62.62±4.56 -64.76±6.40 1.00 
E 46.41±9.43 62.63±4.81 56.53±5.43 1.00 
A 39.90±7.40 51.72±3.35 34.29±4.20 1.00 
 
Twist Peak Twist deg 13.08±1.11 11.69±1.11 12.67±1.13 1.00 
Time to peak Twist (RR=1s) 0.37 0.35 0.36 1.00 
Peak Twist Rate deg/sec 89.05±6.71 85.68±6.83 90.65±6.48 1.00 
Time to Peak Twist Rate (RR=1s) 0.18±0.017 0.20±0.017 0.20±0.017 0.58 
    
Untwist Peak Untwist Rate deg/sec -81.60±8.9 -77.99±7.82 -83.34±8.24 0.89 
Time to Peak Untwist Rate 
(RR=1s)
0.53±0.01 0.51±1.87 0.53±0.02 1.00 
% Untwist @25% of total untwist 
duration
22.95±2.82 23.79±2.68 33.08±3.25 0.015 
% Untwist @50% of total untwist 
duration
53.26±3.58 48.16±3.30 64.48±4.36 0.009 
 
Table 6.3 Effects of Chronic BiV pacing on myocardial Rotation, Twist and Untwist.   
Values are mean±sem. p values are for BiV vs. VV130. 
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Figure 6.1 : No inequality of carry-over effects on the Yu index for patients experiencing 
active pacing for the first four months compared to those who received active pacing during 
the second four months, p=0.36. 
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Figure 6.2 : Box-whisker plot showing myocardial Twist at baseline, following sham pacing (VVi) 
and chronic Active pacing (BiV) in 29 patients. Open circles are values for individual patients, 
bold line is median.   p=ns for difference between sham pacing(VVi) or BiV and baseline and 
between BiV and sham pacing (VVi).  
 
 
150 
 
 
 
Figure 6.3 : Box-whisker plot showing the percentage of total untwist completed at the 50% 
of total untwist duration. This is shown at baseline, following sham pacing (VVi) and chronic 
active pacing (BiV). Open circles are individual patients; bold line is median. **p= 0.009: 
BiV vs. VVi. 
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Discussion 
We found that following 4 months of active BiV pacing in patients with symptomatic non-
obstructive HCM, transthoracic echocardiographic-derived measures of intraventricular and 
interventricular systolic and diastolic dyssynchrony, at rest, were not significantly different 
compared to sham pacing. Thus, the improvements seen acutely in the measures of dyssynchrony, 
described in Chapter 3 were not sustained. In the present study, we demonstrated that in contrast 
to patients with left ventricular systolic heart failure382, BiV pacing had no measurable effect on 
strain and strain rate in multiple planes in patients with non-obstructive HCM, when measured with 
STE. We show that unlike patients with systolic heart failure383  chronic BiV pacing in HCM 
patients does not significantly alter rotation or rotation rates at the apex or base, and that peak twist 
and twist rates are essentially unchanged following 4 months of BiV pacing. Despite lack of effect 
on peak values, BiV pacing does however appear to reduce the duration of time taken in which 
completion of untwisting takes place (Figure 6.2, Figure 6.3).  
As discussed in Chapter 1 there was reason to speculate that myocardium affected with 
HCM may be more dyssynchronous in its mechanical function than normal healthy myocardium.  
We hypothesised that chronic BiV pacing would ameliorate dyssynchronous contraction of 
the myocardium in patients with HCM, speculating that a synchronously contracting ventricle may 
improve myocardial strain and rotation.  
A reduction of interventricular dyssynchrony measured as the difference between RV and 
LV pre-ejection intervals has been shown to be associated with reduction in LVEDV and improved 
systolic function in patients with systolic heart failure183. In patients with HCM this index was 
essentially unaffected by BiV pacing both acutely and chronically. The minimal impact of BiV 
pacing therapy on interventricular dyssynchrony may perhaps be a reflection of there being 
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insufficient baseline interventricular dyssynchrony. Though data is scant regarding normal 
interventricular dyssynchrony intervals, as measured using pre-ejection delays, Matsushita et al.352 
report interventricular delay post BiV pacing, in patients with conventional indication for BiV 
therapy to be 16.2±47.4ms. Given that our HCM patients had a pre BiV paced interventricular 
delay of 15.63±2.73ms, room for further reduction using BiV pacing may have been limited. 
As discussed in Chapter 1, the majority of work on dyssynchrony has been focused on 
intraventricular dyssynchrony.  The Yu index a robust measure of global dyssynchrony has been 
shown to be predictive of reverse remodeling in patients with conventional indication for CRT 
therapy161, 167. In the present study, we report a tendency for improvement in the Yu index, 
following 4 months of BiV pacing, suggestive of amelioration of intraventricular dyssynchrony. 
However, unlike acute BiV pacing (Chapter 3), statistical significance was not achieved, perhaps 
reflecting attrition of the initial acute impact of BiV pacing. Similarly, improvements in TDI 
derived measures of basal LV systolic synchrony, following acute BiV pacing, failed to be 
sustained following four months of BiV pacing. 
As discussed in the Chapter 1, to overcome shortcomings inherent of tissue doppler, 
Speckle tracking 178 has been used to assess mechanical myocardial mechanics. In the present 
chronic study, we used STE to derive two indices of radial dyssynchrony (SDt6s and AS-P delay), 
(Table 6.1).  We find that despite 4 months of BiV pacing ('resynchronisation therapy'), patients 
with HCM did not show a significant change in either index, findings consistent with those seen in 
following acute BiV pacing (see Chapter 3), though there was a tendency for reduction in both.  
Diastolic dyssynchrony has been reported in patients with HCM11, 203 and has been shown 
to be ameliorated by Verapamil147. In the present study using tissue doppler imaging we derived 
indices of diastolic dyssynchrony as described in Chapter 2. We found, that similar to acute BiV 
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pacing, that chronic BiV pacing had a limited if any impact on this TDI derived measure of diastolic 
dyssynchrony. Perhaps not so surprising given the marginal effects seen on systolic dyssynchrony. 
The reasons for there being no measurable change in current measures of dyssynchrony 
may be several-fold. Perhaps most importantly, the substrate may not have been amenable to 
resynchronisation by BiV therapy. Recent studies have demonstrated that the only consistently 
reliable predictor of outcome to BiV therapy is the prolonged QRS interval on the surface ECG.  
Notably, those with the greatest prolongation were shown to be the most likely to benefit, so that 
today a Class 1384 indication for BiV therapy mandates a QRS interval ≥150ms. Our HCM patients 
had QRS (98.82±4.05ms) duration well within limits of normality. So, from an electrical 
dyssynchrony viewpoint (as measured using surface ECG), these patients did not have the electrical 
substrate for dyssynchrony, and given that BiV therapy is first an electrical resynchronisation 
therapy, at first glance, it may not be surprising that there was no effect.  That said this statement 
may be  an oversimplification, as the reduction in QRS width following BiV is not particularly 
sensitive (18%) in predicting of response to BiV therapy385, and there is some evidence that 
suggests that there is a group of patients with a narrow QRS interval who do respond to BiV 
pacing285, 386.  Furthermore, almost a third387 of patients, despite having the prerequisite prolonged 
QRS interval who do not respond to BiV therapy, and often in this group it is the 'paradoxical' lack 
of mechanical dyssynchrony that is cited as the cause for this lack of response388. 
It may be that despite patchy fibrosis, ischemia, and regional variability in mechanical 
function, a critical dyssynchrony threshold was not crossed for it to become amenable to the effects 
of resynchronisation using the modality of BiV pacing. Indeed, our findings demonstrate pre-BiV 
pacing indices of dyssynchrony which are of the order of magnitude often found following BiV 
pacing in patients with systolic heart failure.  
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Myocardial twist as measured using STE, in humans, shows good correlation and 
agreement with MRI177, 199, the gold standard. The relative ease of application of Speckle tracking 
has allowed interrogation of rotational dynamics in a broader cohort of patients.  
Reports of the effect of BiV pacing on rotational mechanics  in patients with systolic heart 
failure has been variable with some investigators reporting an acute improvement383 following BiV 
pacing with others reporting no effect389 even in patients otherwise seen to be responding to BiV 
pacing390. We found no reports on the effect of BiV pacing on rotation/twist in patients with non-
obstructive HCM. 
The important role of myocardial rotation to systolic and diastolic function has now been 
borne out by several studies380 391. Kim et al.392 report a strong correlation between dP/dtmax (a 
marker of contractility) and LV twist, consistent with our findings where we show that BiV pacing 
does not alter LV systolic elastance (a marker of contractility) or LV twist.  
Ischemic myocardium has been shown to reduce systolic rotation and delay untwisting 
using MRI393, the same has been shown using Speckle tracking394. Though overt epicardial 
coronary disease is not a feature of HCM, microvascular ischemia is341. We have previously 
demonstrated the loss of the normal inverse relationship of LV TTPF with increasing heart rates in 
patients with HCM42. Similar has been shown with myocardial ischemia395. Myocardial contraction 
during systole, results in the storage of elastic energy in compressed giant molecules of titin396 and 
transmural shear between myofibril sheets397. This stored energy is rapidly released, predominantly 
during the isovolumic relaxation phase, generating intraventricular pressure gradients80, which 
contributes to suction of blood from atria to ventricle391 and enhanced ventricular filling. It is 
conceivable then that patients with HCM may have loss of this untwist function, with reports of 
delayed untwist in HCM83, 195, 196, with consequent loss of this suction effect, resulting in the delays 
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in times peak filling and consequent diastolic inefficiency. The results of this study show that BiV 
pacing has no statistically significant effect upon peak twist rates, or peak untwist rates, but we 
find that BiV pacing reduced the time taken for completion of untwisting, possibly via a more 
uniformly increased untwisting velocity throughout diastole rather than changes in peak values 
alone.  This would require further study to prove.  Although the present study was at rest, if the 
same were to hold true on exercise, this might contribute to the restoration of the normal inverse 
relationship between heart rate and time to peak filling, and ability to increase stroke volume on 
exercise42 in this patient subset.  
Perhaps reassuring is that we report chronic BiV pacing was not deleterious to myocardial 
rotational mechanics, as was demonstrated by Delgado et al.398 who using RV apical pacing in 25 
healthy volunteers demonstrated significant reduction in LV twist.  
 In the present study, we have also demonstrated that chronic biventricular pacing does not 
have a significant effect on systolic or diastolic, longitudinal, circumferential or radial strain and 
strain rates in patients with non-obstructive HCM at rest. 
Despite systolic function as measured by ejection fraction being preserved or even supra-
normal, subtle abnormalities in myocardial deformation are increasingly recognised in patients 
with HCM. Investigators have reported reduced strain and strain rate201, indeed asymptomatic, 
phenotypically normal  carriers of sarcomeric mutations have been identified as having impaired 
diastolic function, with reduced early diastolic velocities,  using deformation imaging205.  In this 
study, we measured circumferential, radial and longitudinal peak systolic and diastolic strain and 
strain rates at multiple distinct planes (apex, papillary and basal). Though strain and strain rate have 
been reported as reduced in patients with HCM205, we show that BiV pacing is unable to 
 
 
156 
 
significantly alter these at rest, in distinction to the impact of BiV pacing on strain in patients with 
systolic heart failure, in whom BiV pacing has been shown to improve myocardial strain.382 
These studies were performed with the patient lying down at rest. All of the patients were 
asymptomatic in this position. It was on exertion that patients manifest symptoms. A 
dyssynchronously contracting myocardium, that is playing a significant role in limiting exercise 
tolerance may be unmasked on exertion 399. Furthermore, it may be on exercise that the degree of 
dyssynchrony is severe enough for BiV pacing to effect significant re-synchronisation. The present 
study did not examine the effect of BiV pacing on dyssynchrony during exercise. 
In summary, our data do not support our initial hypothesis that chronic BiV pacing would 
significantly ameliorate systolic, diastolic or interventricular dyssynchrony in patients with HCM. 
We thus report for the first time that chronic BiV pacing has no significant effect on resting 
measures of systolic and diastolic dyssynchrony in patients with non-obstructive HCM. 
Furthermore, we report for the first time that BiV pacing does not alter peak twist and untwist 
velocities at rest, but does affect a more rapid completion of untwist. Whether this contributes to 
amelioration of diastolic dysfunction reported in patients with HCM, with consequent 
improvement in exercise capacity requires further study. 
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Chapter 7 	
 
 
The Chronic Study 
 
 
 
The effects of chronic Biventricular pacing on peak Oxygen consumption and quality of life in 
patients with exercise limited non-obstructive Hypertrophic Cardiomyopathy. 
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Introduction 
Patients with HCM frequently experience exertional breathlessness. In the variant of HCM 
where there is no obstruction to the out flow of blood from the LV, as in our cohort of patients, 
symptoms are often cited to be as a result of  diastolic dysfunction7, as discussed in Chapter 1. In 
this group of patients' treatment options are few, in the main consisting of rate limiting medications 
with the hope of improving diastolic filling. However, these strategies are frequently met with 
limited beneficial effects. Although we have recently shown the beneficial effects of Perhexiline, 
utilizing a novel approach, in this group of patients, there remains a pressing need for further 
treatment options for these patients. 
Biventricular pacing has been shown to improve morbidity and mortality in patients with 
systolic heart failure. BiV pacing is now a Class 1 indication with level of evidence A, in patients 
who have LV systolic heart failure, with refractory symptoms, and a broad QRS interval on surface 
ECG. In this group of patients BiV pacing has been shown to improve peak Oxygen consumption 
by up to 1-2ml/kg/min. 
Commonly the mechanism of improvement with BiV pacing, as discussed in Chapter 1, is 
thought to relate to a reduction in dyssynchronous contraction, with improved myocardial 
efficiency, though earlier in this study (see Chapter 6) we report that the effect of BiV pacing on 
parameters of dyssynchrony were limited, at rest at least, in this group of patients. In patients with 
systolic heart failure Frenneaux et al. have shown that that BiV pacing may be operating through a 
mechanism in addition to mechanical resynchronization, via amelioration of deleterious diastolic 
ventricular interaction10.  
There is reason to believe that patients with symptomatic HCM may have deleterious 
diastolic ventricular interaction, particularly on exercise, consequential on the development of 
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elevated pulmonary artery pressure, elevating RV end diastolic pressures, as discussed in the 
Introduction. This may then be amenable to BiV pacing as per analogy with systolic heart failure. 
In Chapter 4, we show that indeed there is evidence in some patients with HCM for deleterious 
diastolic ventricular interaction, particularly on exercise and that this may be relieved by BiV 
pacing, with a consequent improvement in stroke volume.  
Whether this change in myocardial function following BiV pacing would translate into 
improved symptom status and exercise tolerance remained unanswered. The effect of BiV pacing 
on symptom status and on exercise tolerance in patients with non-obstructive HCM has not been 
previously reported. 
To answer the above questions, we undertook a randomized cross over trial (4 months in 
each limb) to assess the effects biventricular pacing (BiV) vs. sham pacing (VVI30) on exercise 
capacity and symptom status in patients with marked exercise limitation due to non-obstructive 
HCM. 
Methods 
 See Chapter 2 (section i) for study design and patient inclusion and exclusion criteria. The 
baseline clinical characteristics and cardiopulmonary exercise test results of the HCM patients are 
shown in Table 3.1. 31 patients were enrolled into the study. Two patients discontinued at the 
crossover phase of the study, both these patients were excluded from all analysis. Data are therefore 
presented for the 29 patients that completed both arms of the chronic cross over study. The 
Biventricular pacemaker was programmed as described in Chapter 2 (section iv). Symptom status 
assessments were carried out using the Minnesota living with heart failure questionnaire, see 
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Chapter 2 (section ix). Exercise tolerance was assessed using peak Oxygen consumption 
measurements (VO2max) see Chapter 2 (section x). 
Statistical analysis 
Data were analyzed using SPSS version. 17.0 for Window and Microsoft Office Excel 
2010, and expressed as mean ± standard error (sem).  Comparisons of BiV pacing and sham 
pacing modes were performed using repeated measures analysis of variance. Statistical 
significance was set at p< 0.05.  
Results 
At baseline (Table 3.1), all patients experienced symptoms of exercise limitation due to 
breathlessness that significantly impacted activities of daily living. The Minnesota living with heart 
failure quality of life score was 49 ± 4 (≈ NYHA II-III). At baseline, echocardiographic 
examination the maximal wall thickness was 18.65 ± 0.88 mm. No patient had a peak left 
ventricular outflow tract gradient of greater than 30mmHg at rest or during exercise. No patient 
had more than mild mitral regurgitation. The mean baseline exercise duration was 422 ± 25s. The 
peak Oxygen consumption achieved at baseline was 17.89 ± 0.78ml/Kg/min (42.99 ± 1.41 % of 
age and gender predicted). Heart rhythm was normal sinus in all patients, with mean resting heart 
rate 67.82±2.7bpm and peak exercise heart rate 119±4.44bpm.   
As described in Chapter 4, those patients who experienced a decrease in LVEDV on 
exercise were classed as Group 1and those who experienced an increase in LVEDV on exercise 
were classed as Group 2. 
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i) Effects of Biventricular pacing on exercise capacity 
In the whole group, Table 7.1, peak VO2 max was higher (by 1.16ml/kg/min) during BiV 
pacing vs. sham pacing (p=0.02). At baseline, peak VO2 max was significantly lower in Group1 
(16.42± 0.87ml/kg/min) vs. Group2 (19.46±1.14ml/kg/min) (p=0.043), (Table 7.1). The increase 
in peak VO2max was also significantly greater during BiV pacing in Group1 (by 1.4ml/kg/min; p= 
0.032) but not in Group2 (p=0.13). Treadmill exercise duration was significantly (p=0.02) 
increased following BiV pacing (465±18s) than that achieved following sham pacing (437±19s) 
and compared to baseline (422 ± 25s). This increase was significant in Group1 (p= 0.008) but not 
in patients in Group2 (p=1.00), as might be anticipated from the VO2 max.  
The mean peak exercise heart rate (HR) at baseline was 119±4.44 bpm, and following 4 
months of sham pacing and BiV pacing, 120±4.47bpm and 121±4.28bpm respectively. Peak 
exercise HR did not significantly differ between Group1 and Group2 at baseline (p=0.09), 
following sham pacing (VVI30) (p=0.07) or when BiV paced (p=0.54). Heart rate and blood 
pressure responses to exercise during BiV pacing were not significantly different compared with 
exercise tests performed at baseline and during sham pacing.  All patients achieved a respiratory 
quotient of 1.0 or more. The VE/VCO2   slope following 4 months of BiV pacing (35.55±1.06) did 
not significantly differ from sham pacing (VVI30) (35.22±1.59) or from baseline (35.53±1.08).  
ii) Effects of chronic BiV pacing on Symptom Status.  
See Table 7.1. The Minnesota Living with heart failure questionnaire (MLHFQ) score, was 
significantly lower with BiV (36.72± 4.08) compared to sham pacing (VVI30) (47.52± 4.08) or 
baseline (49.07±4.08) in the whole group (p=0.001), and in Group1 (p=0.02), with the difference 
being of borderline significance in Group2 (p=0.049). 
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Table 7.1 Effect of Chronic BiV pacing on exercise capacity and quality of life 
  Pacing Mode  
 Baseline VVI30 (sham) BiV p 
Whole group follow up n=29         
HR (beats/min) Rest 67.82±2.7 64.93±2.19 63.10±2.08 0.64 
Peak HR 119±4.44 120±4.47 121±4.28 1.00 
SBP (mmHg) Rest 129.48±3.47 124.69±3.39 123.31±3.91 1.00 
Peak SBP 167.58±5.17 158.68±4.83 165.93±4.42 0.368 
QOL score Minnesota 49.07±4.08 47.52±4.08 36.72±4.08 0.001 
Exercise duration(sec) 422±25 437±19 465±18 0.023 
RER 1.07±0.017 1.09±0.017 1.09±0.017 1.00 
VE/VCO2 35.53±1.08 35.22±1.59 35.55±1.06 1.00 
VO2 max % of max. predicted 42.99±1.41 43.67±1.56 46.56±2.07 0.01  
VO2 ml/kg/min 17.89±0.76 18.0 ±0.80 19.17±1.01 0.02  
Group 1 follow up n=15  
HR(beats/min) Rest 60.2±2.87 62.66±2.86 59.06±2.09 0.28 
Peak HR 112±6.13 111±5.82 118±5.65 0.50 
SBP (mmHg) Rest 131.13±5.54 122.86±4.79 123.73±5.41 1.00 
Peak SBP 164±6.67 158±7.58 163±6.71 1.00 
QOL score Minnesota 48.6 ±6.78 49.73±5.05 35.26±5.89 0.02 
Exercise duration (sec) 424±45 409±26 461±25 0.008 
RER 1.07±0.03 1.09±0.03 1.09±0.02 1.00 
VE/VCO2 35.57±1.71 34.26±2.85 35.99±1.60 1.00 
VO2 max % of max. predicted 41.34±2.34% 41.37±2.49 44.93± 3.23 0.027 
VO2 ml/kg/min 16.42±0.87 16.22±0.94 17.62±1.25 0.032 
Group 2 follow up n=14  
HR (beats/min) Rest 76.00±3.70 67.35±3.33 67.42±3.41 1.00 
Peak HR 127±6.43 128±6.84 123±6.47 0.56 
SBP (mmHg) Rest 127.71±4.19 126.64±4.92 122.85±5.78 1.00 
Peak SBP 171.28±8.14 159.14±6.14 168.28±5.87 0.48 
QOL score Minnesota 49.57±5.54 45.14±6.16 38.29±5.49 0.049 
Exercise duration (sec) 420±29 462±28 469±28 1.00 
RER 1.07±0.01 1.08±0.02 1.09±0.02 1.00 
VE/VCO2 35.49±1.36 36.26±1.35 35.09±1.44 0.82 
VO2 max % of max. predicted 44.77±1.44% 46.13±1.66 48.31±2.59 0.11 
VO2 ml/kg/min 19.46±1.14 19.92±1.14 20.83±1.51 0.13 
    Values are mean±sem. Group 1 and 2 as defined in Chapter 4. p values are given  
 for BiV vs. VV130. 
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iii) Sequence order effect 
 
 A repeated measures analysis of variance examining for carryover effects was carried out 
381. The analysis suggests there was no statistically significant sequence order effect affecting peak 
Oxygen consumption (p=0.28), (Figure 7.1) or Minnesota symptom scores(p=0.83) (Figure 7.2). 
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Figure 7.1 : Sequence order effect on VO2max. 
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Figure 7.2 : Sequence order effect on symptom score 
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iv) Drug effect 
 
 A repeated measure of analysis of variance revealed no significant difference in exercise 
tolerance (VO2max) following BiV pacing, whether on Calcium channel blocker or on beta blocker 
therapy (p=0.68) (Figure 7.3). 
 
 
 
 
Figure 7.3 : Effect of medical therapy on response to BiV pacing 
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Discussion 
This present pilot study shows that Biventricular pacing can improve exercise capacity 
and quality of life in patients with non-obstructive hypertrophic cardiomyopathy who have severe 
exercise limitation due to breathlessness despite being on optimal tolerated standard therapies 
(non-dihydropyridine calcium channel blockers or beta blockers). 
Patients with HCM frequently experience a reduction in exercise tolerance and 
breathlessness on exertion. In the subgroup of patients that we studied, HCM without outflow 
tract obstruction, therapies have been to date limited, mostly based on a small number of studies, 
and are often empirical108, 400. Therapies studied have mainly been focused around use of beta 
blockers97, 401 and calcium channel blockers103, 106, 108, 402, the benefits frequently modest with little 
objective improvement in exercise capacity105, 403. Recently, our group has shown that Perhexiline, 
a metabolic modulator has a beneficial effect on symptoms and exercise tolerance in this group 
of patients, unfortunately it requires assessment of plasma levels of to avoid toxic effects. The 
treatment of refractory symptoms in patients with the non-obstructive variant of HCM remains 
unsatisfactory. 
We found that, except for one patient who experienced diaphragmatic twitching following 
BiV pacing, this was a well-tolerated therapy in patients with non-obstructive HCM, with a low 
complication rate. 
Measuring peak Oxygen consumption (VO2 max) is now considered the gold standard for 
the estimation and monitoring of relative exercise intensity404, having the ability to provide highly 
reproducible metrics of exercise capacity405. Furthermore, numerous studies have demonstrated 
the prognostic utility of measuring peak Oxygen consumption and the VE/VCO2 slope in patients 
with heart failure406, 407. In the present study we have demonstrated that peak Oxygen consumption 
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increased by over 1ml/kg/min in the group as a whole, which is comparable to the order of 
magnitude seen in patients who have BiV pacemaker therapy for systolic heart failure (1-
2ml/kg/min) 408, with no significant increase in peak Oxygen consumption following BiV pacing 
in Group 2, and by 1.4ml/kg/min in Group1, i.e. those patients with most marked diastolic 
dysfunction.  
Symptom status was assessed using the Minnesota living with heart failure questionnaire 
(MLHFQ) at baseline, cross over and at exit from study. A 10.8 point reduction in mean score 
was seen as a whole group, though more marked in Group1 (-14.47 points). This is comparable 
to patients who receive BiV pacing therapy for conventional indications who report an average 
10 point reduction in MLHFQ score408. Borderline reduction in MLHFQ was seen in Group 2.  
Pacemakers have been used in Hypertrophic Cardiomyopathy before. When assessing subjective 
symptom status it is important to bear in mind that that in the early 1990s initial trials of dual 
chamber pacemakers in patients with the obstructive variant of HCM, demonstrated clinical 
improvement119 but that subsequent trials demonstrated that a significant element of the benefit 
seen was in perceived subjective improvement, a placebo effect associated with having a device, 
with little impact on objective exercise capacity122, 127, 409.  Our cross over study which employed 
sham (VVI30 backup) pacing excludes such an effect. 
As discussed earlier, cross-over trials may be limited by carry-over effect, potentially 
blunting the effect seen of the therapy under scrutiny. A washout period between the two limbs 
would have been ideal to mitigate against this effect. In the absence of a washout period in this 
study, an analysis looking for carry-over effect of BiV pacing suggests that this was not a 
significant factor in the results seen (Figure 7.1, Figure 7.2). 
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Thus, for the first time we have shown that BiV pacing objectively improves exercise 
tolerance in patients with non-obstructive hypertrophic cardiomyopathy. Furthermore, we show 
that patients with the most marked diastolic dysfunction (Group1), as opposed to dyssynchrony, 
derive most benefit.  
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Chapter 8 	
 
 
 
General Discussion 
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The aims of this PhD were broadly two-fold. Firstly, to examine the possible 
pathophysiological mechanisms involved in exercise limitation in patients with non-obstructive 
hypertrophic cardiomyopathy, and the acute impact on myocardial function of Biventricular pacing 
in this patient group.  Secondly, we appraised the potential role of chronic Biventricular cardiac 
pacing, as a treatment strategy for severely exercise limited patients with HCM. 
In brief this study has shown that BiV pacing can improve exercise capacity and the quality 
of life of patients with non-obstructive hypertrophic cardiomyopathy who have severe exercise 
limitation due to breathlessness despite optimal tolerated standard therapies (non- dihydropyridine 
calcium channel blockers or beta blockers). 
In patients with systolic heart failure, the predominant mechanism of improvement of 
cardiac performance following BiV pacing has traditionally been considered to be the relief of 
mechanical dyssynchrony. However, the degree of resting systolic mechanical dyssynchrony 
present in the patients in this study was much less marked than is seen in patients with systolic 
heart failure who undergo Biventricular pacemaker implants 264. Furthermore, in these patients with 
HCM, QRS duration was normal and in all patients left ventricular ejection fraction was at least 
50% at rest. Although following BiV pacing we saw acute improvement in TDI derived parameters 
of dyssynchrony, these gains were not sustained, with no significant changes in echocardiographic 
measures of systolic or diastolic dyssynchrony (at rest) being observed with chronic biventricular 
pacing (using tissue doppler and speckle tracking techniques). Perhaps, measuring dyssynchrony 
during exercise would have given a different result, as it is on exercise that patients develop 
symptoms.  It may be then that we would have seen dyssynchrony410, pronounced enough for BiV 
pacing to have its resynchronisation effects. However, we measured dyssynchrony at rest only. 
Applying TDI during exercise is difficult since TDI measures only the vector of motion that is 
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parallel to the direction of the ultrasound beam from the echo probe, and maintaining alignment 
during exercise is challenging.  
The translational movement artifact limitation of TDI may be countered by using speckle 
tracking analysis, as described in Chapter 2. Optimal STE analysis requires acquisition of digital 
routine gray-scale cineloops with high quality images, again this may be difficult to achieve in the 
exercising subject. The ideal frame rate for STE currently appears to be 60–80 Hz.  Frame rates 
that are too high (>100 Hz) result in excessive signal noise, but higher frame rates would be 
necessitated in order to maintain temporal resolution. Furthermore, increased mechanical 
movement during exercise would contribute to greater through plane movement of the myocardium 
during image acquisition leading to further degradation in STE. 
In addition to the marginal effects on parameters of dyssynchrony, BiV pacing had no 
significant effect on LV ejection fraction or on LV end systolic elastance, (a relatively load 
independent measure of LV contractile function) at rest or on exercise. These findings argue against 
a substantial beneficial effect of BiV pacing on LV contractile function that might explain the 
improved stroke volume response on exercise and the increase in exercise capacity observed. 
However, there was a modest reduction in the duration of systole suggesting that there may have 
been a subtle improvement in contractile function, potentially related to reduced mechanical 
dyssynchrony on exercise, but we only have dyssynchrony data at rest. 
Biventricular pacing however, did have marked effects on the filling of the left ventricle. 
In health, LV end diastolic volume increases during exercise, and thereby the Starling mechanism 
contributes to the increase in stroke volume364. This is a consequence of both an increase in the rate 
of LV active relaxation during exercise280, 281 and of translocation of blood from the venous 
compartment to the central compartment due the effects of the muscle pump and to active 
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vasoconstriction in the intestinal and splenic venous capacitance beds366. We have previously 
shown that the rate of LV active relaxation paradoxically slows during exercise in many patients 
with HCM on exercise, and that amelioration of the marked cardiac energetic impairment with the 
metabolic modulator Perhexiline reverses this abnormality95.  In approximately 50% of the patients 
in the present study there was an abnormal fall in LV end diastolic volume during exercise, and an 
associated fall in stroke volume (Group 1). This pattern was associated with more severe exercise 
limitation and with worse symptoms than in those patients in whom LVEDV increased on exercise 
(Group 2). Biventricular pacing substantially corrected these abnormal responses in Group 1 
patients (indeed overall there was a modest mean increase in LVEDV during exercise during BiV 
pacing) with no significant effect observed on the increase in LVEDV during exercise seen in 
Group 2 patients. This was associated with a significant increase in LV stroke volume during 
exercise with BiV pacing in Group 1, but not in Group 2 patients and during the chronic study a 
significant increase in peak VO2 was also observed with BiV pacing in Group 1, but not in Group 
2 patients. These findings argue that the improved cardiac performance on exercise and the 
resulting increase in exercise capacity is in large part related to a partial restoration of the ability 
to use the Starling mechanism to increase stroke volume on exercise. 
How might this have been achieved? Potential mechanisms might include an increase in 
the rate of LV active relaxation on exercise or a reduction in intrinsic left ventricular stiffness, an 
increase in diastolic filling time or a reduction in external constraint to left ventricular filling. 
Diastolic dyssynchrony has been reported in HCM11, 367 and a reduction in the degree of diastolic 
dyssynchrony by BiV pacing (especially on exercise) might translate into more rapid LV active 
relaxation and reduced LV stiffness.  However, at least at rest, we observed no significant effect of 
BiV pacing on measures of diastolic dyssynchrony. Furthermore, BiV pacing was associated with 
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a reduction in first third filling fraction at rest and on exercise, which argues against this being an 
important mechanism. External constraint to left ventricular filling by the pericardium368 
(pericardial constraint) and by the right ventricle through the interventricular septum (diastolic 
ventricular interaction) is observed in experimental models associated with acute RV volume 
and/or pressure overload216 214. We have shown that these phenomena are seen in an experimental 
model of chronic heart failure367 and in those patients with chronic heart failure who have elevated 
left ventricular end diastolic pressures (typically >15mmHg)4.  
Bleasdale et al. have previously shown that in patients with severe chronic heart failure, 
both biventricular and left ventricular pacing reduced this external constraint to left ventricular 
filling and thereby recruited LV preload, presumably by shifting the timing of LV vs. RV filling10. 
We report in the present study, a paradoxical increase in left ventricular diastolic volumes during 
application of lower body negative pressure in 4 patients (all of whom were in Group 1), suggesting 
the presence of significant DVI in these patients. In 3 of these patients this paradoxical increase in 
LVEDV during application of LBNP was normalised by BiV pacing, suggesting alleviation of 
DVI.  Although only a minority of patients with HCM have pulmonary hypertension and markedly 
raised LVEDP at rest, both PA pressure and LVEDP markedly rise during exercise in many patients 
with symptomatic HCM239 . Therefore a priori, DVI might be expected to be a frequent occurrence 
on exercise in these patients. We suggest that the restoration of the Starling mechanism on exercise 
by BiV pacing in Group 1 patients is the most likely explanation for our findings. Diastolic 
ventricular interaction is typically associated with a restrictive LV filling pattern236 in which rapid 
early filling then ceases with the onset of external constraint. Of note, BiV pacing reduced the rate 
of early filling but markedly increased filling in the later part of diastole during exercise, consistent 
with our assertion.  
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 The anatomical position of the septum makes it an ideal surrogate of the diastolic 
interactions between the two ventricles, akin to a membrane separating two fluid volumes411, as 
described in earlier Chapter 2 (section vii). The normal shape of the intraventricular septum 
(convex to the RV412) is dependent on the presence of a positive LV - RV pressure gradient. In 10 
patients with hypertrophic cardiomyopathy, we show that during sham pacing, on exercise there 
was a tendency for septal flattening (with an increased Rs p=0.08), as might be anticipated with 
the development of adverse DVI. Furthermore, we see that during BiV pacing on exercise there 
was a reduction in the degree of septal flattening (reduction in Rs). We suggest that this is due to 
the phase shift in ventricular filling following BiV pacing, allowing the LV to fill unimpeded by 
RV, (in distinction to RV pacing by Kingma et al.370),  with the development of an appropriate 
transeptal gradient, restoring the normally concave to the left conformation of the ventricular 
septum. These findings lend further weight to the argument for the development of DVI during 
exercise, and its correction following BiV pacing. 
Biventricular pacing markedly increased the diastolic filling period on exercise in Group 
one, but less so in Group 2 patients. This may also be an important mechanism contributing to 
improved LV filling. This may in turn be a consequence of reduced ventricular interaction resulting 
in a longer period of filling and/or (by reduced LVEDP) reducing pre-systolic mitral regurgitation 
on exercise. Alternatively, it might in part be related to the shortening of systolic duration observed.  
These findings would have been more conclusive of DVI development if we had been able 
to measure simultaneous RV and LV volumes. On exercise a simultaneous increase in right 
ventricular (RV) end diastolic volume with associated fall in LV end diastolic volume, and on 
application of LBNP, a reduction in RV end diastolic volumes with a simultaneous increase in LV 
end diastolic volumes would argue strongly for the presence of DVI. However, our image quality 
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was not good enough to analyse RV volumes with sufficient fidelity, and further increasing already 
significant radiation doses (1:3300 fatality) to achieve this would be ethically difficult. We 
demonstrated the potential development of DVI in only 50% of patients on exercise, when 
exercised to only 50% of heart rate reserve. Likely the number demonstrating potential DVI would 
have been larger, and effects of DVI more dramatic, at greater workloads due to associated increase 
in pulmonary artery pressures. However, maintaining gated radionuclide ventriculography data 
integrity at high workloads is challenging, due to difficulties in maintaining constant heart rates 
(patient fatigue) and movement artefact, seriously degrading statistical reliability of systolic and 
diastolic indices measured.  
Conclusion 
In this pilot study, we have shown for the first time that Biventricular pacing can improve 
symptoms and exercise capacity in patients with non-obstructive Hypertrophic Cardiomyopathy. 
As this was a crossover study there is always the concern of carryover effect. However previous 
investigators have demonstrated that the symptomatic benefits and the effects of reverse modelling 
of BiV pacing begin to diminish within a week of halting BiV pacing, and have completely reversed 
back to baseline by 3 months161. 
 The benefit we report was most marked in those patients with the most marked diastolic 
impairment during exercise. We suggest that the mechanism of improvement is primarily through 
the relief of DVI, a mechanism not previously described in HCM patients, with consequent 
improvement in the ability to utilize the Starling mechanism to increase stroke volume. We have 
shown that there is a subset of patients with HCM who may derive particular benefit from BiV 
pacing however this group is small, 15 patients.  To show more definitively the benefits of BiV 
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therapy it would be better to recruit potential patients for a trial of this therapy by screening for 
deleterious DVI pre-implantation. 
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Chapter 9  
 
 
 
Future Direction 
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This pilot study has shown that there may be a role for BiV pacing in patients with 
symptomatic, exercise limited non-obstructive Hypertrophic Cardiomyopathy. However, we show 
that this benefit was restricted to those patients with the most marked diastolic dysfunction on 
exercise. We have argued that one of the mechanisms contributing to this is diastolic ventricular 
interaction.  Atherton et al.4 showed that almost 50% of patients with chronic heart failure had 
evidence of DVI at rest.  Furthermore, they showed, using transthoracic echocardiography, that a 
restrictive transmitral LV filling pattern at rest was associated with DVI in patients with chronic 
heart failure236. We show that at rest most non-obstructive HCM patients do not have evidence of 
DVI, however over half had evidence suggestive of the development DVI on exercise. It then 
follows that a restrictive LV filling pattern on exercise in patients with non-obstructive HCM may, 
similarly to patient with chronic heart failure, be able to identify patients with DVI. Transmitral 
doppler maybe a simple non-invasive tool for identifying HCM patients who may benefit from BiV 
pacing. A further study would be required to establish the relationship between restrictive LV 
filling patterns on exercise and the development of DVI on exercise in patients with non-obstructive 
HCM.  
Geske et al.413 in a retrospective analysis of 321 patients with HCM, showed that those with 
most marked pulmonary hypertension had the greatest elevations in brain natriuretic peptide (BNP) 
and in n-terminal BNP. Information which may lend additional support for the presence of 
significant DVI. A future full scale study of BiV pacing in patients with NOHCM may then be 
restricted to those who are most likely to benefit, identified with easily available blood tests, and 
straight forward transthoracic echocardiography. 
The relief of DVI, allows an increase in LVEDV and utilization of the Starling mechanism. 
On exercise this should manifest as an increase in cardiac output. Peak Oxygen consumption, 
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a powerful prognostic index414, is an indirect measure of cardiac output, is influenced by peripheral 
factors415, 416. The Innocor rebreathing system, a relatively easy to apply, non-invasive method, by 
using the Fick principle is able to measure cardiac output, both rest and on exercise417. A future 
study may incorporate this technique to provide direct evidence for improvement in cardiac output 
following BiV pacing. 
Myocardial mechanical dyssynchrony is an appealing and relatively easy idea to grasp, 
qualitatively is often easily recognised, but to quantify has proven to be far more challenging then 
initial reports suggested289, 418. As imaging technology rapidly advances with the advent of 
techniques such as 3D Speckle tracking419 and MRI, measures of dyssynchrony420 are likely to be 
developed that are more robust, sensitive, and easily applied. Utilising these future measures, it 
would be useful to study and quantify the role mechanical dyssynchrony is playing in producing 
cardiac dysfunction in patients with HCM, particularly on exercise. Furthermore, if ameliorating 
mechanical dyssynchrony by therapies such as BiV pacing offers benefit to patients.  
More recently investigators have reported changes in molecular and cellular function 
induced by BiV pacing, going beyond the traditional mechanical and hemodynamic effects421. In 
animal models, BiV pacing has been shown to have a positive impact on mitochondrial function, 
altering expression of at least 30 different proteins within the mitochondrial proteome302. Recently, 
we have shown using magnetic resonance spectroscopy, that Perhexiline a metabolic modulator 
improved myocardial performance in patients with HCM. With increasing availability of MRI 
compatible BiV pacemakers (Medtronic SureScan device series), it would be of interest to see if 
both, BiV pacing and Metabolic manipulators such as Perhexiline share common metabolic end 
pathways in patients with HCM, different means to the same ends! 
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